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Abstract 
Rheumatoid arthritis (RA) is an autoimmune disorder for which there is no 
known cause. The disease is characterized by progressive joint destruction, 
mediated by breakdown of immune tolerance by immune system dysfunction, 
influenced by several factors. This results in the development of self-reactive 
proteins, called autoantigens. In RA, the dominant autoantibodies are directed 
to modified host proteins that are citrullinated and carbamylated. These 
modifications are driven by peptidyl-arginine deiminase (PAD) and 
myeloperoxidase (MPO), which are found in the greatest quantity in neutrophils, 
the major white blood cell of the immune system.  The primary anti-microbial 
activity of these cells is characterized by several distinct functions: 
phagocytosis, degranulation and neutrophil extracellular trap (NET) production. 
NETosis is a unique cell death mechanism in which neutrophils unwind 
chromatin fibres from histone proteins, and through packaging with antimicrobial 
peptides, are released from the cell to ensnare and kill bacteria. These cells 
have been previously suggested as a driver in RA pathogenesis. The toxic 
heavy metal, cadmium, has been suggested in recent years as a potential 
contributing factor in RA, although the effect of cadmium exposure on neutrophil 
biology and function has not been fully explored. This thesis aimed to 
investigate serum autoantigens in RA, and explore the potential interplay 
between cadmium and neutrophil function in order to discern any dysfunctional 
processes that could promote autoantigen development. 
Primary neutrophils were incubated with cadmium chloride and the effect on 
essential cellular functions was examined. Cadmium did not modify the 
phagocytic capacity of neutrophils, although it increased intracellular calcium 
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levels. Cadmium also enhanced the processes of the reactive oxygen species 
production and NETosis upon co-stimulation with phorbol 12-myristate 13-
acetate (PMA) - an activator of protein kinase C.  
Serum samples from 10 healthy control donors, 18 patients with RA, 4 patients 
with bronchiectasis (BR) and 4 patients with bronchiectasis and RA (BRRA) 
were analysed by western blotting to identify citrullinated proteins. Bands of 
interest were excised and identified using mass spectrometry. The heavy chain 
of immunoglobulin G, in addition to alpha-1-antitrypsin were found to be 
citrullinated in all samples, though in a much greater extent in RA patients. In 
addition, the same proteins also had a greater level of carbamylation than 
citrullination.  
Taken together, these modifications provide novel evidence into how post-
translational modifications may play a role in rheumatoid factor development in 
RA patients. As both PAD and MPO require elevations in the cytosolic calcium 
level to function, the effect of cadmium on neutrophil function may play a 
priming role in the cell, such that a second stimulus may give rise to a more 
exaggerated response during inflammation and a more permissive environment 
for autoantigen development.  
Future work should examine the effect on MPO and PAD release after a period 
of cell priming with cadmium, and direct effects on immunoglobulin 
carbamylation/citrullination. This may allow greater insight into potential 
pathways through which RA may develop.  
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1.1 Cadmium and the effects of exposure on human physiology 
Cadmium is highly toxic to both humans and animals alike, with several 
avenues of exposure in the general population. By exploring the bioavailability 
of cadmium once ingested into the body, it is possible to hypothesise how long-
term exposure to cadmium may lead to cumulative cellular dysfunction, 
potentially resulting in chronic disease development. 
 
1.1.1 Uses of cadmium in industrial applications and routes of 
occupational exposure 
Once harvested from the earth, the aforementioned characteristics allow it to fill 
a niche role that other metals may not. The primary usage for cadmium, 
accounting for 86% of all cadmium globally used, is in the manufacturing of 
nickel-cadmium rechargeable batteries (1). An emerging use in recent years for 
cadmium is its application in solar-powered technologies. Cadmium-Tellerium 
batteries can convert sunlight into electricity at a higher rate, lower carbon 
footprint, and ultimately, lower cost than conventional silicon solar cells. This 
poses a potential health implication in the future given the current expansion of 
the solar technology industry. 
Additionally, 9% of cadmium used globally is used in the process of colour 
pigmentation. It is added to plastics or paints, in order to make the red, yellow 
and orange shades look more vibrant.  In recent years, this has prompted 
discussion to consider banning the use of cadmium in this practice, though 
ultimately it was allowed to continue. The final and less-common application for 
cadmium is to use as a coating for alloys and metals to protect them from 
corrosion (1). 
22 
 
Because of the manufacturing processes that the above products undergo, the 
individuals most commonly exposed to cadmium are typically employed in the 
metalworking industry. Metal workers  inhale cadmium particles from 
dust/fumes from the processes of  smelting, grinding and welding, where metals 
or alloys coated in cadmium particles are shed during processing where they 
may be subsequently inhaled (1, 2). 
 
1.1.2 Non-occupational routes of cadmium exposure 
The main sources of cadmium exposure for the general population are from 
food products and smoking. In food products, agricultural use of phosphate 
fertilizers containing cadmium, result in trace quantities to be present in food. In 
addition to this, run-off from industrial processes causes dispersal into the water 
systems and nearby soil, resulting in low levels of cadmium to be present in the 
environment. It is a consequence of this that cadmium is taken up rather avidly 
in certain plants and animals compared to other metal contaminants such as 
lead and mercury (3). This bio-accumulation of cadmium in plants crosses to 
organisms higher up in the food chain, whereby feeding on plants and animals 
containing high levels of cadmium can lead to long term detrimental health 
effects. The average person ingests roughly 30-50μg cadmium/day, though the 
amount ultimately accumulated can vary from 6-44% of the original dose, 
depending on age, though the authors of this study could not explain why this 
was the case (4). 
For the general population, the largest and most abundant route to be exposed 
to cadmium is through smoking. The tobacco plant species (Nicotiana spp.) has 
a genetic predisposition to cadmium accumulation compared to other plants (5). 
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As this cannot be removed in the manufacture of cigarettes, it is passed on to 
smokers through the means of inhalation. Cigarettes from popular brands 
contain as much as 2μg of cadmium per cigarette, with roughly 10% of this 
transferring to inhaled cigarette smoke (6, 7). Considering the average person 
over 16 in the UK smokes roughly 11 cigarettes per day, as much as 2.2 μg of 
Cadmium could be inhaled by an individual on a daily basis (8). 
 
1.1.3 Human response to cadmium exposure 
The primary response to cadmium exposure is mediated by metallothioneins 
(MT). MTs are a family of proteins where the primary function is to bind mono 
and divalent metal ions, in order to maintain homeostasis of essential ions such 
as zinc or copper in the blood (9-11). MTs are also important in scavenging free 
radicals,  providing protection against oxidative stress (12). They achieve this 
function through a high content of cysteine, which readily binds free metal ions 
or reactive oxygen species. Binding of MT to cadmium somewhat mitigates the 
toxic effects (13). The genes coding for production of MTs are found in all cell 
types throughout the body (particularly hepatocytes,) becoming activated upon 
exposure to metals (14). It is important to note that these levels in cells are very 
minute, and do not prevent cadmium from circulating in the body. 
Upon inhalation of cadmium, between 10-40% of inhaled cadmium is retained in 
the lungs up to 94 days, though different sources of cadmium appear to result in 
differing levels of deposition (15). Cadmium chloride appears to be retained in 
the lungs at roughly twice the amount of cadmium sulfide. This could be due to 
the routes of administration, as CdCl2 was administered via aerosol compared 
to the dose of CdS, which was given via dust particles, suggesting a droplet 
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containing cadmium may pose a greater risk than dust during inhalation (15). 
High abundance of Cadmium in the lungs can have negative consequences, 
which will be discussed later in Chapter Three. The entrance of cadmium into 
the body is hypothesised to be as a result of “ionic mimicry” (16). Ionic mimicry 
is a concept where cadmium ions act as homologues for other elements that 
may be transported across epithelial cell membranes (16). From here it can 
subsequently cross the pulmonary capillary bed and enter the circulation. 
Once cadmium enters the bloodstream, cadmium binds to albumin, 
haemoglobin, cysteine residues and glutathione and circulates in the body. 
These complexes eventually accumulate in the liver (17). Fortunately, the MT 
anti-oxidants are also prevalent in the liver (18). Here, these complexes induce 
production of additional MTs that form new complexes with cadmium in place of 
the aforementioned proteins as a result of greater binding affinity (18). Chronic 
low doses of cadmium have been found to increase levels of MT in the body, 
leading to a protective effect against the toxic effects of cadmium (19).  
However, as MT-cadmium-protein complexes accumulate,  hepatoxicity can 
occur in hepatocytes, resulting in additional release of stored cadmium-MT 
complexes into the local tissue environment and blood circulation (20).These 
complexes ultimately become deposited in the kidney via renal circulation. 
Cadmium-protein complexes are not easily internalised by cells, apart from cells 
in the proximal tubule of the kidney (21).  This deposition occurs through 
glomerular filtration, whereby the cadmium becomes transported into the 
cortical and distal tubules, as a result of protein reabsorption (22). It is important 
to recognise that not all cadmium-protein complexes are replaced by cadmium-
MT complexes, and some complexes, such as cadmium-cysteine or cadmium-
glutathione are capable of being internalised by proximal tubule epithelial cells 
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(20). Storage of cadmium in the kidney can last between 14-25 years (23). A 
person who is routinely exposed to cadmium could accumulate a substantial 
amount of cadmium over time, resulting in substantial health implications. A 
summary of routes of exposure and the physiological response to cadmium 
exposure can be seen in Figure 1.1. 
 
1.2 Toxic effects of cadmium exposure 
The cytotoxic effects of cadmium have been well-documented (24-29). Given 
the long-lasting duration of cadmium retention in the body, cadmium can induce 
both acute and chronic toxicity. 
Acute toxicity is defined by the International Union of Pure and Applied 
Chemistry as the adverse effects that occur within two weeks after exposure to 
a single or multiple dose within 24 hours of a starting point  (30). Chronic toxicity 
covers any symptoms observed after this time frame. 
 
1.2.1 Oxidative stress 
Oxidative stress plays a role in cadmium toxicity. As previously stated, cadmium 
bio-accumulation in hepatocytes induces production of MTs, through free Cd2+ 
ions entering the mitochondria and triggering oxidative stress (31). Here, 
Cadmium is capable of inhibiting the electron transport chain through impairing 
the function of cytochrome bc1, driving generation of reactive oxygen species 
(ROS) (31).  Cadmium abundantly binds intracellular glutathione and indirectly 
contributes to further ROS production (20, 32). These ROS are then able to 
induce DNA damage and apoptosis in the cells. This is evidenced by studies 
demonstrating apoptosis of renal and hepatic cells exposed to low  
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Figure 1-1: The routes of exposure and physiological human response to 
cadmium.  
Smoking, food and workplace exposure are the primary routes of entry into the 
human body. Cadmium first arrives in the lungs and gastrointestinal tract 
based on route of exposure and enters the bloodstream. Here, cadmium forms 
complexes with various proteins in the blood and migrates towards the liver, 
increasing metallothionein production in order to sequester circulating 
cadmium and unbind it from the circulating proteins. These Cadmium-MT 
complexes then circulate to the kidneys, where they are absorbed by the 
proximal tubule component, and are retained in the kidneys for up to 25 years. 
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concentrations of 0.5μM of Cadmium over a 24h period, or 10μM leading to cell 
death within 6 hours. Higher doses of cadmium (50μM) were found to induce 
necrosis in mesangial cells (33). In the liver, ROS generation is further 
exacerbated by observations of cadmium initiating the Fenton reaction, another 
means of ROS production as shown in Figure 1.2 (32). 
1.2.2 Acute toxic effects 
Ingestion of cadmium can cause vomiting of blood, severe abdominal pain, 
diarrhoea and myalgia (34). These symptoms can be brought on by as little as 
3mg of cadmium in total, with a dose greater than 100mg being considered a 
lethal dose, with death resulting from cardiovascular collapse (35). Ingestion of 
such levels of cadmium over an acute period would be unlikely unless 
intentional. A more realistic form of acute toxicity would be through inhalation of 
cadmium. 
Pulmonary cadmium toxicity is well documented in the form of chemical 
pneumonitis or metal fume fever (36-40). These conditions consist of thoracic 
pain and incredible difficulty breathing (36, 41). Although metal fume fever 
typically resolves due to a minimal extent of damage in the upper airways, 
chemical pneumonitis has a much more severe prognosis (34). Cadmium-
induced chemical pneumonitis can lead to haemorrhagic bronchoalveolitis 
which has a mortality rate of 10-25% in cases (34). Both conditions are due to 
occupational exposure in areas of poor ventilation and lack of protective 
equipment. This presents little concern for modern industrial applications in 
western countries where health and safety measures are well maintained. 
Developing countries with less strict working conditions present the greatest risk 
for cadmium-related toxicity; with jewellery workers in India presenting a large 
group of individuals at risk (40). 
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Figure 1-2 How cadmium contributes to the Fenton reaction.  
Oxygen radicals are generated from the reaction between a free electron and 
oxygen. This radical is then converted to hydrogen peroxide through superoxide 
dismutase. The hydrogen peroxide then reacts with free copper and iron ions to 
form a hydroxyl radical. Cadmium releases copper and iron ions from cytosolic 
and membrane proteins such as ferritin through displacement. The other 
hydroxide with an unpaired electron then reacts with other iron ions to form an 
additional hydroxyl radical. 
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1.2.3 Chronic toxic effects 
1.2.3.1 Pulmonary toxicity 
The long-term effect of chronic cadmium exposure in the lungs should not be 
understated. Chronic obstructive pulmonary disease (COPD) and emphysema 
are the most common form of adverse events from cadmium exposure, with 
factory workers displaying the highest amount of cadmium exposure showing 
the greatest degree of lung abnormalities (42, 43). Interestingly, it has been 
proposed that it is in fact cadmium in cigarettes that is one of the driving factors 
in COPD and emphysema pathogenesis (37, 44). 
 
1.2.3.2 Nephrotoxicity 
The kidney represents the site of long-term cadmium deposition in the body, 
and subsequently is the primary organ affected by chronic cadmium toxicity. As 
previously mentioned, cadmium is capable of inducing cell death through 
oxidative stress (33). Tubular epithelial cells undergo apoptosis upon 24 hours 
of exposure to CdCl2, which was prevented by treatment with Propolis (an 
antioxidant product produced by bees,) evidencing the role of oxidative stress in 
renal cell death (45). Much of the damage to renal epithelial cells in the proximal 
tubule is facilitated by ionic Cd2+ as a result of breakdown of cadmium-MT 
complexes, rather than the complexes themselves (20) (28). Production of ROS 
induces cell death via DNA damage, though this damage also has another 
outcome: cancer. 
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1.2.3.3 Cancer 
Cadmium is recognised by the World Health Organisation for Research on 
Cancer as a carcinogen. The most common cancer attributed to cadmium 
exposure is lung cancer (46-49). One study found that of 42 workers exposed to 
cadmium as part of their profession, four developed lung cancer -  a hazard 
ratio of 3.23 (49). However, a recent meta-analysis of cohort studies examining 
the effect of cadmium exposure on lung cancer development found no 
statistically significant relationship to exist, but cited multiple reasons for the 
association to be underestimated (47). One of these reasons may be attributed 
to the “Healthy Worker Effect” whereby occupational studies can only recruit 
people who are currently healthy enough to work as opposed to severely ill 
people excluded from employment, potentially due to the variable in question 
(50). Most importantly, upon collating all the studies found into two groups of 
exposed and non-exposed individuals, there was found to be a statistically 
significant association between cadmium exposure and lung cancer.  Given the 
highly toxic nature of cadmium in both acute and chronic cases, coupled with 
evidence of increased MT levels from repeated low-dose exposures, it is 
entirely possible for the severity of outcomes in occupational workers to be 
underrepresented (19). 
The risk factor for renal cancer development is elevated in high-cadmium 
exposed individuals, in particular occupationally exposed individuals presenting 
the highest-risk group (51). Other cancers have been suggested to be in-part 
influenced by cadmium exposure, although there is insufficient evidence in 
human populations to verify any substantial risk (52, 53). 
Further evidence of cadmium-induced carcinogenicity has shown that 
osteoblast cells exposed to 20 and 50µM of Cd for 24 and 48 hours caused 
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downregulation of checkpoint kinases and CDK2, whilst upregulating cyclin E2. 
Upregulation of cyclin E2 through upregulation of the CCNE2 gene is 
associated with cancer (54). The commonly used micronuclei assay as a means 
to detect genotoxicity in cells also found that both bone marrow and peripheral 
blood cells displayed higher levels of micronuclei in rats treated with 15mg/kg a 
day for 60 days (55). 
 
1.2.3.4 Itai-Itai disease and associated bone defects 
The first observed symptom of cadmium toxicity was in 1960’s Japan, in the 
form of “Itai-Itai” (ouch-ouch) disease. A river was heavily polluted by mining 
slag, causing heavy metal pollution in the water, contaminating the crops with 
high levels of cadmium (56). This disease consists of renal dysfunction, severe 
bone pain and osteomalacia and osteopathy (57). Cadmium affects bone 
mineral metabolism in rats given a continuous dose of cadmium in drinking 
water, with calcium uptake in the intestines being negatively affected compared 
to untreated rats (58).  
 
1.2.3.4.1 Reproductive dysfunction 
Cadmium is known to interfere with hormonal functioning through binding both 
the nuclear and membrane bound receptor for oestrogen (59). In animal 
models, cadmium exposure elicits several detrimental effects to reproductive 
function (60). There is evidence to show testicular necrosis, failure of 
spermatozoa maturation, failure of oocyte maturation, and failure of oocyte 
implantation (60). Interestingly cadmium is stored in the testis of rats treated 
subcutaneously with cadmium daily over 6 weeks, reducing numbers of 
32 
 
spermatocytes compared to untreated rats (61). Human sperm have statistically 
significantly reduced motility when treated with cadmium  as well as playing a 
role in impaired embryonic development in fertilised embryos (62). This 
evidence has been used to suggest cadmium as a cause for male infertility in 
certain parts of the world where high levels of exposure are common (63, 64). 
 
1.2.4 Concluding remarks 
Taken together, it can be concluded that cadmium has a highly detrimental 
effect on the human body. Through both cytotoxic and genotoxic means, 
cadmium exposure can cause or contribute to diseases that require substantial 
healthcare intervention. Cadmium causes disease pathologies that have been 
typically associated with smoking, and given the high affinity of the tobacco 
plant for Cadmium sequestration, it poses the question: how many pathologies 
caused by smoking are due to cadmium exposure? (37, 65) 
 
1.3 The immune system 
The immune system is essential for protection against microbial threats that 
could pose a problem for general physiological functioning. It consists of a 
variety of cells derived from different sites in the body that elicit different 
antimicrobial functions based on cell type. Each cell releases cytokines: 
signalling molecules which elicit a variety of functions based on the cell to which 
they bind. The immune system is broadly subdivided into two components: the 
innate and adaptive immune system. The innate immune system represents an 
evolutionarily conserved system that recognises pathogens via general 
recognition receptors and subsequently attempts to kill them upon activation. 
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This component alone does not resolve all infections, as not all pathogens may 
be recognised and killed at a rate that exceeds the rate at which they multiply. 
Alongside the innate immune system, the adaptive immune system works 
concurrently behind the scenes to generate antibodies that bind to pathogens 
and aid the innate system in resolving the infection. Each immune cell 
expresses a variety of surface proteins, called Cluster of Differentiation markers 
(CD). Each subclass of cell has different levels of expression of these markers, 
which makes identification based on these rather simple. A summary of each 
immune cell and how its’ lineage is derived can be seen in Figure 1.3. 
1.3.1 Cells of the innate immune system 
The innate immune system presents the first line of cell-mediated defence upon 
infection of the host body. These cells are capable of activating through 
receptors which recognise both pathogen associated molecular patterns and 
damage associated molecular patterns. This class of receptors are called toll-
like receptors, which consist of ten members (TLR1-10) in humans. These 
receptors each recognise specific components (TLR4, for example, recognises 
lipopolysaccharide from gram-negative bacteria, whereas TLR2 recognises 
peptidoglycan found in gram-positive bacteria.) The variety of stimulatory 
antigens that activate this class of receptors is vast so that the cells can 
respond immediately to a plethora of stimuli and initiate an immune response as 
quickly as possible before substantial damage can be inflicted (66). 
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Figure 1-3: An overview of the lineages of hematopoietic stem cells and 
how each immune cell is generated.  
  
 
  
35 
 
1.3.1.1 Granulocytes 
Granulocytes are a family of cells that are characterised by the presence of 
granules in their cytoplasm. Granules act as a repository for various cytokines 
and other immune mediators. The family of granulocytes includes four cells: 
basophils, mast cells, eosinophils and neutrophils. 
 
1.3.2 Neutrophils 
Neutrophils are the most abundant immune cell in the body. They are short 
lived cells, lasting roughly 16-24 hours in the body (67). Neutrophils circulate in 
the blood patrolling every aspect of the body and respond rapidly to threats. 
They are similar to macrophages in that both cells elicit their primary function 
through phagocytosis and the subsequent respiratory burst.  
1.3.2.1 Life cycle 
Neutrophils are derived from myeloid progenitor cells in the bone marrow at a 
rate of roughly 1011 cells per day (68).This can be even further increased during 
time of infection where cytokines influencing production are actively being 
produced. After production, neutrophils are stored in the bone marrow awaiting 
a stimulus in the form of a chemoattractant to induce release (68). 
Once circulating, upon exposure to proinflammatory cytokines such as tumour 
necrosis factor-α, neutrophils become primed. Primed neutrophils are thought to 
have an enhanced capacity for functionality, with unprimed neutrophils 
possessing only a fraction of the antimicrobial potential (69, 70). This process is 
also thought to increase longevity of neutrophils, in order to prolong the activity 
of cells at sites of inflammation (70). Research suggests that neutrophils are 
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capable of de-priming upon resolution of inflammation through movement in the 
lung capillary bed (71, 72). 
Once an infection has been resolved and stimulatory signals are no longer 
causing the cells to be activated, neutrophils enter an apoptotic state. During 
this state it upregulates the chemokine receptor CXCR4 so that there is 
increased responsiveness to CXCL12, a chemokine that directs neutrophils to 
migrate to the bone marrow or spleen in order to undergo apoptosis (73). 
Alternatively, apoptotic neutrophils may also remain at the site of infection and 
undergo cell death which is thought to exert anti-inflammatory effects which in 
turn switch macrophages into a phenotype that seeks to resolve inflammation 
(74). Once the process of neutrophil apoptosis has completed, the cellular 
remnants are then phagocytosed by the resident macrophages.  
1.3.2.2 Phagocytosis 
The process of phagocytosis is performed by neutrophils, macrophages and 
dendritic cells, and is outlined in Figure 1.4. As previously mentioned, innate 
immune cells have various pattern recognition receptors such as toll-like 
receptor-4, which recognises bacterial lipopolysaccharide however, in most 
cases, pathogen recognition is facilitated by opsonins such as immunoglobulins 
and complement proteins. 
The receptors for immunoglobulin G on neutrophils are the FcγR family, 
receptors FcγRI-III. FcγRII (CD32) and FcγRIII (CD16) are constantly 
expressed on neutrophil surfaces, whereas FcγRI (CD64) is found on 
monocytes (75). FcRγI is only expressed on neutrophils after they have been 
activated, indicating signs of infection.  
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Figure 1-4 A summary of the process of phagocytosis.  
1) The neutrophil encounters a pathogen and is activated through pattern 
recognition receptors, or opsonising agents. 2) The cytoskeleton surrounds the 
pathogen. 3) The pathogen is then encased in a membrane termed the 
phagosome. 4) Vesicles of highly antimicrobial compounds in the lysosome are 
trafficked towards the phagosome. 5) The fusion of the lysosome and 
phagosome forms the phagolysosome, and the antimicrobial compounds, in 
addition to production of reactive oxygen species result in pathogen lysis. 6) 
The contents of the phagolysosome are digested, and undigested components 
are released into the extracellular space. 
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The receptor for IgA, FcαR elicits a similar response to FcγR receptors, though 
IgA is unable to activate the classical pathway of the complement system, 
unlike IgG (75). Complement protein C3b binds to the CR3 receptor on 
neutrophils in order to trigger the same response as Igs. Toll-Like receptors 
(TLRs) may also be used for pathogen recognition, with each TLR recognising a 
particular form of pathogen associated molecular pattern. 
In order for Ig-opsonised pathogens to initiate the process of pathogen 
engulfment, the antibody must activate both FcγRII and FcγRIII in neutrophils 
(76). These receptors contain immunoreceptor tyrosine-based activation motifs 
(ITAMs), which, when activated are phosphorylated by the Src-family kinases. 
Phosphorylated ITAM then activates the Syk-family kinases (77). The Syk-
kinases in turn phosphorylate SLP-76, which recruits Vav and ADAP, resulting 
in actin cytoskeletal reorganisation, allowing the cell to engulf the pathogen 
(78). 
After engulfment of the pathogen, compartmentalisation occurs, forming the 
phagosome organelle. A lysosome containing digestive enzymes and ROS 
moves in the cytoplasm to fuse with the phagosome. Here, the phagolysosome 
forms and the contained organism is subjected to a variety of products that 
facilitate its lysis and degradation. The components of the phagolysosome than 
can be digested are absorbed by the neutrophil, and the components in the 
residual body that remain are released via exocytosis. 
In the context of antigen presenting cells, rather than ejecting debris out of the 
cell, it may be processed into antigens and packaged with MHCII in order to 
present the organism components as antigens in order to facilitate antibody 
development. Lipid antigens such as mycobacterial cell wall components, may 
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also be presented by the CD1 marker, to provide an additional means of 
activating T-cells.  
 
1.3.2.3 Respiratory burst 
As stated in the process of phagocytosis, the predominant mechanism through 
which organisms are killed is via generation of reactive oxygen species, in a 
process termed the respiratory (or superoxide) burst. It is mediated by the 
enzyme NADPH oxidase, a multi-subunit protein complex. This complex is 
assembled upon cell activation, where phosphorylation-mediated activation of 
the cytosolic proteins, 40, 46 and 47 causes them to translocate to B 
cytochrome (p22 and p67 subunits)-containing membranes (79-81). Once the 
complex is assembled, the following reaction takes place: 
2 O2 +NADPH → 2 O2- + NADPH+ + H+ 
This alone does not provide sufficient antimicrobial activity, though serves as a 
precursor molecule for several ROS (79, 82). The oxygen radicals are then 
paired with hydrogen H+ ions to form the intermediate complex of hydrogen 
peroxide, H2O2. This intermediate is then used as a substrate for the enzyme 
myeloperoxidase (MPO), which is used in generation of hypochlorous acid. 
Chloride ions are the most common substrate used in MPO-mediated reactions 
as Cl- is highly concentrated in bodily fluids (83). Hypochlorous acid is a highly 
antimicrobial molecule that can create chloramines as an additional mechanism 
that may kill pathogens. Hydrogen peroxide may also be used as a substrate for 
the Fenton reaction. This reaction involves the oxidation of Fe2+ ions to produce 
hydroxyl radicals (84). These radicals are highly reactive and oxidise proteins of 
bacterial cell walls. 
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In the process of phagocytosis, the NADPH oxidase complex is formed on the 
membrane on the phagolysosome, resulting in the environment becoming a 
highly destructive and reactive zone through which pathogen lysis is achieved. 
The NADPH complex is also found on the membrane of phagocytes, allowing 
ROS to be released into the extracellular space in order to kill pathogens that 
have not yet been internalised (81). Unfortunately, the extracellular release 
presents a problem in that the ROS are then free to damage the surrounding 
area, which may kill local cells (83). Cells attempt to protect themselves from 
damage by upregulating cellular glutathione, though this is insufficient to protect 
the cells from apoptosis and necrosis if sufficient extracellular concentrations of 
ROS are produced (85). 
 
1.3.2.4 Antimicrobial function through granule contents 
In addition to phagocytosis and the respiratory burst, neutrophils contain potent 
antimicrobial proteins contained in the granules. Granules may be divided into 
several categories based on granular contents: primary, secondary and tertiary 
granules (86). Primary granules contain high levels of MPO, cathepsin G and 
various serine proteases(86). Secondary and tertiary granules, often referred to 
as peroxidase-negative granules, contain high levels of lactoferrin and matrix 
metallopeptidase-9 – MMP9 (also referred to as gelatinase B) though may 
exhibit a highly heterogeneous nature (87, 88). 
Lactoferrin functions through chelation of Fe3+ ions produced through the 
Fenton reaction, so the free ions are unable to be metabolised by bacteria in 
order to reproduce (89). It also binds to bacterial membranes through binding to 
lipopolysaccharide (LPS), an abundantly expressed bacterial cell wall sugar 
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found in gram-negative bacteria (89). MMP9 is part of the matrix 
metalloproteinase family of enzymes that act on membrane proteins of cells or 
the extracellular matrix (90, 91). MMP9 is used to neutralise serine protease 
that may degrade the enzyme neutrophil elastase (NE). 
Neutrophil elastase is an enzyme also stored in the primary granules of 
neutrophils. This enzyme works in tandem with ROS in the phagolysosome, 
though may be released additionally into the extracellular space during 
inflammation and infection. In the extracellular space, NE catalyses the 
breakdown of extracellular matrix components, in addition to structural proteins 
such as elastin, laminin and collagens (92). The remodelling of the extracellular 
matrix through NE activity aids the immune system in directing cells to the site 
of infection (93). It has also been found to kill bacteria through cleaving bacterial 
membrane proteins, as well as playing a large role in the formation of neutrophil 
extracellular traps (NETs) (94). 
 
1.3.2.5 Antigen presenting cells 
Antigen presenting cells circulate in the body, internalising molecules. Upon 
ingestion of pathogens, the bacterial debris is presented as an antigen on the 
MHCII. Macrophages, dendritic cells and B cells are all classed as antigen 
presenting cells. These cells Dendritic cells, in particular, act as a bridge linking 
innate and adaptive immunity. Following stimulation, and upon internalising a 
pathogen, dendritic cells travel to the lymph nodes to activate T cells and initiate 
the adaptive response, as outlined below.  
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1.3.3 Cells of the adaptive immune system 
1.3.3.1 T lymphocytes 
T lymphocytes develop in the thymus, though before they can leave the thymus 
and enter lymph nodes around the body, the T-cell is tested for binding affinity 
against self-proteins in order to prevent self-reactivity (95). Accompanying this, 
is expression of two key surface molecules, CD4 and CD8. The key defining 
characteristic of T-cells is the presence of the T-Cell Receptor (TCR) (96). This 
receptor is crucial to T-cell activation, and the interaction between the TCR and 
the major histocompatibility complex (MHC) determines the cell fate (Figure 
1.5). When the TCR on T cells interacts with MHC class II, it sheds the CD8 
surface marker and undergoes maturation and develops into a T-helper cell. 
Alternatively, if the TCR interacts with the MHC class I, the cell sheds the CD4 
receptor, maturing into a cytotoxic T lymphocyte (CTL) (97). 
T-helper cells can be further separated into predominantly two subtypes, Th1 
and Th2 cells. Other variants of T helper cells include Th17 cells and T-
regulatory cells. Th1 cells are principally involved in enhancing cell-mediated 
immunity, which involves enhancement of phagocyte and cytotoxic T-
lymphocyte function. Contrastingly, Th2 are involved in stimulating antibody-
producing cells and supressing certain functions of phagocytic cells (98). These 
cells both share similarities in that without these cells, widespread activation of 
the immune system could not take place. 
To dampen the immune response after resolution of bouts of inflammation, T-
regulatory cells inhibit the function of T helper cells to prevent further stimulatory 
signals for the rest of the immune system. CTLs are involved in cell-killing 
functions.  
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Figure 1-5 A summary of the process of T and B-cell activation.  
1) Antigen presenting cells express the component of an antigen via the major 
histocompatibility complex surface protein. Naïve T-cells interact with this MHC 
with the T-cell receptor and activation occurs based on the MHC interaction. 
MHCI is expressed on all nucleated cells, and the MHCI-TCR complex induces 
generation of CD8+ cytotoxic T lymphocytes. MHCII is expressed on 
macrophages, dendritic cells and B-cells and the MHCII-TCR complex induces 
CD4+ T-helper cell generation. 2) T-helper cells present antigens via CD40-L to 
naïve B-cells via the CD40 marker and drive the generation of plasma cells that 
produce antibodies to the antigens. Upon successful generation of high-binding 
immunoglobulin, a B-memory cell is produced in addition to large quantities of 
plasma cells. B-memory cells provide a means to rapidly expand into antibody-
releasing plasma cells upon re-exposure to the previously encountered antigen. 
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The majority of this killing is reserved to recognising and killing cancer cells, 
though in cases of viral infection, cells overexpress MHCI containing viral 
antigens, marking them for identification and death by CTLs (99). 
1.3.3.2 B Lymphocytes 
B-lymphocytes are generated in the bone marrow. Upon differentiation, B-cell 
fate can be predominantly B-memory cells, or plasma cells. The role of B-cells 
in the body centres on production of a crucial family of proteins: antibodies. This 
antigen is then internalised and displayed on the surface of the immature B-cell 
through the MHCII (100). Here, B cells attempt to synthesise antibodies 
greatest binding affinity for the antigen in question through somatic 
hypermutation (101). Once successful, the-B cell in question proliferates 
massively into plasma cells and enters the circulation.  
A copy of the B-cell is retained in the form of a long-lived B-memory cell, 
retaining the BCR with the high affinity for the antigen, ensuring that upon 
encountering the antigen once more, a more rapid adaptive immune response 
occurs. 
 
1.3.3.3 Antibodies 
Antibodies are one of the most abundant family of proteins in the body. They 
are glycoproteins consisting of two heavy chains and two light chains linked by 
a S-S disulphide bridge (102).  
Each immunoglobulin is composed of a constant and variable region (Fc and 
Fab). The Fc region is responsible for interaction with complement proteins and 
docking with Fc receptors. The Fab region is the antigen-binding region. An 
antibody molecule has two binding sites, given the Y-shaped structure of the 
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molecule. There are five classes of antibody: IgG, IgM, IgA, IgD and IgE. IgG is 
by far the most abundant class of antibody in serum (~12mg/ml), followed by 
IgA (~3mg/ml), IgM (~1.5mg/ml), and trace amounts of IgE and IgD (102). IgM 
is the first class of antibody produced in the early stages of an immune 
response due to the high avidity, though weak affinity for antigens.  
IgG is a monomeric molecule with the greatest binding affinity for antigens, 
produced from immune system activation as described above. There are 4 
subclasses of IgG (IgG1-4). IgG1 is the main subclass, produced in response to 
membrane proteins and soluble protein antigens (103). IgG2 is produced in 
response to bacterial polysaccharides, IgG3 is a potent proinflammatory 
antibody compared to other subtypes and IgG4 is produced in response to long 
term non-antigen stimuli (103).  IgA is typically found in mucosal regions of the 
body, meaning it will be the first line of defence in most points of entry for the 
human body.  
Immunoglobulins can perform multiple functions in the body. IgA is thought to 
cause aggregation of pathogens to allow mucous to trap them, in order to 
prevent further entry into the body (104). The action of antibodies binding 
surface antigens may also prevent entry of viruses and other pathogens by 
neutralising the proteins that facilitate infiltration into host cells (105). 
Additionally, by binding the surface of the pathogen, complement activation 
through the classical pathway occurs, resulting in pathogen death through 
formation of the membrane attack complex (106). IgG and IgM are particularly 
strong activators of the complement system.  Finally, and most commonly, 
antibodies act as opsonising agents. Opsonisation is the process of tagging an 
organism with multiple antibodies, to allow phagocytic cells to bind the Fc region 
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of an immunoglobulin and engulf the bound organism by the process of 
phagocytosis (107). 
 
1.3.3.4 Neutrophil extracellular traps 
Discovered in 2004 by Brinkmann and colleagues, NETs presented a novel 
death mechanism through which neutrophils were able to respond to pathogens 
(108). Neutrophils when exposed to immunostimulatory compounds were found 
to release fibres into the extracellular space that were composed of nuclear 
material that were able to ensnare and subsequently kill bacteria. In brief, the 
process of NETosis involves bonds between histone proteins in the nucleus 
becoming weakened, followed by chromatin relaxation. The unwound chromatin 
is then packaged with antimicrobial proteins in the cytosol, and then released 
from the nucleus into the extracellular space. It is activated by pathogenic 
stimuli such as LPS and is mediated by multiple enzymes. Since this discovery, 
NETosis has received considerable attention, with many questioning the 
literature regarding the authenticity of data, in addition to the mechanisms that 
underpin activation of the process (109-114). An overview of the process of 
NETosis, how it is activated, signalling pathways and the outcomes of the 
process are shown in Figure 1.6. 
 
1.3.3.4.1 Function of NETs 
Neutrophil extracellular traps are an antimicrobial mechanism that is exerted 
when a pathogen is resistant to phagocytosis due to size or resistance. NETs 
have been found to contain MPO and NE and defensins, providing a 
mechanism through which extracellular killing may be achieved.  
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 Figure 1-6 An overview of the process of NETosis.  
NETosis can be induced through various molecules such as phorbol 12-myristate 13-
acetate, lipopolysaccaride, heparin/platelet factor 4 antigenic complexes or interleukin-
8 by various immune cells, generally neutrophils but also lymphocytes and 
macrophages. These molecules bind to their respective receptors and induce activation 
of PI3K/Akt pathways, protein kinase C activation, and increases in cytosolic calcium 
levels. These all result in formation of the NADPH oxidase complex, resulting in 
production of reactive oxygen species. This triggers degranulation and release of 
myeloperoxidase and neutrophil elastase into the cytoplasm. Increases in calcium level 
also lead to activation of cytosolic peptidylarginine deiminase-4. Here, MPO, NE and 
PAD translocate to the nucleus and weaken chromatin-histone bonds. These chromatin 
fibres are then repackaged with MPO, PAD and NE and released extracellularly, to aid 
in antimicrobial activity.  
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As DNA is highly sticky in nature, pathogens may be trapped in the web of DNA 
and subsequently killed by the proteins adsorbed to it (115). 
1.3.3.4.2 NETosis induction pathways 
In vitro, the only stimulus that consistently activates the process of NETosis is 
the protein kinase C activating, diacylglycerol mimetic Phorbol 12-myristate 13-
acetate (PMA). NETosis has been observed in neutrophils treated with PMA 
concentrations as low as 4nM, though most research uses concentrations 
between 25-100nM (113, 116-119). This is most often used as a positive control 
for NETosis experiments when testing against other agonists. 
Lipopolysaccharide and Interleukin-8 (IL-8) were the first biological agonists 
tested by Brinkmann and colleagues, initially suggesting this process as a 
means to degrade bacterial virulence factors (108). These results have been 
corroborated by other groups, suggesting that NETosis can be directly induced 
from not just bacterial extracellular stimuli, but also as a response to endothelial 
cell stress whereby IL-8 is released (120-122). Further research into cytokine-
mediated NETosis reports that TNF-α and IL1β are capable of inducing 
NETosis, though various levels of success are reported (113). Of most 
importance, is that cigarette smoke has recently been shown to induce 
NETosis, of which cadmium is a substantial contaminant (123). 
 
1.3.3.4.3 Types of NETosis 
Although NETosis was first observed as a death mechanism separate to 
apoptosis, autophagy or necrosis, it appears that this mechanism can be further 
stratified into different strands of outcome. 
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1.3.3.4.3.1 Suicidal NETosis 
The classical form of NETosis has been dubbed “Suicidal” in that the fate of 
cells that undergo this process is death. Fuchs and colleagues confirmed 
Brinkmann’s findings of NETosis being a form of cell death by observing several 
steps before nuclear fibres were protruded out of the cell (121). After PMA 
stimulation, chromatin decondensation was preceded by nuclear envelope 
disintegration. This nuclear material was then found to be mixed with granule 
proteins in a vacuole-like organelle in the cytoplasm, before being expelled out 
of the cell (109). This process was found to take 3-4 hours before completion, 
suggesting cell death, given that bacterial-induced apoptosis in neutrophils has 
been observed to take roughly 2 hours (124).  Yipp and Kubes make the point 
that suicidal NETosis seems counter-intuitive, as a mechanism that actively 
promotes cell death at the cost of cessation of other neutrophil antimicrobial 
activity seems redundant (109). They present a counterargument that when 
bacteria such as S. aureus produce toxins that can induce neutrophil cell death 
over a similar time frame, the process of suicidal NETosis may serve as a 
cellular kamikaze to ensnare bacteria that kill the NETing neutrophil, in the hope 
that another cell may be able to kill them (109). 
 
1.3.3.4.3.2 Vital NETosis 
Vital NETosis however, presents the idea of NET release without compromising 
the neutrophil’s ability to perform other antimicrobial functions. It has been 
suggested that NET-producing cells may be a subset of neutrophils, as 
neutrophils undergoing NETosis after having ingested bacteria would simply 
release the encapsulated bacterium back into the extracellular space. As NETs 
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are reported to occur in 20-25% of neutrophils, the hypothesis of this “NET 
positive” subset of cells may have some grounding (109). 
Clark et al. found a population of neutrophils that released NETs, as confirmed 
by the extracellular, membrane impermeable dye SYTOX green when treated 
with LPS (125). Interestingly, the neutrophils did not uptake the dye, providing 
evidence that membrane integrity was not compromised in this instance. This is 
thought to be the first evidence of “Vital” NETosis. Of note is the rapid induction 
of this process (5 minutes), compared to the findings that the process is thought 
to take 3-4 hours. 
Pilsczek and colleagues further corroborated this finding of NETosis induction 
upon treatment of neutrophils with S. aureus within a 60 minute window (126). 
This could be explained from the nature of which NETosis is induced. Suicidal 
NETosis has historically been observed from treatment of neutrophils with PMA. 
Given that PMA induces cell death in neutrophils, vital NETosis may occur 
through a more rapid signalling pathway (127). Fungal carbohydrates and 
proteins also induce NETosis in a short timeframe. The C.albicans derived cell 
wall component β-glucan were found to produce fast-response NETosis similar 
to those previously reported above (128). 
In all cases, the authors highlighted this process being reactive oxygen species 
independent, stating this could be the explanation for the short window before 
NET release. The common ground between the works of Clark et al., Pilsczek 
et al. and Byrd et al. is the receptor to which these stimuli bind. Toll like 
receptors 2 and 4 are shown to be involved in fungal host responses, not just 
bacterial, suggesting that this could be the shared signalling route for vital 
NETosis (129). It may well be that TLR2/4 signalling activates NET signalling 
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pathways much faster than other stimuli and would make sense given that the 
immune system is required to respond to pathogenic stimuli as fast as possible 
in order to eliminate threats. 
 
1.3.3.5 Signalling mechanisms underpinning NET formation 
As previously stated, NETosis has been observed through TLR4 signalling, 
PKC activation, resulting in NADPH oxidase activation. This section will 
summarise the various intracellular systems in place based on existing 
knowledge of these activation pathways, and how NETosis is activated through 
them. 
PKC activation is shown to potently induce NETosis. Protein kinase C is a 
family of 12 kinases that are involved in cellular responses from a variety of 
agonists. Typically, PKC is activated by diacylglycerol production due to 
hydrolysis of the inositol phospholipids PIP2 and phosphitdylcholine in response 
to extracellular signals (130-132). This hydrolysis also raises levels of Ca2+ to a 
sufficient level that allows these ions to bind to the inactive C2 domain of PKC, 
in addition to DAG binding the C1 domain of the enzyme (133). The binding of 
calcium to the C2 domain causes a confirmation change in the C2 site opening 
up phospholipid binding site of the enzyme (133). The chelation of Ca2+ by the 
C2 domain changes the nature of the protein from repelling phospholipids, to 
becoming attracted to them, causing rapid translocation of PKC to the 
phospholipid membrane (134, 135). From here, PKC is cleaved and released 
into the cytosol in an active form (136). Nauseef et al. found that PMA treatment 
in neutrophils caused phosphorylation of the p47 and p67 subunits, resulting in 
association with b cyt, forming the NADPH oxidase complex (137). PKC-
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mediated p47phox translocation to the membrane has been further confirmed by 
Dang and colleagues, further explaining the mechanism through which PKC 
facilitates NADPH oxidase formation (138). 
Superoxide produced via the respiratory burst is then able to generate high 
levels of anionic charge, which compensated by increase in intracellular K+ ions. 
These rapid shifts in ionic charge lead to release of NE and cathepsin G (139). 
In addition to degranulation, superoxide generation and neutrophil activation 
cause calcium release from the endoplasmic reticulum, as well as from 
extracellular sources, creating a high calcium ion environment in the neutrophil 
cytoplasm (140). 
Work by Gray and colleagues found no sign of NETosis upon blocking of 
NADPH oxidase or protein kinase C with various inhibitors for either enzyme 
(141). The only agonist that neutrophils were treated with, however, was PMA. 
Phorbol esters degrade at a much slower rate than diacylglycerol, as well as 
forming irreversible membrane-bound forms of PKC that result in long term 
activation compared to DAG (142). This then poses the question… how 
biologically relevant is PKC activation in NETosis? 
The PI3K/Akt pathway is crucial in induction of NETosis. DeSouza-Vieira and 
colleagues have demonstrated that inhibition of PI3K subunits PI3Kγ and 
PI3Kδ, as well as downstream activation of ERK from PI3Kγ resulted in reduced 
levels of NETosis (143). 
The pathway itself is activated through a vast array of stimuli, though in terms of 
relevance to NETosis, the toll-like receptors activate this pathway (144). Upon 
LPS binding to TLR2 and 4, receptor dimerization occurs, recruiting Toll-IL-1 
resistance domain-containing adapter protein (TIRAP) by binding to PIP2 (145). 
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TIRAP then anchors in the membrane, signalling MyD88 to be recruited from 
the cytosol to the TLR complex. Laird et al. found that MyD88 then facilitates 
the interaction of PI3K with the TLR complex (145). Class I PI3K kinases are 
kinases consisting of two subunits: p85, used to bind to proteins, and p110, 
used to phosphorylated phosphoinositol lipids (146). The p110 subunit on PI3K 
is then brought into close proximity of PIP2, causing phosphorylation into PIP3, 
phosphorylating phosphoinositide-dependent protein kinase 1, in turn 
phosphorylating Akt (145). The primary target of Akt is the mammalian target of 
rapamycin, or MTOR. McInturff et al. has shown MTOR as a mediator of 
NETosis through regulation of the hypoxia-inducible factor 1α (HIF- 1α) pathway 
(147). LPS induces activation of the HIF pathway, even in the absence of 
hypoxia, the condition through which this pathway is typically triggered (148). In 
the study of McInturff et al, HIF-1α was genetically knocked out in HL-60 
leucocytes, and found to result in severely reduced levels of NET formation 
compared to wild-type cells (147). Additionally, this group was the first group to 
show regulation of HIF-1α by mTOR in neutrophils. Unfortunately, a mechanistic 
means through which the HIF- 1α regulates NETosis remains unclear. 
Reports of Raf/MEK/ERK pathway activation have been reported, though this 
may serve to inhibit apoptosis in order for NETosis to proceed through NADPH 
oxidase activation (149, 150). Douda et al. have also shown a protective effect 
of Akt activation by diverting cells from apoptosis towards NETosis (151). 
Autophagy has been reported several times in being required for NETosis (112, 
121). The observations of vital NETosis by Fuchs et al. noted large vacuole 
formation after stimulation before membrane rupture and DNA release (121). 
These vacuoles were found to be autophagosomes at various stages of 
maturation (112). The size of the autophagosomes have been suggested to be 
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produced from the endoplasmic reticulum, with this loss of integrity further 
contributed to increased Ca2+ levels in the cytosol as a result of leakage in the 
endoplasmic reticulum (112). 
 
1.3.3.6 Mechanisms of NET formation 
As stated above, the key events regarding NETosis involve increase in Ca2+ 
levels and release of granule proteins. The point of convergence can be 
focused on activation of three key enzymes: myeloperoxidase, neutrophil 
elastase and peptidylarginine deiminase (PAD). 
 
1.3.3.6.1 The role of myeloperoxidase in NETosis 
Myeloperoxidase is stored in primary neutrophil granules. Upon neutrophil 
activation, MPO is released and enters the cytosol, primarily functioning to 
generate reactive oxygen species in reactions mentioned previously. Chemical 
inhibition of MPO through use of 4-aminobenzoic acid hydrazide has been 
reported to result in lack of NETosis (152).This has been further corroborated in 
patients completely lacking MPO, failing to make NETs in response to stimuli, 
though patients with MPO deficiency still produced NETs, but in a reduced 
capacity (117). 
Papayannopoulos et al. has provided the greatest insight into the role of MPO in 
facilitating NETosis (153). Upon release from the granules into the cytoplasm, 
MPO translocates to the nucleus where it digests histones and binds to 
chromatin. Once bound, MPO facilitates substantial chromatin relaxation, 
resulting in decondensation of the fibres before forming NETs (153). 
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Interestingly, neutrophils stimulated with live pathogens did not require MPO in 
order to undergo NETosis, though this could be linked to the type of NETosis 
triggered (154). Bacterially induced NETosis appears to act independently of 
NADPH oxidase and given the intimate relationship between NADPH oxidase 
and MPO, it would make sense for this enzyme to partake in NADPH oxidase-
independent NETosis. 
MPO is also found extracellularly localised in NETs, and as such is used as a 
detection marker alongside DNA in immunofluorescence studies to confirm the 
presence of NETs. 
 
1.3.3.6.2 The role of neutrophil elastase (NE) in NETosis 
The role of NE in NETosis is not dissimilar to the role of MPO. Degranulation as 
a result of ROS production triggers the release of granular proteins (153). 
Similarly to MPO, NE translocates to the nucleus from the cytoplasm during 
NETosis in a ROS-dependent pathway. Papayannopoulos et al. used the NE 
inhibitors GW311616A and serum leucocyte protease inhibitor to inactivate NE 
and observe and changes in levels of NET production (153). The study found 
that histone H4 was degraded by NE, not H3, which is typically found to be 
altered during NETosis (155). NE fully degraded H4, compared to other 
histones which were only partially degraded (153). The authors concluded that 
chromatin structure had an influence on the pattern of histone degradation, 
though whereas MPO facilitates chromatin decondensation, the role of NE 
appears to be involved in histone degradation (153). 
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1.3.3.6.3 The role of peptidylarginine deiminase in NETosis 
Peptidylarginine deiminases are a family of enzymes of which there 5 isotypes: 
PAD1, 2 3, 4 and 6 (156). The function of these enzymes is to convert the 
amino acid arginine it’s a citrulline residue on proteins. This subtle change has a 
profound effect on the function of the protein. The deimination reaction 
neutralises the positive charge of arginine, into a neutral residue that serves to 
alter the tertiary structure of the protein (157). This change may affect protein-
protein, protein-DNA and protein-RNA interactions.  PAD4 has a nuclear 
transfer signal, allowing PAD to translocate from the cytosol to the nucleus and 
participate in gene regulation  (158). Interestingly, PAD4 is integral to the 
process of NET induction, though appears to play no other role in general 
neutrophil function (118, 159). PAD4 is the most prevalent PAD isoform present 
in neutrophils and is involved in NET formation (160, 161). PAD4 is activated 
through exposure to high levels of cytosolic calcium, in the region of 100 times 
greater concentration than the normal resting Ca2+ cytosolic levels of ~ 100 nM  
(162). Interestingly, regulation of this enzyme was found by Neeli to be 
mediated by two isoforms of PKC, PKCζ activating PAD, and PKCα inhibiting it 
(163).  During neutrophil activation in response to stimuli via pathways 
previously described, the calcium level in the cytosol rises to substantial levels, 
triggering the adequate levels for PAD activation. Upon activation, PAD4 was 
found by Liu et al. to form a dimer, considered to be the active form of the 
enzyme. The monomer elicits ~ 25-50% of the activity of its’ dimer counterpart 
(164). 
Upon translocation to the nucleus, PAD citrullinates the arginine residues on 
histones, weakening the bonds between chromatin fibres and the histones they 
are bound to (165). Neeli found the primary target of PAD4 in the nucleus to be 
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histone H3, and that citrullinated histone H3 is also present in NETs that are 
released into the extracellular space (165). As histones are found to be potently 
antimicrobial, Neeli proposes that the citrullinated variant may interfere with 
bacterial cell wall integrity (165, 166). 
Between the activity of MPO, NE and PAD4, this triad of enzymes appears to 
be the key regulators of NET induction, though recent controversial opinions 
have been proposed that PAD4 does not in fact induce NETosis but occurs by a 
separate independent mechanism termed:- “Histone hypercitrullination” (111). 
Konig and Andrade argue that citrullination of histones and subsequent DNA 
release is due to membranolytic damage, not NETosis (111). 
In conclusion, NETosis provides an additional weapon in the arsenal of 
neutrophils to kill pathogens. It is activated through a variety of means, and 
signals a plethora of intracellular pathways in order to achieve DNA release 
from the cell (167). 
There has been great interest with how this process pertains to autoimmunity 
pathology. Given the dual-functionality of some proteins implicated in pathway 
activation, these may carry a detrimental element in certain autoimmune 
diseases. Given the involvement of PAD and MPO in NETosis induction, one of 
the most relevant autoimmune diseases that is proposed to result from aberrant 
levels of NETosis activation is rheumatoid arthritis. 
 
1.4 Rheumatoid Arthritis 
Rheumatoid arthritis belongs to a group of diseases that share a common 
aetiology in that immune system dysfunction drives the disease pathology. This 
dysfunction occurs from a breakdown in immune tolerance, the mechanism 
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through which the host immune system is programmed to not mount a response 
to host antigens.  In RA, the joints of the victim are under continuous immune 
system attack, leading to degradation of the synovium due to prolonged 
inflammation in the joints. 
Unfortunately, like other autoimmune diseases, RA lacks a definitive causative 
element that results in disease onset, merely risk factors and associations.  Well 
established genetic factors are found to account for 50% of the risk factors for 
RA development (168). 
 
1.4.1.1 Epidemiology and risk factors 
Rheumatoid arthritis  occurs at a frequency  of 0.5-1% in the general population, 
with women being two to three times more likely to develop RA than men (169, 
170). The incidence of RA is  between 20 and 50 cases per 100,000 people in 
North America and Europe (171). Women on average develop RA around the 
age of 45, whereas men develop RA at a much older age, where the gap 
between the incidence of RA between men and women becomes more 
homogenous (F:M ratio of 4.84 at 40-49, to 1.65 at 70-79) (172). 
As women develop RA at a younger age than men, sex hormones are thought 
to play a role in the earlier age of onset. The contraceptive pill appears to 
protect against RA, which may suggest that it is the cycling levels of sex 
hormones, not the high levels of certain hormones themselves, that may drive 
RA pathology (173, 174). Oestrogen enhances humoral responses on cells, 
further driving the suggestion that women also have a stronger immune system 
than men (175). The paradoxical question then arises of why the contraceptive 
pill appears to protect against RA? The only answer appears to be that as 
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progesterone is capable of eliciting an immunosuppressive effect, that this 
balance of progesterone and oestrogen must weigh in favour of progesterone, 
ultimately reducing the activity of immune system in women (176, 177). 
Heritability is thought to be around 60%, and GWAS studies have shown over 
100 genetic loci that are associated with RA (178-180). The largest genetic risk 
factor for RA is the shared epitope (SE) allele. The ‘shared epitope’ is actually a 
series of peptides encoded for as part of the HLA DRB1 gene, and is part of the 
antigen binding groove of MHCII, suggesting that mutations in the SE may lead 
to a malfunction in antigen presentation (181-184).  
Other genetic risk factors in RA code for various enzymes and receptors in 
cells. A haplotype of the PADI4 gene, coding for the enzyme PAD4, has shown 
an increased risk for RA, as well as an association between the haplotype and 
antibodies to citrullinated proteins (185, 186). The protein tyrosine phosphatase 
non-receptor 22 gene (PTPN22) presents another important risk allele for RA, 
with polymorphisms of this gene resulting in an odds ratio of 1.6 for RA 
development (179) . PTPN22 is a negative regulator of the Src and Syk family 
kinases, which are required to internalise and reprocess antigens bound to 
antibodies upon Fc receptor binding (187). 
Two major environmental  non-genetic risk factors for RA are smoking and 
inhalation of dust particles, through occupational exposure or general air 
pollution (188). 
Smoking is a substantial risk factor for RA development (189). In a cohort of 
700 cases and 850 controls, ever smoking was considered to provide an 
increased risk for RA with an odds ratio of 1.7 (190). Furthermore, a positive 
correlation was found between pack years of cigarette smoking and  
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seropositivity in diagnostic tests for RA, which focus on measuring levels of 
autoantibodies in the blood (191). This is even more pronounced in heavy 
smokers, who are 3.1 times more likely to test positive for RA than never 
smokers (191, 192). 
 
1.4.1.2 Clinical presentation 
Compared to osteoarthritis, RA occurs symmetrically in the joints of the human 
body. Swelling of the joints is common, which often results in inability to fully 
move the inflamed joints (193). Early stages of RA typically involve the joints of 
the hands and feet, often undetectable by radiological scanning (193). The key 
features of early stages are characterised by the “Three Ss”: which are early 
morning stiffness of longer than 30 minutes, joint swelling in more than 3 joints, 
and tenderness upon squeezing (194). If these clinical features are present, 
referral to a specialist should be advised. In later stages of RA, the larger joint 
spaces (knee, shoulder and elbow) become infiltrated with inflammatory cells 
resulting in further synovitis. 
The consequences of RA are not restricted to joint inflammation. The constant 
activation of the immune system can affect the wellbeing of the patient through 
fatigue, fever and weight loss. Other organ systems may also be affected, with 
pulmonary involvement in RA usually manifesting as interstitial lung disease, 
with around 30% of RA patients reporting some form of lung disease as a co-
morbidity of RA development (195). 
Another hallmark of RA is development of rheumatoid nodules. These 
subcutaneous nodules are the most common feature of RA, but are  not 
involved in the joint pathology, typically appearing on the hand and arms (196) 
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and also in the lungs (197). Nodule formation appears to affect roughly 10% of 
RA patients, and although inconvenient, are not normally of concern for patient 
health. Paradoxically, methotrexate and possibly tumour necrosis factor 
inhibitors can increase nodule development and subcutaneous nodule formation 
has been linked to increased cardiovascular events in RA patients (198). 
Surprisingly, very little is known about the composition of these nodules or if 
they are a source of pro-inflammatory mediators. 
 
1.4.1.3 Testing for RA 
The criteria that is used to diagnose RA has been developed between the 
American College of Rheumatology and the European League Against 
Rheumatism to create Rheumatology 2010 rheumatoid arthritis Classification 
Criteria (199). This new framework serves to aid in early diagnosis, as prior 
criteria used to define RA by late-stage symptoms of the disease (199). This 
criteria assigns a score based on serology and physical examination results, to 
ultimately diagnose a patient with RA. 
C-reactive protein (CRP) is used as a measure of active inflammatory activity in 
RA. It is an acute-phase protein that is produced as a by-product of 
inflammation (200). CRP is thought to work similarly to antibodies, in that it is 
capable of binding to Fc receptors on innate cells, activating complement, and 
initiate proinflammatory cytokine release (201). The level of CRP is used to 
calculate the disease activity score, (DAS)28. DAS28 can also be calculated 
through measurement of erythrocyte sedimentation rate, though DAS28-CRP is 
thought to be the better tool as CRP is more sensitive to rapid changes in 
disease activity (202). Ultimately, both formulae use the serology from the 
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respective marker alongside feeling 28 joints of the body, to check if they are 
tender or swollen (202). 
The core hallmark of autoimmune diseases is the presence of autoantibodies. 
Each autoimmune disease typically has a characteristic autoantibody indicative 
of the disease. Importantly, the reasons why these autoantibodies are 
generated by plasma cells remains unknown, driving the need to understand 
why autoantigens are generated, in order to develop more efficient methods in 
early treatment of autoimmune disease. 
Anti-Citrullinated Protein Antibodies (ACPAs) are autoantibodies specific to RA. 
ACPAs are used to diagnose RA prognostically with varying levels of assay 
sensitivity and specificity through measurement of antibodies to cyclical 
citrullinated peptide (anti-CCP). Aggarwal et al. reviewed various commercially 
available anti-CCP assays , the sensitivity of  anti-CCP assays ranged from  56-
78%, and specificity between 87-99% (203). These antibodies can be detected 
in RA patients long before symptoms begin to appear, though these 
observations were discovered before the criteria was updated in 2010, therefore 
the observation of ACPAs up to 14 years before RA symptoms develop (204). 
The highly specific nature of ACPAs is important, as ruling out patients 
suspected of RA is integral, to prevent highly immunosuppressive and 
expensive therapies from being used on those that do not need it.  
The other diagnostic biomarker in RA is rheumatoid factor (RF). RF is an 
autoantibody immune complex, comprised of two immunoglobulins IgG and one 
other that can exist in three forms: IgM-RF, IgA-RF and IgG-RF, and exist in 
that level of prevalence, with the IgM-RF typically being the dominant complex 
in serum (205-207). RF is not restricted to RA pathology; it can also be used in 
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the diagnosis of systemic lupus erythematosus and primary Sjögren's syndrome 
(208, 209). It exists merely as tool to complement the other assays used in 
diagnosis of autoimmune disease, and as such has a sensitivity and specificity 
of 75% and 85%, respectively (210). 
More recently, anti-carbamylated protein antibodies (Anti-CarPs) have been 
identified in RA and show promise of a new biomarker in RA diagnosis (211, 
212). The sensitivity and specificity of Anti-CarPs is lower than ACPAs at 26-
44% and 89-95%, respectively (213, 214). Although the lower sensitivity of the 
assay does not make it suitable as a primary diagnostic assay. It may prove 
useful in RA patients who appear to be RF-negative and ACPA-negative due to 
its high specificity, and may prove useful as an additional tool in overall RA 
diagnosis and management. 
Autoantibodies to other proteins which may be citrullinated in RA have been 
detected in seronegative RA patients, such as citrullinated calreticulin (citCRT). 
Citrullinated calreticulin binds to the SE component of the MHCII as discussed 
in Section 1.4.1.1, resulting in immune system dysfunction (215). Anti-citCRT 
antibodies have been previously detected in 49% of patients with RA compared 
to 9% of patients who displayed antibodies to the unmodified form (216). 
Furthermore, it was demonstrated that anti-citCRT antibodies can capture 35% 
of a cohort of RF –ve ACPA –ve RA individuals, providing further promise in 
detection of this disease (216). 
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1.4.1.4 Pathophysiology 
RA develops in part as a result of multiple cell dysfunctions, with the central 
focus of this being a result of aberrant post-translational modifications: 
citrullination and carbamylation of cell proteins. A summary of how this process 
occurs can be shown in Figure 1.7. 
Anti-citrullinated protein antibodies (ACPA’s) have long been recognised as a 
key feature of RA. As mentioned earlier, citrullination is mediated by the PAD 
family of enzymes. The production of citrullinated proteins in RA pathology is 
well documented, but  PAD enzymes also play a role in NETosis (217-222).  
Citrullination is an irreversible process through which the amino acid arginine is 
replaced by citrulline on proteins. This change in residue negates the overall 
charge of the protein, leading to implications for overall protein structure, or 
possibly function (223). The large portion of ACPAs in RA are directed against 
abundant structural proteins such as fibrinogen and vimentin  (224, 225). 
Although ACPAs are seen as a biomarker of RA, their pathophysiological role is 
unclear. Although initially reported by Krishnamurthy et al. to initiate the 
inflammatory response in RA through osteoclast-mediated IL-8 release, the 
authors corrected their article years later to clarify that this was not the case, 
casting doubt on the role of ACPAs as a potential driving force in join 
inflammation (226, 227). Trouw et al. demonstrated the ability of ACPAs to 
activate complement system years before (228). The role of complement 
activation to antibodies typically results in immune complex clearance, though 
antibodies bound to tissue-bound antigens typically trigger the membrane attack 
complex and subsequent cell death, along with immune cell chemotaxis (229, 
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230). Taken altogether, this may suggest that ACPAs binding the 
aforementioned citrullinated structural proteins above in the joint could help 
facilitate and potentiate the inflammatory process through complement activity.  
Similarly to citrullination, carbamylation has recently been found to play a similar 
role in RA pathology, with anti-CarPs being detectable in similar levels to 
ACPAs in early RA patients (211, 212, 214).  Unlike ACPAs however, 
carbamylation is a chemical reaction principally between cyanate and lysine 
residues on proteins (231). Although the reaction is chemical, myeloperoxidase 
catalyses the reaction between thiocyanate (inhaled in cigarette smoke) and 
H2O2 to produce cyanate.  
When this level is raised during bouts of inflammation, the free cyanate is free 
to react with lysine to form carbamyl-lysine (232). This alters the function and 
structure of the protein, similarly to citrullination. 
Through citrullination and carbamylation, the host protein may be marked as a 
neo-antigen, in that the process creates a variant of the protein that the immune 
system has not raised tolerance against (221). During cell death the newly 
modified proteins produced in dying cells are released into the extracellular 
space. Here, they are recognised by innate cells as an antigenic molecule, 
prompting internalisation and processing and subsequent expression through 
MHCII. From here, dendritic cells present the antigen to the adaptive immune 
system, resulting in autoantibody generation. 
Carbamylation of vimentin induces autoantibody production by B-cells, as a 
result of cigarette smoke, though no association between smoking and positivity 
of anti-CarPs has been established to date (233). 
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Figure 1-7 A summary of the pathophysiology of Rheumatoid Arthritis.  
In RA, macrophages in the joint release proinflammatory cytokines that attract neutrophils and lymphocytes. Lymphocytes generate T-helper cells 
that increase activity of surrounding cells, and induce monocytes into macrophages or osteoclasts, which break down the bone tissue in the joint. 
Lymphocytes also generate plasma cells that release autoantibodies to structural proteins in cartilage, which result in an immune-directed attack 
from neutrophils and macrophages via production of reactive oxygen species. The loss of bone and cartilage causes fibroblast over-proliferation in 
the joint area, resulting in pannus formation and immobilisation of the joint. 
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In RF, Igs bind the Fc region of IgG in the CH2 domain, through mechanisms 
currently unknown (234). What is known in RA pathology however, is that these 
three autoantibody classes circulate in the body long before RA pathology 
begins, increasing slowly before joint damage occurs (235). The joint is 
relatively uninvolved in early stages of RA, suggesting that autoantibody 
development occurs at a site away from the synovium (236). 
The link between autoantibody development and the initial stages of synovial 
inflammation remains elusive (237). Multiple theories have been suggested, 
such as deposition of immune complexes in the physical spaces of the body, or 
epitope switching of autoantibodies resulting in the non-citrullinated targets in 
ACPAs being targeted (235). However, after the initial inflammation takes place, 
the end result is that the joints become a highly active inflammatory 
environment. 
The synovium consists of synovial fibroblasts, alongside synovial macrophages. 
In RA, rapid proliferation of fibroblasts occurs, to a density of 5x the normal 
thickness (238). These fibroblasts remain persistently activated, and release 
factors that degrade the surrounding cartilage in the joint (239). In the initial 
stages of RA, resident macrophages release the proinflammatory cytokines 
TNFα, IL-1 and IL-6 and attract other immune cells towards the joint  (240). This 
attracts neutrophil and lymphocytes towards the synovium in later stages of the 
disease (241). CD4+ cells are the most prevalent lymphocyte subtype in the RA 
joint, which further augment macrophage function and promote ROS production 
and joint degradation (242). CD4+ cells also stimulate B-cell proliferation and 
further drive plasma cell differentiation, which in turn produce more 
autoantibodies that cause further inflammation (242). The final function of CD4+ 
cells in the joint is to promote generation of osteoclasts that degrade bone 
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tissue, and contribute to pannus formation (243, 244). The pannus is the term 
given to the overgrown fibrous tissue that replaces cartilage and bone as a 
result of the synovial fibroblast activity.  
 
1.4.1.5 The role of neutrophils in RA pathology 
Neutrophils are thought to play an essential role throughout all stages of RA. 
Immune complexes in the joint activate neutrophils and promote degranulation 
resulting in ROS production and release of enzymes that degrade the structural 
proteins in the synovium (245). Synovial fluid of RA patients routinely contains 
high levels of neutrophils compared to other cell types, which in turn exacerbate 
the inflammatory environment of the joints causing further damage (246). 
Posttranslational modifications of proteins found in RA by the process of 
citrullination and carbamylation, are mediated by PAD and MPO, respectively. 
Neutrophils contain both of these enzymes, and of greater interest is the dual 
role of these enzymes in NETosis. NETosis has been suggested as a potential 
mechanism through which posttranslational modification of host proteins occurs 
(219, 247, 248). Neutrophils isolated from RA patients undergo spontaneous 
NETosis, in addition to more enhanced NETosis when stimulated with PMA 
(249). Chowdhury also found higher mRNA expression of MPO and NE, as well 
as higher levels of citrullinated histone H3 (249). PAD4-DNA complexes were 
also detected in the supernatants of neutrophils stimulated with PMA, 
demonstrating the ability of PAD to be released extracellularly in NETs (249). 
This novel finding along with the discovery of MPO in NETs, suggests that this 
process could be a crucial pathway through which RA associated autoantigens 
may develop (152).  IgA-RF further induces NETosis in RA neutrophils, 
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suggesting that as well as the initial stages, NETosis may be generating 
citrullinated and carbamylated proteins in a continuous feedback loop (205, 
206). In the context of RA, Corsiero et al. isolated B-cells from RA patient 
synovial tissue and tested them for reactivity to citrullinated proteins (250). They 
found 40% of B-cells in the joint produced antibodies reactive against 
citrullinated proteins, with the largest portion of these antibodies having 
reactivity to citrullinated histones H2A and H2b, demonstrating NETosis as a 
mechanism for RA pathology. 
 
1.4.2 The relationship between lung disease and autoimmunity 
The lungs have been proposed as the initial site of autoimmune disease 
development (251). The constant exposure of the lungs to pathogens in the 
environment highlights the need for a strong immune presence to defend 
against infection and disease. In the lungs, several specific defences exist. 
Alveolar macrophages reside in the lungs to deal with day-to-day pathogens 
that may persist in the lungs. Their function is similar to conventional 
macrophages, with phagocytosis, ROS production, and proinflammatory signals 
to attract other leucocytes during high levels of pathogen loads (252). The 
interplay between antigen presenting alveolar macrophages and B cells is 
crucial in the maintenance of pulmonary immunity. Bronchial associated 
lymphoid tissue (BALT) provides a reservoir of B-cells close by in germinal 
centres that produce vast quantities of IgA (253). IgA a broad spectrum binding 
class of immunoglobulin, and is secreted in mucosal tissues of the body in 
higher daily amounts compared to IgG (254). In mucosal sites, dimeric IgA is 
the most common form of synthesised IgA, which is transported through 
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epithelial cells into the bronchial lumen to bind pathogens that are subsequently 
trapped by mucus. 
On epithelial surfaces, release of mucins from goblet cells is integral to 
pulmonary immunity. Mucins are highly adhesive glycoprotein molecules that 
bind to and trap inhaled pathogens and toxins, and are continuously wafted up 
out of the lungs and into the gullet by ciliary fibres (255). Disruptions in mucus 
clearance can lead to opportunistic infections, as bacteria trapped in the mucus 
are free to infiltrate the lungs and then infect the body. Several lung diseases 
highlight mucociliary clearance as a causative element to disease 
pathophysiology, such as cystic fibrosis and bronchiectasis. 
Cystic fibrosis (CF) occurs from defects in the CTFR gene, which regulates the 
transfer of sodium and chloride ions, as well as formation of molecular 
complexes on the plasma membrane (256). The impaired ion exchange system 
leads to less liquid being present in the lumen of the lungs, producing thicker 
mucus. Thicker mucus is harder to be cleared by cilia, leading to recurrent, 
serious infections in the lungs (255). 
Bronchiectasis (BR) is a chronic lung disease characterised by the permanent 
dilation of the bronchial airways (257). The dilation may be mediated by loss of 
elastin in the lumen, with the initial damage occurring during adolescence as a 
result of a serious bacterial infection (258).  Bronchiectasis can be classified as 
CF or non-CF bronchiectasis, as CF sufferers frequently suffer from BR 
pathology, prompting clinicians to first rule out a diagnosis of CF before 
diagnosing a person with non-CF BR. Patients suffer from the same problems 
as CF patients, with inability to clear mucus resulting in frequent infections 
(258).  These frequent infections result in a cycle of infection, inflammation, lung 
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damage, poor clearance of mucus, and further infections, all amongst the 
backdrop of increasingly poor lung function. Mortality from BR occurs in roughly 
30% of BR patients, occurring in the later, more severe stages of the disease 
(259). 
Neutrophil infiltration is a key driver of BR pathology (259-262). In order to clear 
trapped pathogens in the lungs, neutrophils enter the lung as a result of IL-8 
release from alveolar macrophages alongside TNFα release from epithelial cells 
(262). Inhibitors of the IL-8 receptor have been reported to reduce the neutrophil 
presence in sputum counts, though interestingly did not improve any clinical 
outcomes in BR patients (263). 
Once in the lungs, the highly potent antimicrobial activity of neutrophils is 
commenced. Primary immune function is elicited in the form of phagocytosis of 
pathogens, opsonised by secretory IgA produced by plasma cells in the local 
area from BALT. In BR, neutrophils have been shown to be reprogrammed and 
last longer before undergoing apoptosis, release higher levels of antimicrobial 
proteins and are incapable of efficient phagocytosis of pathogens (260, 264). 
The ability of Pseudomonas aeruginosa to form biofilms in the lung, when faced 
against faulty neutrophil phagocytic mechanisms is one of the reasons that 
chronic infections in BR most commonly occur from P. aeruginosa (265). 
Production of ROS in addition to degranulation creates a highly damaging 
environment towards lung tissue however, with neutrophil elastase degrading 
the elastin fibres in the lung, driving the aforementioned cycle of lung function 
degradation (264). 
Similarly to neutrophils in RA, BR neutrophils have also been shown to have 
enhanced capacity to produce NETs (266). These NETs have in turn been 
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shown to induce proinflammatory cytokine release, as well as cell death in 
some cases (267, 268). 
Higher levels of NETs, proinflammatory cytokine release from both bacteria and 
NETs, and loss of integrity of lung structural proteins essentially turns the lungs 
into a never-ending source of inflammation, and the constant activity of the 
immune system provides a perfect storm that has been the hypothesised to be 
the initiating site for autoimmune disease development. 
Bronchiectasis has been associated with rheumatoid arthritis since 1967 (269). 
The incidence of both BR and RA (BRRA) is thought to occur in roughly 30% of 
RA patients, suggesting BR as either a cause or a consequence of RA 
pathology (270). Cigarette smoke has been proven to be one of the biggest risk 
factors for RA onset, with PAD4 levels being increased in the bronchial lavage 
fluid and lung tissue of smokers, leaning into the idea that that BR leads to RA, 
as opposed to vice versa (189-191, 271). 
RA patients with lung disease have been shown to have higher ACPA titres 
compared to those without (272). This may be attributed to higher levels of 
citrullinated protein in patients with lung disease. RA patients show the 
presence of inducible BALT, which are additional lymphoid follicles that develop 
as a result of infection, compared to BALT which exists as a protective lymphoid 
follicle (273). In this study, RA patients had ACPA producing B cells in the 
iBALT in the lungs, suggesting that ACPA production can occur in both the 
lungs and the joint (273). 
In 60 newly diagnosed RA (<12 months), Wilsher found correlations between 
ACPA titres and lung function, though no correlation with disease activity. 
Bronchiectasis was found to be present in 48% of the cohort, with 55% vs 41% 
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having ever/never smoked (274). The high prevalence of BR in this cohort, 
which is otherwise a rare disease affecting 21-35 people per 100,000 
population, strengthens the argument that BR is a risk factor for RA (275). 
Reynisdottir et al. corroborated these lung abnormalities in newly diagnosed RA 
patients, being present 63% of ACPA positive RA patients, compared to 37% of 
ACPA negative RA patients, and 30% of healthy controls  (276). Lung biopsies 
of this cohort stained positively for citrullinated proteins in the ACPA positive 
patients, as well as finding ACPAs in lavage fluid in the same patients (276). 
Perry et al. propose the “two-hit hypothesis” for RA pathogenesis (Figure 1.8) 
(277). Based on existing evidence, the lungs are the initiating site of RA through 
immune system activation in the lungs.  
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Figure 1-8 A hypothesis for RA autoantigen formation in bronchiectasis.  
1) In bronchiectasis patients, the airways are dilated, leading to ineffective clearance of 
pathogens trapped in mucus. 2) Trapped pathogens cause cytokine release from alveolar 
macrophages and epithelial cells. These cytokines attract neutrophils that migrate into the 
bronchial lumen. Neutrophils are incapable of engulfing pathogens, and so undergo 
NETosis to clear the pathogen in addition to release of reactive oxygen species and 
neutrophil elastase that damages lung tissue.  The release of myeloperoxidase and 
peptidylarginine deiminase in NETs into the extracellular space causes posttranslational 
modification of structural proteins in the lungs that results in autoantibody formation by B 
cells found in bronchial lymphoid tissue. These circulating cells then travel around the 
body and upon encountering similar proteins in the joint, commence an autoimmune 
attack. 
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This activation arises from both infectious and environmental stimuli, resulting in 
citrullination/carbamylation of proteins through neutrophil enzymes (PAD and 
MPO). Along with NETosis, extracellular presentation of these antigens gives 
rise to autoantibodies that result in memory B-cell formation, as a “first-hit”. In 
the “second-hit”, inflammation in the joint that occurs from trauma, where once 
again, modified proteins are produced as a by-product of immune system 
activity. The B-memory cells that contained the autoantibodies then recognise 
the modified structural proteins and expand, resulting in an immune response to 
the joint. 
Bronchiectasis fits nicely into this hypothesis, with BR being a disease of 
recurrent infections, therefore frequent bouts of inflammation. NETs are 
involved in RA development, and neutrophil dysfunction has been reported in 
both BR and RA (260, 266, 278-280). Although citrullination has long been the 
focus of RA pathogenesis, carbamylation of extracellular proteins by neutrophils 
occurs irrespective of NETosis, further corroborating the notion that neutrophils 
are the driving autoantigen formation in RA (281). 
Further examination into bronchiectasis and rheumatoid arthritis by Perry used 
conventional testing for RA on BR patients, measuring RF and ACPA titres 
(282). Of 122 BR patients tested, 25% of the cohort were positive for RF, with 
61% of the cohort having never smoked. 4 patients who tested positive for RF 
also displayed very strong positivity for ACPAs (282). Of these 4 patients, 2 
proceeded to develop RA, and Perry et al. were the first group to demonstrate 
ACPA positivity in BR. This cohort was examined further in a follow up study, 
comparing the original BR cohort against BRRA patients, and RA patients with 
no history of lung disease (283). 
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The BRRA cohort of this study were found to have significantly higher DAS28, 
RF and ACPA titres compared to the RA alone cohort. This BRRA cohort also 
had low levels of smoking recorded, suggesting BR as the driving factor for 
autoantibody positivity (283). 
Sadly, no study exists that examines neutrophil function in BRRA patients, 
which would prove invaluable to determining any overlap between these two 
diseases. It is apparent that NETosis has been the focal point of research for 
good reason, with most well-studied diseases coming under scrutiny once again 
due to the revelation of this process in 2004. Key pieces of the puzzle for 
breakdown of immune tolerance in RA are slowly being unravelled. The 
evidence of NETosis induction through cigarette smoke exposure could open 
the door to finding out the causative stimulus for the greatest environmental risk 
factor in RA (123). Cigarettes are composed of a multitude of toxic compounds, 
and so it is of great importance to elucidate the NET-inducing element in 
cigarettes, in the hope any other routes of exposures in the population can be 
examined that may lead to RA development. 
As previously mentioned, cadmium is present as a contaminant in cigarette 
smoke, and inhalation of cadmium is a frequent occupational exposure for 
industrial manufacturing, with recent research suggesting cadmium as a 
causative agent for RA. 
 
1.4.3 Cadmium exposure as a risk for RA pathogenesis 
Silica exposure, or dust inhalation has recently emerged as a risk factor for RA 
(284). As men appear to have a later age of onset in RA than women, it 
suggests that cumulative environmental stimuli may be the cause of RA 
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development. Stolt and colleagues found in a case-control study that silica 
exposure had an odds ratio of 2.2-3.0, depending on age, and exposure to silica 
(284). This has further been corroborated by Blanc et al, who found that foundry 
workers exposed to silica who had been occupationally exposed had a 57% 
increased risk for RA (285). 
More recently, inhalation of nanoparticles, not just silica, has been suggested as 
a contributing factor to RA pathogenesis. Textile dust has also shown a strong 
correlation with RA patient serology, with those having ever been exposed to 
textile dust having an odds ratio of 2.8 for RA pathogenesis (286).  Research by 
Murphy et al. found that in a cohort of 726 male RA patients in the south west of 
the UK, 75% had occupational exposure to dust for over a year, in addition to 
77% of the cohort having ever smoked (287). Interestingly, RF levels were 
statistically significantly higher in both smokers and non-smokers with a history 
of dust exposure compared to those never exposed (287). The authors propose 
that nanoparticle inhalation provides a surface for cigarette smoke to adhere to, 
to further induce and prolong inflammation induced from smoking (288, 289). 
Nanoparticles and fibres are able to penetrate deep into the lungs and cause 
inflammation (290). This combination of nanoparticle inhalation and cigarette 
smoke may provide a system whereby the lungs are subject to constant 
sources of inflammation, which could provide a system of dysfunction through 
persistent over-activation, resulting in aberrant levels of NETosis, resulting in 
protein modifications in a similar mechanism to those proposed in 
bronchiectasis. 
In the context of RA, cadmium may pose an additional mechanism for disease 
pathology through increasing the rate of bone destruction. Chen treated rats 
with various doses of cadmium for 12 weeks and performed histological 
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analysis on bone tissue after killing them (291). Cadmium exposure was found 
to reduce the bone mineral density in rats, as well as increasing levels of 
osteoclasts around the bone (291). In RA, monocyte/macrophage involvement 
is rather substantial in terms of destructive outcomes, but these cells also have 
the capability to transform into osteoclasts (292, 293). Taken altogether, this 
may provide a possible route for cadmium to contribute to RA pathology. 
 
1.5 Effect of cadmium on immune system function 
Research on cadmium exposure in the context of immunity has focused 
primarily of mouse models rather than in vitro work with human cells. 
1.5.1 Lymphocytes 
Borella et al. found that healthy B-cells exposed to cadmium at very low 
concentrations (50nM-1μM) resulted in increased immunoglobulin production in 
resting cells, but not B-cells that were activated (294). Interestingly, at 
concentrations of 10μM or higher, immunoglobulin production was markedly 
decreased in both stimulated and unstimulated B-cells, posing a risk for high-
exposed individuals. If high doses of cadmium inhibits antibody production in B-
cells, this may open up individuals to a diminished immune response in 
response to infections (294). The authors also found high levels of cadmium in 
the nucleus of cadmium-exposed lymphocytes, compared to the cytoplasm. 
Daum et al. investigated this further, and found that CdCl2 exposure on healthy 
B-cells inhibited RNA and DNA synthesis, with cadmium exhibiting an IC50 for 
this at around 30μM, as well as arresting the cell cycle within 2h of exposure 
(295). In live rats, Kataranovski et al. found similar findings, with the proliferative 
capacity of splenic lymphocytes being reduced after being dosed with various 
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concentrations of cadmium (296). Notably, LPS induced expression of MHCII 
was inhibited by CdCl2, further adding to the idea that cadmium suppresses host 
immunity, with the authors suggesting that the PKC pathway may be inhibited 
by cadmium (295). In terms of immunoglobulin production, IgG production was 
substantially affected by cadmium, with LPS-treated lymphocytes producing 
significantly less immunoglobulins at as little at 18μM of CdCl2. 
A study on the effect of cadmium exposure on rat lymphocytes was published in 
2004, contradicting previous results, showing that as well as reductions in B and 
T-cell populations at low doses, higher doses appeared to increase general 
lymphocyte levels (297). 
A more long-term examination of cadmium exposure on rats by Yuan et al.  
looked at a daily 0.5mg/kg treatment for 12 weeks in the context of lymphocyte 
viability, to attempt to explain the results found by Lafuente et al. (297, 298). 
Daily exposure of 0.1μM CdCl2 for 12 weeks resulted in increased rates of 
proliferation, though doses of 0.5 μM and 1μM significantly reduced cell growth 
over a 48h period. Additionally, white blood cell volume was found to be 
significantly increased, though no effect on granulocyte or monocyte was 
observed, suggesting that this increase is most likely lymphocyte driven (298). 
In a model of viral infection in mice, lymphocyte levels were found to be 
significantly elevated in mice exposed to cadmium and the H1N1 virus, 
compared to either cadmium or the virus alone (299). 
 
1.5.2 Monocytes 
Macrophages appear to tolerate cadmium at rather substantial levels, though 
lose function of certain processes at much lower doses. Coin and Stevens 
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treated alveolar macrophages isolated from rabbits with cadmium and 
calculated an LC50 of 200μM in these cells (300). Phagocytosis of yeast cells 
was found to be inhibited at around 31μM, around the same concentration when 
the alveolar macrophages started to show morphological changes in cell shape 
(300). This study has several issues, however. The lethal concentration that 
was calculated to be an LC50 of 200μM was extrapolated from just 4 different 
treatment concentrations, which is an insufficient number to adequately 
calculate an exact dose at which cytotoxicity occurs. Additionally, this study 
predates the invention of flow cytometry, and so the means of assessing 
phagocytosis, by counting 50 macrophages on a slide and examining labelled 
yeast internalisation, of which the EC50 for phagocytosis inhibition was 
calculated, was from a treatment conferring a standard error between 40-90% 
of the control sample. One may argue that there are differences between rabbit 
and human alveolar macrophages in terms of phagocytic capability, though 
Nguyen concluded that there are relatively similar mechanisms and stimuli that 
are shared between these two species (301). 
In the same viral infection study stated above, monocyte levels were found to 
be significantly raised in mice exposed to 1mg/L CdCl2 then infected with H1N1, 
compared to cadmium or H1N1 alone (299). 
Cox et al. explored the effect of macrophage function when exposed to 
cadmium before stimulation with LPS. In this study, THP-1 monocytes were 
differentiated into macrophages from PMA stimulation. In addition to this, 
primary rat alveolar macrophages were isolated and both were incubated with 
various concentrations of cadmium, before being challenged by 100ng/ml of 
LPS, then examined the effects on the cell biology (302). Cadmium 
preincubation induced gene expression of IL-6, IL-8 and TNF-α in monocytes 
82 
 
after LPS treatment more so than no cadmium treatment, though the opposite 
effect is seen in primary macrophages (302). Cytokine expression in both 
untreated, and between 0.1 to 1μM cadmium treated macrophages retained 
similar levels of gene expression that significantly dropped in a dose-response 
manner after 2.5μM cadmium pretreatment (302). Macrophages were also 
shown to release significantly lower levels of these cytokines when challenged 
with LPS after a 12h incubation with 10μM cadmium, though in the case of TNF-
α, a significant reduction was also observed after a 4h treatment. Cox et al. also 
found that cadmium treatment in mice lead to increased activation of the NFκB 
pathway in monocytes yet inhibited in macrophages upon stimulation with LPS. 
Jin and colleagues confirmed these findings in a different cell line, RAW264.7 
cells, though used a smaller window of cadmium concentration (0.1-3μM 
compared to 0.1-100μM in the other study) for a 24h period, compared to 
overnight in the study by Cox et al. (303). The macrophages were stimulated 
with a stronger dose of LPS (1μg/ml vs 100ng/ml) for 6h and 24h, versus 4h 
and 12h. Cell viability was shown to be significantly affected at 3μM. Jin’s 
findings were in line with Cox et al, who also found a dose-response mediated 
decrease in TNFα, IL1β and IL6 release (303). 
Oxidative stress is induced by cadmium, resulting in cell death (304-306). In 
macrophages, cadmium induced apoptosis from concentrations as low as 5nM 
over a 48h incubation period (307). This study found significant increases in 
incidence of early and late apoptosis, however this shift was from 0.8% to 2% in 
terms of annexin V positivity, and 2.5% to 3.5% annexin V/PI positivity. While 
statistically significant, the question of biological relevance of this finding comes 
in to question. The more interesting finding from this study was that a significant 
dose-response increase in mitochondrial ROS generation was observed in 
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macrophages treated with 5nM-2μM of cadmium whilst reducing mitochondrial 
membrane potential in a similar fashion (307). 
 
1.5.3 Neutrophils 
Similarly to most other immune cell studies, very little data explores the effect of 
cadmium on neutrophil biology. Kataranovski et al. found that granulocytes in 
live rats exhibited signs of activation, as well as increased survival signals 
(296). This was followed up by the same group, who treated rats with 0.5 or 
1mg cadmium /kg body weight, and examined lung homogenates from 
sacrificed rats (308). Upon cadmium treatment, cell numbers were calculated 
from enzyme digestion to determine cell infiltration in the lungs. Neutrophils 
numbers were significantly increased in both cadmium-treated mice after 24 
hour exposure, though neutrophil infiltration is still possible up to 48 hours after 
cadmium treatment (309, 310). MPO levels in the lungs also increased, though 
this is not surprising, given the elevated levels of proinflammatory cytokines that 
are produced by monocyte and lung epithelial cells that are strong 
chemoattractants for neutrophils. Elevations in both neutrophil cell numbers in 
the lungs, along with increases in MPO level signify that neutrophil involvement 
is present in the lungs in response to cadmium inhalation. Although 
macrophages are also sources of myeloperoxidase, neutrophil granules 
account for the majority of MPO in the body (309). 
CD11b expression is increased upon cadmium treatment, potentially as a 
mechanism to bind to ICAM-1, a binding ligand of CD11b that is upregulated on 
hepatocytes after cadmium treatment (310). 
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Cadmium does not induce the respiratory burst in rat neutrophils treated with 
1mg/kg for 48h, although in vitro experiments have shown evidence of ROS 
production from 2.5μM of CdCl2 (311, 312). The authors of this study calculated 
the proportion of cells positive for DHR123, stating that cadmium diminished the 
amount of positive cells when treated with 100ng/ml PMA (311). This 
impediment to ROS production may be due to cadmium-induced p47phox 
phosphorylation, which could attenuate the conventional respiratory burst when 
stimulated with conventional molecules such as fMLP (313). 
Chemotaxis is also affected by cadmium, with neutrophils of cadmium-treated 
mice exhibiting lower levels of ERK 1/2 phosphorylation, as well as reduced 
migration capacity when stimulated with fMLP (312). 
Phagocytic ability of neutrophils has not been examined since 1978, when it 
was shown that cadmium inhibited the phagocytic capacity of mice neutrophils 
and alveolar macrophages, although it did not affect the ability of these cells to 
kill the internalised particles (314). This technique used light microscopy and 
counting of ingested particles, which is prone to inaccuracy. 
 
1.5.4 Cadmium as a contributor to autoimmunity 
Based on the literature shown above, it is evident that cadmium is both 
proinflammatory and immunosuppressive. Rat and mouse models of cadmium 
exposure note increases in white blood cell volume, though most notably 
macrophage and neutrophil populations. This suggests a heavy innate cell 
involvement in responding to cadmium entering the lungs. The cadmium 
present in the pulmonary environment diminishes the general functions of these 
cells, as research demonstrates that upon stimuli with molecules such as 
85 
 
endotoxin or fMLP, functional capacity is reduced. This then leads to the 
question: how could cadmium exposure possibly lead to RA development? 
Cadmium may not directly induce the breakdown of immune tolerance. What 
remains important to consider however, is that the high cadmium level in RA 
patients shows that it contributes to pathology somehow (315). Silica and dust 
exposure is a risk factor for RA, and this was elaborated by suggesting that 
these molecules provide a deeply penetrating absorber of cadmium ions (316, 
317). Smoking provides a continuous low-dose into the lungs, which can only 
be worsened through nanoparticle inhalation. 
Here, cadmium induces chemoattraction of various immune cells to the lungs 
through induction of proinflammatory cytokines. Once in the lungs, immune 
system function is dampened down to cause dysfunction. This dysfunction may 
lead to ineffective clearance of pathogens in the lungs, predisposing an 
individual to infections, of which smoking is known to cause (318). Neutrophils 
are thought to undergo the process of NETosis when conventional means of 
antimicrobial activity are insufficient, typically due to pathogen size (319). It is 
unknown if NETosis is a last-resort for the cell when all other mechanisms are 
inadequate. NETosis can be induced from a variety of pathogenic stimuli and 
has been long suggested to be the process through which autoantigens, and 
subsequently autoantibodies, are formed. This hypothesis is summarised in 
Figure 1.9.  
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Figure 1-9 A hypothesis for how Cadmium may result in RA.  
1) Cadmium is inhaled into the lungs. 2) Here, cadmium induces proinflammatory 
cytokine release from epithelial cells and alveolar macrophages. Neutrophils are 
drawn to the pulmonary tissue where cadmium neutralises activity, resulting in 4) 
NETosis as a last resort to pathogen clearance. 5) The enzymes involved in 
NETosis activation indirectly modify host proteins, facilitating autoantigen 
formation, and subsequent opportunity for B-cells to generate autoantibodies to 
these modified proteins. 
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1.6 Introduction summary and hypothesis 
Cadmium is a dangerous element with many toxic effects in the body and has 
recently been suggested as a causative agent in RA. This would explain the 
major risk factor of smoking in RA development. Therefore, it is hypothesized 
that chronic cadmium inhalation causes prolonged inflammation in the lungs, 
which results in neutrophil dysfunction, where essential functions are hindered. 
This hindrance results in ineffective clearance of pathogens in the lungs, further 
causing inflammation. Ultimately, the diminished functional capacity causes 
NETosis to be a last-resort antimicrobial process, resulting in autoantigen 
formation. This occurs through activation of MPOs and PADs, which alter amino 
acid residues on structural proteins. Bronchiectasis is a risk factor for RA 
development through similar mechanisms, with the double hit hypothesis 
sharing similar steps in autoantigen formation. These autoantigens then trigger 
autoantibody formation towards structural proteins, of which similar-binding 
epitopes are generated. These epitopes then trigger a “second hit” in the joint, 
resulting in RA development, an autoimmune disease of poor quality of life in 
patients, for which there is no cure. 
1.7 Aims of this thesis 
This thesis aims to: 
• Further investigate the impact of cadmium exposure on neutrophil 
biology, including respiratory burst and phagocytosis 
• Examine if cadmium is capable of inducing NETosis in neutrophils 
• Explore serum biomarkers in RA patients with either bronchiectasis or a 
history of cadmium exposure that may yield clues to mechanisms of 
autoantigen formation. 
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2 Materials and methods 
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2.1 General lab techniques 
2.1.1 Protein sample quantification 
Sample protein concentrations were determined employing several methods. 
First, a Denovix DS-11 series spectrophotometer/fluorometer was used to 
measure sample protein concentrations based on absorbance at 280 nm 
wavelength of ultraviolet light. 
Alternatively, a bicinchoninic acid assay was performed using a Pierce™ BCA 
Protein Assay Kit (Pierce, UK). Serial dilutions of 2mg/ml of Bovine serum 
albumin were prepared in a  96 well microplate  to generate a standard curve. 
Samples were diluted 1:10, 1:20 and 1:50 in double-distilled H2O and added to 
the microplate at a volume of 25μl per well. A 200μl aliquot of BCA working 
reagent was then added to each well and mixed with the sample. Plates were 
then sealed and incubated at 37oC for 30 minutes and then read on an Optima 
Fluostar microplate reader (BMG labetech, UK). Absorbance was measured at 
550nm excitation for each well and a standard curve based on absorbance 
values from the bovine serum albumin (BSA) serial dilutions was generated. 
The linear portion of this curve was then used to extrapolate sample protein 
concentration. 
 
2.1.2 Western blotting 
2.1.2.1 Gel loading 
Test samples had their protein concentration measured in order to ensure equal 
protein loading of all samples.. Samples were mixed with sample buffer (Bio-
Rad, UK) containing 84mM diothiothreitol (Sigma, UK.) Samples were heated to 
90oC for 5 min to denature proteins. A precast 15-well, 8-16% acrylamide  SDS-
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PAGE tris-glycine gradient gel was inserted into a Bio-rad gel tank and filled 
with 500ml of tris/glycine/SDS running buffer (Bio-Rad, UK). Each gel was 
loaded with 3μl of precision plus all blue protein standards™ (Bio-Rad, UK) 
molecular weight markers. .Then 15μl of each denatured sample was  added to 
each lane of the loading gel and run at constant voltage, initially at 70V for 20 
min, followed by 120V for 100 min.  
 
2.1.2.2 Transfer 
Gel transfers were performed using the Bio-Rad turboblot system (Bio-Rad, 
UK). Once gel runs were completed, the gel was removed from the casing and 
placed between the bottom and top layer of a Trans-Blot® Turbo™ mini 
polyvinylidene fluoride membrane transfer Pack. The moist filter 
paper/gel/membrane/filter paper sandwich was then placed inside one of the 
two cassettes in a turboblot system, sealed, and subsequently inserted back 
into the equipment. The proteins were ran on a mini-TGX program, consisting of 
a 3 min, 2.5A 25V transfer. 
 
2.1.2.3 Antibody staining 
On completion of the transfer, , the membrane was removed from the cassette 
and was washed in phosphate-buffered saline (PBS) for 5 min. The membrane 
was then blocked with Pierce protein-free blocking buffer (Pierce, UK) for 1 h at 
room temperature. Primary antibodies were added at optimal concentrations 
diluted in protein-free blocking buffer and membranes were incubated overnight 
at 4oC with gentle rocking. The following day, membranes were washed in 
phosphate buffered saline with 0.1% v/v Tween-20 (PBST) for 3x 5 min. The 
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appropriate secondary antibodies were then added and incubated at room 
temperature in the dark for 1h. A final wash step of 3 x 5 min washes in PBST 
was performed before imaging the blot. 
 
2.1.2.4 Blot imaging 
Blots were scanned using near-infrared fluorescence using the Odyssey CLx 
Imager system (Li-Cor Biosystems, UK). Blots were kept moist before a 
scanning run was performed. Image analysis and quantification was performed 
using the Li-Cor image studio lite software (version 5.2). Fluorescence intensity 
for each band was measured via densitometry analysis. 
 
2.2 Cell culture 
2.2.1 General plastic consumables and chemical reagents 
All consumable plastics used for experimental purposes in cell culture were 
purchased from Greiner Bio-One, Austria. This includes sterile microplates, 
culture flasks, centrifuge and microcentrifuge tubes, serological pipettes and 
pipette tips. Cell culture grade, sterile Hanks Buffered Salt Solution without 
calcium and magnesium ions (HBSS) was purchased from Gibco (Thermo 
Fisher Scientific, UK).  
 
2.2.2 Cell culture conditions 
All cells were incubated at 37oC with 5% v/v CO2, with atmospheric levels of 
oxygen. Cells were cultured with RPMI-1640 or and supplemented with 10% v/v 
foetal bovine serum (Gibco, UK) and 1% v/v Penicillin/Streptomycin (10,000 
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U/ml)  (Gibco, UK) and 1% v/v L-Glutamine (200mM). Cells were passaged 
every 7-14 days. During passaging, cells were pelleted via centrifugation at 300 
RCF for 5 min. After discarding the supernatant, the pellet was resuspended in 
fresh culture medium and transferred to a fresh flask. 
 
2.2.3 Cell lines 
Initially, neutrophil experiments were first conducted and optimised employing a 
HL60 cancerous promyeloblast cell line (ATCC, USA). This cell line was 
differentiated into a neutrophil-like phenotype via treatment with 1µM 1-All-
Trans-Retinoic Acid (Sigma, UK). This process required 1x105 HL60 cells to be 
centrifuged at 500 g for 5 minutes, followed by resuspension of the pellet with 
10ml differentiation media. This consisted of RPMI-1640 (Gibco, UK), 1μM 1-
ATRA, 1.3% v/v DMSO and 5% v/v FBS. After 3-5 days of incubation, 
confirmation of differentiation was confirmed via Diffquik stain. 
 
2.3 Primary neutrophils  
2.3.1 Volunteer selection for blood donation 
Blood was obtained from volunteers who provided written informed consent in 
accordance with University of Exeter Medical School research ethics committee 
code May18/B/152Δ1. Venous blood samples were collected from the median 
cubital vein with butterfly 21-gauge needles (BD, Oxford, UK) and 10ml capacity 
EDTA-coated vacutainer tubes (BD, Oxford, UK). Each volunteer donated up to 
50ml of venous blood no more than three times, at least two weeks apart before 
being excluded from providing any further samples for 3 months. 
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2.3.2 Primary human neutrophil isolation procedure 
Five ml aliquots of  venous blood waswerelayered carefully on top of 5ml of 
Polymorphprep (Abbott, UK) in 15ml centrifuge tubes. The tubes were then 
centrifuged 650 RCF for 30 mins at 18-22 °C. The translucent PMN layer was 
harvested from the tubes and osmolarity of cell suspension was restored by a 
v:v addition of 0.45% w/v NaCl. The cell suspension was then centrifuged at 18-
22 °C at 400 RCF for 10 min and resuspended in 5ml isotonic NH4Cl2. 
Following a 5 min incubation at 37oC to allow red blood cell lysis to occur, the 
tube was centrifuged again at 18-22 °C at 400 RCF for 10 min and resuspended 
in HBSS without calcium or magnesium ions. 
2.3.3 Determination of Neutrophil population cell purity 
2.3.3.1 Romanowski Staining 
To assess neutrophil purity, 50μl aliquots of cell were spun onto a glass slides 
via a cytospin centrifuge. The adherent cells  were air dried by shaking and  
fixed in 100% methanol for 10 secs, then stained rapidly stained with Eosin G 
for 10 secs, followed by a Methylene blue stain for 10 seconds. The slides were 
washed in ddH2O and then imaged via light microscopy. The purity of the cells 
was cells was assessed by nuclear staining and morphology.  
 
2.3.3.2 Flow Cytometric analysis of surface marker expression 
Purified isolated  cells  were counted using the Bio-Rad TC20 automated cell 
counter. Next 50,000 cells were transferred to fresh 1.5ml reaction tubes and 
resuspended  in  100μl  HBSS with 2% w/v BSA. Neutrophils were probed with 
a panel of  antibodies against  the following targets: CD11b, CD16, CD62L and 
CD66.  Cells were incubated  with 1:50 dilution for each antibody  for 30 
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minutes in the dark on ice. Further details on the selected antibodies can be 
found in Table 2.1. Following incubation, excess antibody were removed  by 
washing the cells in 900μl of ice-cold HBSS with 2% w/v BSA was added and 
centrifuged at 300RCF for 5 mins. Cells were fixed by resuspension in 4% w/v 
Paraformaldehyde and kept at 4oC in the dark until analysis. Flow cytometry 
was performed on a Guava Easycyte Mini2 (Millipore,UK). The process of 
gating to assess neutrophil purity can be seen in Figure 2.1.  
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Antibody 
Target 
Fluorophore Product 
Code 
Excitation Emission Supplier 
CD11b PerCP-
eFluor710 
15589076 490 710 eBioscience 
CD16 AlexaFluor488 15347394 495 519 Invitrogen 
CD62L PE 11519242 480 575 Invitrogen 
CD66 APC 15517966 650 660 eBioscience 
Table 2-1 Fluorescent antibodies used for flow cytometry 
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Figure 2-1 An example run of neutrophil population gating to assess Polymorphprep  isolation purity.  
Cells were gated for positivity of the following markers in subsequent steps: CD16, CD11b, CD62L and CD66. The positive 
population in each step was used as the gating population for the next step. Neutrophil purity using this method was consistently 
85-90%.  
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2.3.4 Flow cytometry 
2.3.4.1 Samples used for flow cytometry 
A number of fluorimetric assays were established to assess neutrophil function 
upon treatment with various test reagents as detailed below.   Neutrophils were 
treated with various concentrations of cadmium chloride (CdCl2): 1μM, 3μM, 
10μM, 30μM and 100μM. Additionally serum from RA patients of varying 
disease severity or healthy control serum was added to cells at a 1:50 dilution. 
Finally, unmodified or citrullinated and carbamylated Fc fragment of 
immunoglobulin G (hereto referred as mod-Fc) was added to cells at 100ng/ml. 
 
2.3.4.2 Measurement of Neutrophil Respiratory Burst 
To examine if various molecules and compounds were capable of inducing the 
respiratory burst in neutrophils, the fluorescent dye dihydrorhodamine 123 
(DHR123 - Invitrogen, UK) was used. DHR123 works by emitting a fluorescent 
green colour in the presence of reactive oxygen species. This is an oxidation 
reaction whereby DHR123 is converted to cationic Rhodamine 123 in the 
presence of hydrogen peroxide, an intermediate product of ROS generation in 
neutrophils. Aliquots of  5x104 cells in HBSS were incubated with 1μM DHR123 
and the treatments listed above. HBSS alone  or containing  100nM of PMA 
acted as a negative or positive control, respectively. Samples were incubated at 
37oC for 30 minutes and the reaction was terminated by placing the sample 
tubes on ice for 10 minutes. Cellular levels  of green fluorescence a 488 nm 
was quantified using a Guava Easycyte Mini2 flow cytometer (Millipore,UK). 
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2.3.4.3 Measurement of Neutrophil internal calcium flux 
Human neutrophils (1-5x106 cells/ml) were loaded with the fluorometric calcium 
indicator fluo-4 AM (Invitrogen, UK) at a concentration of 2.5μM in HBSS and 
incubated for 45 minutes at 37oC. After incubation, cells were centrifuged at 300 
RCF and resuspended in fresh HBSS. A cell count was performed and 5x104 
cells were transferred into a 1.5ml reaction tube and resuspended to a volume 
of 500μL in HBSS. The experimental fluorometric  procedure occurred in three 
sequential steps in each sample tube, to measure basal, treatment and 
maximum calcium flux. During these steps, green fluorescence emission from 
the Fluo-4-AM dye detecting calcium release was measured.  First, 100μl of cell 
suspension was ran through the flow cytometer and the MFI measured , then 
the run was terminated. Second,  100μL of treatment compounds of interest 
were added at 5x concentration to the cells. In the case of the patient serum, a 
1:10 dilution of serum was prepared and immediately added to each 
experimental tube. The final experimental dilution was a 1:50 dilution and 
fluorescence was immediately recorded upon addition of serum. HBSS was 
added as a negative control, or 15ng/ml of interleukin-8 (final concentration of 
3ng/ml - Peprotech, UK) to act as a positive control. Once again, 100μl of cell 
suspension with the added treatments was ran through the machine and then 
terminated. Third, 100μL of 1μM ionomycin (Sigma, UK) was added to the tube 
and ran through the machine. Median fluorescence intensity for each step was 
measured and compared between treatment groups. 
 
2.3.4.4 Measurement of Neutrophil phagocytic capacity 
Firstly, pHrodo Green fluorescently labelled heat killed E.Coli (BioParticles – 
Invitrogen, UK) were opsonised in autologous donor serum at a concentration of 
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10µg/ml at 37oC for 30 minutes. 5x104 neutrophils were then incubated with the 
opsonised particles at a final concentration of 1μg/ml along with a series of 
concentrations of CdCl2 (1- 100μM).  
2.3.4.5 Determination of cytotoxicity of cadmium chloride 
An Alexafluor 488 annexin V/ dead cell apoptosis kit (Invitrogen, UK) was used 
to examine any potential cytotoxic effects of cadmium exposure to neutrophils. 
Purified Neutrophils were diluted in HBSS supplemented with 10% v/v 
autologous donor serum, then added to 1.5ml reaction tubes at 1x105 cells per 
tube.  Cells were treated with 1,3,10, 30 and 100μM of CdCl2 for 3, 12 and 24 
hours. HBSS and 1μM H2O2 were used as negative and positive controls, 
respectively. After each of the respective incubations, cells were centrifuged at 
300RCF for 5 minutes, and washed once in ice-cold fresh HBSS-/-. Cell pellets 
were resuspended in annexin V binding buffer (as supplied by the assay kit), 
1μM of propidium iodide, and a 1/40 dilution of annexin V. Cells were incubated 
at room temperature for 15 minutes, then placed  on ice and analysed by flow 
cytometry immediately.  
 
2.3.4.6 Analysis 
For all flow cytometry experiments conducted, flow cytometry files were 
exported from the native Incyte software and analysed using FlowJo  
(TreeStar Inc, UK). Cell populations concluded to be 
CD11b+CD16+CD62L+CD66+ were determined to be neutrophils and gated for 
analytical purposes. For further analysis of fluorescence values, the median 
values in relevant channels were calculated and used in statistical analysis. 
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2.3.5 Induction and measurement of NETosis 
2.3.5.1 Live Cell Imaging 
In order to visualise primary neutrophils undergoing NETosis, cells were first 
incubated with 1μM of the cytoplasmic stain DiI for 1 hour at 37oC. Purified 
neutrophils were resuspended in HBSS.  For 1-ATRA differentiated HL60s were 
suspended in serum-free, penicillin/streptomycin free RPMI-1640 for. Both cell 
types were plated into wells of 96 well plates at a density of 5x104 cells per well 
in a 100μl final volume. After seeding, the plate was placed inside the JuLi 
stage live cell imaging system (NanoEntek, Korea), situated inside an incubator. 
The plate was incubated at 37oC for 1 hour to allow cells to adhere to the 
bottom of the plate. Once adhered, cells were treated with 10x concentration of 
PMA, SYTOX Green (Invitrogen, UK) and Hoescht 33342 stain (Invitrogen, UK). 
SYTOX Green is a non-permabilizing DNA dye that fluoresces green in the 
presence of DNA.  The combination of the three dyes used allows visualisation 
of cell cytoplasm whilst discerning between externalised DNA and live cells that 
had not yet undergone NETosis. Final concentrations in each well were 50nM 
PMA, 500nM SYTOX Green and 1μg/ml of Hoescht. Images of each well were 
taken every 5 minutes for 4 hours, capturing blue, green and red fluorescence. 
Images were analysed using JuLi EDIT software (Nanoentek, Korea.) 
 
2.3.5.2 SYTOX Green Spectrofluometric Assay 
Aliquots of neutrophils (1x105 cells/ well in 100μl in HBSS) were seeded onto a 
96 well plate and allowed to adhere to the bottom of the wells for 1h at 37oC. . 
Next equal volumes of  2x concentration of treatment compounds were added, 
to provide  final concentrations in each well of 50nM PMA, 50, 100, 500 and 
1000ng/ml, LPS derived from Pseudomonas aeruginosa (Sigma, UK) and 1, 
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2.5, 5, 25 and 50μM of CdCl2. Additionally, in some experiments, serum from 
RA patients or healthy donor was added at 1:10 dilutions.  Plates were 
incubated at 37oC for 4 and 24 hours followed by subsequent addition of 1μM 
SYTOX green. The fluorescence was then measured on an Optima PHERAstar 
plate reader (BMG Labtech, UK) at 485nm excitation and 525nm emission 
wavelengths and RFUs were recorded.  
2.3.5.3 Immunofluorescence 
Aliquots of 1x105 Neutrophils were incubated into 8-well Nunc Lab- Tek II 
chamber slides and left to adhere for 1 hour at 37oC. 100nM PMA (final 
concentration) was then added to induce neutrophils NETosis over 4 hours at 
37oC . Given the fragility of NETs, after treatment, 8% w/v paraformaldehyde 
was added to each well to fix cells. Supernatants were then aspirated and slides 
were washed in 250μl of PBS three times. Cells were blocked in 10% v/v goat 
serum for 1 hour at room temperature. The slides were washed in 3x250μl of 
PBS and the cells incubated with a 1:100 dilution of rabbit anti-citrullinated 
histone H3 antibody (Abcam, UK) and mouse anti-myeloperoxidase (Abcam, 
UK) for 1h at room temperature. Slides were washed three times in PBS and 
incubated with AlexaFluor 594-conjugated and AlexaFluor488-conjugated goat 
anti-mouse and anti-rabbit secondary antibodies, respectively (Life 
Technologies, UK) for 1h at room temperature in the dark. Slides were washed 
3 times in PBS and then the well divider on the slide was removed.  Slides were 
then mounted with Prolong Gold Antifade Reagent with DAPI (Invitrogen, UK) 
and sealed. Slides were then visualised on an EVOS fluorescence microscope 
at 10x and 40x magnification (Thermo Fisher Scientific, UK). The native 
microscopy software on the microscope was used to generate overlays for 
double and triple stained images.  
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2.4 Immunoglobulin G and patient serum biochemistry 
2.4.1 Patient population. 
Patient samples were obtained through a multi-centre ethics IRAS 12324, with 
patient recruitment taking place between May 2012 and May 2013. Sera from 
patients and controls were selected from the BRACRA (bronchiectasis, asthma, 
control, rheumatoid arthritis) study: a prospective, multicentre, case–control, 
observational study, conducted to determine the relationship between 
bronchiectasis and RA development and the overall study design, the assays 
used for the determination of RF and anti-CCP levels and approval has been 
previously reported (320). All the RA patients fulfilled the ACR 2010 
classification criteria for RA and the definition of a negative, low positive and 
high positive RF and anti-CCP is as per the above classification criteria (199). 
An additional cohort of 220 serum samples was gathered from RA patients in 
the south west. The samples used in this study were gathered as part of a 
project as part of project IRAS ID 194833, approved by South West Regional 
Ethical Committee (UK).  
 
2.4.2 Sample preparation for mass spectrometric analysis 
Equal serum protein loads as determined by nanodrop spectrometry were 
separated on 8-16% SDS-PAGE gradient gels (Bio-Rad, UK).  A protein band 
identified by immunoblotting with anti-human citrulline antibody (Abcam 
ab100932, Abcam, UK), contained numerous citrullinated proteins in the region 
of 37-50 kilodaltons (KDa). 
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2.4.3 Mass spectrometry 
2.4.3.1 Band digestion 
The bands were excised from Bio-safe Coomasie (Bio-Rad,UK) stained 
gradient gels and subjected to in-gel tryptic digestion using a DigestPro 
automated digestion unit (Intavis Ltd, UK). 
 
2.4.3.2 Mass spectrometry sample analysis 
The resulting peptides were fractionated using an Ultimate 3000 nanoHPLC 
system. Tandem mass spectra were acquired using an LTQ- Orbitrap Velos 
mass spectrometer controlled by Xcalibur 2.1 software (Thermo Scientific,UK) 
and operated in data-dependent acquisition mode. . 
The raw data files were processed and quantified using Proteome Discoverer 
software v1.4 (Thermo Scientific, UK) and searched against the UniProt Human 
database (131351 entries) using the SEQUEST algorithm. Search criteria 
routinely included carbamidomethylation of cysteine (+57.0214) as a fixed 
modification and oxidation of methionine as a variable modification. In addition, 
citrullination (+0.984Da) at Arg, AsnN and GlnQ and carbamylation (+43.006Da) 
at Lys, Met, ArgR, Ser, Thr and TyrY, were included as variable modifications in 
two separate searches. Only peptides where citrullination at Arg and 
carbamylation at Lys were ranked 1 in the respective searches (indicating that 
those residues were the most likely sites of modification) were considered. 
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2.4.3.3 Protein Modelling 
The UCSF Chimera protein viewing software (http://www.rbvi.ucsf.edu/chimera/, 
USA) was used to annotate the amino acid modifications of interest to highlight 
the citrullinated and carbamylated sites on the proteins of interest. 
 
2.4.4 Immunoglobulin G purification 
Immunoglobulin G was isolated from commercially available human serum 
(Sigma, UK) and purified on a Hitrap Protein G column on an AKTA FPLC 
purifier (GE Healthcare, USA). Samples were diluted 1:5 in 20mm sodium 
phosphate buffer pH 7.0 and eluted off the column by 0.1M Glycine-HCl pH 2.7. 
Fractions collected during the elution window are classified as pure IgG. 
 
2.4.5 Fc fragment preparation 
2.4.5.1 Immunoglobulin G papain digestion and Fc fragment purification 
2 mg/ml of purified IgG in Sodium Phosphate Buffer (pH 7.4) was treated at 
1:20 Enzyme:Protein ratio (w/w) with Papain (Sigma, UK) in digestion buffer. 
Digestion buffer consisted of 0.02M EDTA and 0.02M L-Cysteine in phosphate 
buffered saline (PBS).  The reaction was incubated at 37oC for 2 hours and 
terminated with 0.3M Iodoacetamide dissolved in PBS. Samples were buffer-
exchanged using vivaspin 500 MWCO protein concentrators into 20mM sodium 
phosphate buffer pH 7.0. Samples were then rerun on the AKTA purifier using 
the above protocol. Successful papain cleavage was confirmed via SDS-PAGE 
using an 8-16% tris-glycine gradient gel.  
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2.4.5.2 Post-translational modifications of Fc fragment 
To citrullinate Fc fragment, 1 unit of Peptidyl Arginine Deiminase from rabbit 
skeletal muscle (Sigma, UK) was used per 250μg of protein. The reaction was 
buffered by a solution of 0.1M Tris/HCL, pH7.6, 10mM CaCl2, 5mM DTT. 
Reactions were incubated overnight at 37oC. 
For carbamylation, Fc fragment isolate was diluted to a concentration of 2mg/ml 
and incubated with 0.1M Potassium Cyanate in 0.15M sodium phosphate buffer 
(pH 7.4). The reaction was then incubated overnight at 37oC for 24h and then 
buffer exchanged with sodium phosphate buffer to remove unreacted cyanate. 
Considering double modification of Fc fragment would require a chemical and 
enzymatic approach, it was deemed suitable to enzymatically and then 
chemically modify Fc fragment, in order to preserve potential substrate sites on 
the protein. After the initial enzymatic reaction, deimination buffer was removed 
by buffer exchange before resuspension in cyanate reaction buffer. 
 
2.4.6 Fc fragment ELISA 
In order to measure serum antibody levels to the unmodified and modified Fc 
fragment of IgG in the sera of each test cohort, an in-house capture ELISA was 
designed. 96-well high binding microplates (Greiner Bio-One, Austria) were 
coated with a 5μg/ml dilution of either untreated Fc fragment (UT-Fc), or double 
modified Fc fragment (mod-Fc). UT-Fc was added to rows A-D of the 
microplate, and mod-Fc was added to rows E-H. The plate was then sealed and 
incubated overnight at 4OC to allow the antigens to adhere to the plate. 
Following incubation, the plate was washed 4x with 200μl of 0.1% v/v PBST and 
remaining binding sites were subsequently blocked with 200μl of 5% w/v BSA in 
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0.1% v/v PBST for 30 minutes at 37oC. Well were washed again 4 times in 
0.1% v/v PBST. At this point, the plate was divided into four quadrants, detailed 
in Table 2.2. Next, 100μl of a 1:50 dilution of cohort sera in 0.1% v/v PBST was 
added to the top-left corner of each quadrant and added to each of the four 
quadrants, resulting in 24 samples being added to the plate four times each.  
PBST was used as a blank, occupying the bottom-right well of each quadrant. 
The plate was sealed and incubated for 2 hours at 37oC. The wells were 
washed 4x in PBST once more, and an anti-human IgM or IgA HRP-conjugated 
secondary antibody was added to the plate in Table 2.2 at a 1:2000 dilution in 
PBST. Following a 1h incubation at 37pC, the plate was washed as mentioned 
above, and 100μl of SureBlue™ TMB 1-Component Microwell Peroxidase 
Substrate (KPL, UK) was added to each well on the plate and left to incubate in 
the dark for 15 minutes.  This reaction was then terminated by adding 50μl of 
1M H2SO4 to each well. The optical density of each sample was measured on a 
BMG Labtech Fluorostar plate reader at 450nm excitation.  
 
2.5 Statistical analysis 
All statistical analysis used throughout this thesis was performed using the 
Graphpad Prism software (version 8-10). To compare two groups, a Mann-
Whitney test was performed. Analysis between multiple groups used either a 
Krusall-Wallis test with Dunn’s post hoc test, or a Within Sample two-way 
ANOVA with Dunnett’s or Holm-Sidak’s multiple comparison post hoc test as 
appropriate, unless stated otherwise. Statistical significance was classified as a 
p value of less than 0.05.  
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 1       2       3       4       5       6 7       8       9     10      11     12 
A 
B 
C 
D 
1       2 
          UT-Fc 
IgM response 
1       2 
           UT-Fc 
            IgA response 
 
E 
F 
G 
H 
1       2 
     Mod-Fc 
        IgM response 
1       2 
             Mod-Fc 
        IgA response 
Table 2-2 Template for Fc fragment ELISA.  
Either unmodified or mod-modified Fc fragment was added to a 96 well plate. 
Unmodified Fc fragment was added to the top four rows (rows A-D) and the 
modified Fc fragment was added to the bottom four rows (E-F). After blocking, 
serum samples were added to same well in each quadrant (i.e. sample 1 in A1, 
A7, E1, E7, sample 2 in A2, A8, B2, B8 and so forth). After serum sample 
incubation and subsequent wash step, secondary antibody was added. 
Secondary antibody was added as follows: anti-human IgM was added to 
columns 1-6, and anti-human IgA was added to columns 7-12. After incubation, 
substrate was added and the OD450nm was measured. This results in the 
quantification of the IgM and IgA response to both unmodified and modified Fc 
fragment. 
 
108 
 
 
 
 
 
 
 
 
 
3 The effect of cadmium on neutrophil biology 
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3.1 Introduction 
As outlined in the introduction, research into the effect of cadmium on neutrophil 
biology remains rather limited, with no substantial investigations having been 
explored since the 1980’s. The link between cadmium and RA recently 
suggested by this research group indicates that the lungs are the initiating site 
for RA development in exposed individuals (321). In most pulmonary diseases, 
heavy neutrophil involvement is a key driver of pathology. Coupled with the 
recent evidence of cigarette smoking inducing NETosis, the role of cadmium on 
general neutrophil function may lead to clues as to how autoimmune-associated 
mechanisms may be triggered. The objectives of this chapter were to:  
• Explore the effects of cadmium on general neutrophil physiology, and 
any resulting dysfunction which may link to RA pathology. The cellular 
functions examined were:  
o Cell viability 
o Oxidative burst  
o Phagocytic capability  
o Calcium flux 
o NETosis 
It was theorized that cadmium would principally induce NETosis in neutrophils, 
highlighting this as the causative agent found in the work of Qiu et al (123). 
Calcium flux was examined as the increase of cytosolic calcium levels is also an 
essential step in NET formation, which may hint at further clues to this 
relationship.  
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3.2 The effect of cadmium on cell viability 
To investigate the effect of cadmium on neutrophil biology, the cytotoxic effects 
of cadmium on neutrophils was examined. Isolated neutrophils were suspended 
in HBSS-/- supplemented with autologous donor serum and treated with a range 
of concentrations of cadmium chloride (1, 3, 10, 30 and 100μM CdCl2) for 3, 12 
and 24 hours, and cytotoxicity was determined by flow cytometry using annexin 
V-PI staining. 
Early apoptosis is defined as cells binding only annexin V, whereas late 
apoptosis is defined as cells binding both annexin V and PI. Necrosis is 
classified as cells only testing positive for PI, though no necrosis was observed 
in these cells. Incidence of both early and late stage apoptosis was not 
significantly increased at any of the time points measured. Based on these data, 
it would suggest that cadmium is not toxic to healthy neutrophils (Figure 3.1 
and figure 3.2). 
Cadmium is known to oxidative stress in various cell types in the human body 
(33). Production of reactive oxygen species is an essential function of neutrophil 
innate immune biology (79-81). The production of ROS can also lead to 
damage in the surrounding tissues.  To current knowledge, the effect of 
cadmium on ROS production in the context of neutrophil biology has not been 
examined before. Consequently an assay was established to measure 
intracellular ROS production using the fluorescent probe dihydrorhodamine 123 
(DHR123). DHR123 is converted to rhodamine 123 in the presence of hydrogen 
peroxide, an intermediate molecule generated during ROS production. This 
reaction converts a non- fluorescent molecule to a green fluorescent molecule, 
allowing semi- quantification of ROS production in cells by fluorescent 
monitoring using flow cytometry.  
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Figure 3-1 Cadmium chloride is not cytotoxic to freshly isolated neutrophils. 
 Cytoxicity of cadmium chloride to neutrophils was used by annexin-V/PI staining 
over a 3, 12 and 24h timepoint. Gating was compared against untreated cells. 
Statistical significance was tested by Kruskal-Wallis with Dunn’s post-test. Data are 
presented as median % of cells in early/late apoptosis ± IQR over 3 independent 
experiments using different donors. 
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Figure 3-2 Representative scatter plot of annexin-V/PI staining to 
determine cell viability. 
Scatter plots showing cell positivity for annexin V (x axis) against cell positivity 
for propodium iodide (y axis). Scatter plots for each treatment are shown at A) 3 
hours, B) 12 hours and C) 24 hours. Positivity for each stain was calculated by 
gating the 99th percentile of single stain controls. This gating was then applied 
to all experimental samples.  
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Based on the method first developed by Chen and Junger, Isolated neutrophils 
were exposed to cadmium chloride for 30 minutes to test the acute response to 
cadmium treatment, compared to PMA which is a rapid inducer of the 
respiratory burst in neutrophils through PKC activation (322). 
Cadmium chloride in the doses and time tested did not induce production of 
reactive oxygen species compared to above untreated cells (Figure 3.3).  No 
statistical significance (Kruskal-Wallis test with Dunn’s post test) in median MFI 
between unstimulated neutrophils and 1, 3, 10, 30 and 100μM CdCl2 (P>0.05) 
was observed.  
These results suggest that direct exposure of neutrophils in vitro to cadmium 
does not induce acute production of ROS. 
An additional observation from the respiratory burst assay found that upon 
stimulation with PMA, morphological changes in neutrophils were observed, 
with cells increasing in size as shown by increase in FSC. In contrast, neutrophil 
morphology remained unchanged when exposed to various doses of cadmium 
chloride (Figure 3.4). There was no statistically significant difference in cell 
morphology based on neutrophil volume upon treatment with any of the 
experimental doses of cadmium (P>0.05). PMA induced significant (P= 0.059) 
increases in neutrophil size (Figure 3.5). Taken together, this would suggest 
that cadmium does not induce changes that causes potent activation of these 
cells. 
Cadmium appears not to induce an acute respiratory burst directly.  Next, 
whether cadmium played a role in attenuating the respiratory burst in the 
presence of a ROS stimulant (PMA) was investigated.  
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Figure 3-3 Cadmium does not induce the respiratory burst in primary 
neutrophils.  
A) Neutrophils were incubated with dihydrorhodamine 123 and 1, 3, 10, 30 
and 100μM CdCl2 for 30 minutes after which green fluorescence was 
measured at 488 nm. Statistical analysis using a Kruskal-Wallis test with 
Dunn’s post-test found no statistical significance between cadmium 
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treatment and MFI compared to the untreated HBSS control, 
demonstrating no effect of cadmium on ROS production in neutrophils. 
Data are shown as median MFI ±IQR as a result of 5 independent 
experiments with different donors. * = P<0.05. B) Flow histograms 
displaying a representative DHR run. Red peaks indicate the 
fluorescence recorded from HBSS treatment. Blue peaks indicate the 
fluorescence recorded from PMA treatment. Yellow peaks indicate the 
fluorescence recorded from treatment with the concentration of cadmium 
chloride listed above each histogram.  
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Figure 3-4 Neutrophil morphology is changed by PMA treatment, but not cadmium treatment.  
Neutrophils were incubated with the treatment conditions indicated in each panel above indicated by the blue plots. Forward scatter and side 
scatter were examined compared to untreated neutrophils (indicated in red). Increases in the size of neutrophils was observed upon PMA 
treatment, but not in any of the cadmium treatment cohorts. Dot plots representative of five independent experiments.  
118 
 
 
Figure 3-5: PMA induces significant increases in cell size, but not 
cadmium.  
PMA statistically significantly increased cell size by means of FSC 
measurement. Cadmium did not induce any change in cell size. Statistical 
analysis used a Friedman’s test with Dunn’s post test. Data are presented as 
median MFI ± IQR over five independent experiments. ** = p<0.01 
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As described above, neutrophils were treated with 1, 3, 10, 30 and 100μM 
CdCl2, with 100nM PMA and DHR123 and compared to PMA-only stimulated 
neutrophils (Figure 3.6). 
A single 3μM cadmium dose increased production of ROS in neutrophils treated 
with 100nM PMA (P = 0.0019). All other concentrations of cadmium used 
showed no statistically significantly difference. 
 
3.3 Cadmium does not affect the phagocytic capacity of cells 
Phagocytosis is a major function of neutrophils, and along with ROS production, 
these two mechanisms are integral to the innate immune clearance of 
pathogens.  
As cadmium does not directly induce ROS production under the concentrations 
used, the effect of cadmium on phagocytic capacity was examined by 
quantifying the uptake of fluorescently labelled heat-killed bacteria with and 
without opsonisation. 
Initial experiments found poor uptake of particles when incubated directly with 
the neutrophils. Subsequent experiments employed bioparticles that had been 
opsonised with autologous serum from donor subjects for 30 minutes. After 
opsonisation, these particles were directly added to 5x104 neutrophils and after 
2 hours, cell fluorescence in the cells was measured to quantify uptake of 
bioparticles. Fluorescence peaks were normalized to untreated cells. A 30 
minute pre-incubation with cadmium did not significantly alter the uptake of 
bioparticles over a subsequent 2 hour period at any of the concentrations tested 
(Figure 3.7).  
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Figure 3-6 The respiratory burst induced by PMA is enhanced by 3μM of 
cadmium chloride.  
Isolated primary neutrophils were incubated with or without 100nM PMA 
alongside cadmium chloride in the concentrations shown. Production of reactive 
oxygen species was detected through incubation of neutrophils with 1μM 
DHR123 alongside treatments. After 30 minutes, green fluorescence was 
measured. A significant increase in fluorescence was found in neutrophils 
incubated with 3μM of CdCl2 and PMA. Statistical significance was tested by 
within sample two-way ANOVA with Dunnett’s multiple comparisons post-test. 
Data are shown as the mean MFI ± SD over two independent experiments. 
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Figure 3-7 Cadmium does alter the rate of uptake of fluorescent 
bioparticles.  
A) Phagocytosis was measured through use of fluorescent labelled E. Coli 
bioparticles. Opsonised bioparticles were added to tubes containing neutrophils 
at concentration of 1μg/ml along with the treatments indicated above. After 2 
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hours, fluorescence in each cell was measured to assess phagocytosis. Cells 
were determined to be particle negative based on gating of 100% of cells that 
were not incubated with bioparticles and subsequently applied to all samples. 
Cadmium did not affect the uptake of fluorescently labelled particles. Statistical 
significance was tested using a Friedman test with Dunn post-test. Data is 
presented as median MFI ± IQR over five independent experiments. B) A 
representative flow histogram of the phagocytosis experiment. Treatment 
conditions are displayed above each histogram.  
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In terms of quantity of particles ingested, cadmium also did not influence the 
median fluorescence intensity in neutrophil populations tested (Figure 3.8). 
Overall, this would suggest that phagocytic capacity of neutrophils is not 
influenced by treatment of cadmium chloride. 
 
3.4 Neutrophil cytosolic calcium levels increase upon treatment with 
cadmium. 
With conventional neutrophil functions being unaffected by cadmium treatment, 
along with cadmium demonstrating no cytotoxic effects, it was then investigated 
whether cadmium could affect certain secondary messenger systems. 
Intracellular signalling is reliant on many cascades, though one common 
molecule that is involved in multiple steps of neutrophil biology is calcium.  
Measurement of cytosolic levels of calcium in neutrophils was achieved through 
usage of the fluorometric dye Fluo-4-AM. Cells were loaded with the dye for 1 
hour and then treated with experimental doses of cadmium, or interleukin-8 at a 
final concentration of 3ng/ml to act as a positive control. Flow cytometry was 
used to measure the changes in calcium level in each population. Baseline 
cytosolic calcium level was first measured in the neutrophil population, before 
spiking in the experimental treatment to monitor any changes in cytosolic 
calcium levels, then finally adding ionomycin to measure maximum calcium 
levels inside the cell. 
Cadmium induced increases in cytosolic calcium levels beyond those recorded 
by 3ng/ml of interleukin 8 (Figure 3.9).  
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Figure 3-8 A low dose of cadmium does not increase the quantity of 
bioparticles ingested by neutrophils.   
Phagocytosis was measured through use of fluorescent labelled E. Coli 
bioparticles. Opsonised bioparticles were added to tubes containing neutrophils 
at concentration of 1μg/ml at the same time as cadmium. After 2 hours, 
fluorescence in each cell sample was measured to assess phagocytosis. Of the 
cells classified as being positive for bioparticle engulfment, median fluorescence 
intensity was measured in each population of cells. Cadmium treatment of cells 
caused no significant increases in bioparticle uptake as assessed by changes in 
MFI. Statistical significance was tested by Friedman test with Dunn’s post-test. 
Data is presented as the average MFI ± IQR over five independent 
experiments. 
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Figure 3-9 Cadmium increases cytosolic calcium levels beyond those 
induced by low levels of interleukin-8.  
Neutrophils were loaded with the fluo-4-AM dye and resting calcium level was 
recorded indirectly by flow cytometry. After baseline measurement, treatments 
were added to each sample and the measurements were taken again. A) 
Comparison between cytosolic calcium levels before and after treatment with 
experimental compounds. Cadmium-treatment induced statistically significant 
increases in cytosolic calcium levels as measured by flow cytometry with some 
cadmium test concentrations, surpassing the calcium levels induced by IL-8. 
Statistical significance was tested by a Within Sample two-way ANOVA with 
Sidak’s multiple comparisons post-test. Data are presented as the average MFI 
recorded ± SD over three independent experiments. ** = p<0.005, *** = 
p<0.001, **** = p<0.0001 B) The fold increase in cytosolic calcium levels before 
and after treatments. Cadmium induced a statistically significant, non-dose 
response increase in cytosolic calcium levels. Statistical significance was tested 
by a Within Sample one-way ANOVA with Holm-Sidak’s multiple comparisons 
post-test. Data is presented as the average MFI recorded ± SD over three 
independent experiments. *= p<0.05 ** = p<0.005, *** = p<0.001. 
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Every concentration tested (1, 3, 10, 30, 100μM) of cadmium chloride induced 
statistically significant increases in calcium levels (p=0.0048, p=0.0047, 
p=0.0002, p<0.0001, p<0.0001 and p<0.0001, respectively). A statistically 
significant positive correlation in calcium levels was observed with increasing 
cadmium concentrations (spearman’s rank correlation coefficient (r=1.000, 
p=0.0028)). 
3.5 Neutrophil extracellular traps 
Neutrophil extracellular traps have been an important focus of neutrophil biology 
since their discovery (108), with excessive levels of NETosis playing a central 
role in several diseases throughout the body. In the context of RA, cellular 
processes which induce higher levels of MPO and PAD during inflammation are 
believed to play a dual role in both NET induction and autoantigen generation 
(155). Having examined the effect of cadmium exposure on several common 
neutrophil functions, attention was focussed on determining if cadmium 
exposure play a role in altering NETosis.  NETosis is a complex process, 
consequently a number of techniques have been established to measure this 
process, with varying degrees of success.  In this study several NETosis 
methodologies were established and evaluated with respect to cadmium 
exposure on neutrophils. 
 
3.5.1 Initial experiments regarding cadmium and NETosis 
Initially, overnight neutrophil-cadmium experiments were conducted to discern 
any neutrophil morphological changes, or evidence of cell death via Diffquik™ 
staining.  
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Neutrophils were isolated and suspended into reaction tubes at volumes of 
1x105 cells and incubated with 1, 2.5, 5, 10 and 50μM of CdCl2 in RPMI1640 
without serum. After incubation, cells were cytospun and Diffquik stained; 
neutrophils appeared to form protrusions that resemble features of strands of 
DNA, akin to NETosis (Figure 3.10). NETosis by definition is composed of 
nuclear material released into the extracellular space. To examine if these 
extracellular strands detected by this method of staining were truly NETs, the 
experiment was repeated employing an immunofluorescent method.  
In brief, 1x106 neutrophils were incubated for 16h at 37oC with various 
concentrations of cadmium chloride and a fraction of cell suspension was spun 
onto a microscope slide via cytospin centrifuge at slow speed (200 RCF). Slides 
were stained for nuclear material with DAPI and citrullinated protein. DAPI 
staining confirmed that the projections were in fact nuclear material, indicative 
of NETosis (Figure 3.11). Even more interesting was the detection of 
citrullinated protein in an extracellular space, providing the first suggestion that 
cellular exposure to cadmium may result in post translational modification of 
neutrophil proteins (bottom left image in Figure 3.11, stained in green). 
 
3.5.2 Immunofluorescent staining of NETs 
To confirm the initial findings of cadmium induced NETosis, a further 
immunofluorescent method was established using HL60-derived neutrophil-like 
cells.     
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Figure 3-10 Neutrophils produce NET-like protrusions upon treatment of 
cadmium chloride.  
Diffquik staining of treated neutrophil isolates treated with cadmium was 
performed after a 16 hour incubation. Concentration of cadmium is shown in the 
bottom right corner. Neutrophils can be seen releasing strands of material into 
the extracellular space, forming a network of protrusions. 
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Figure 3-11 Initial immunofluorescent staining of neutrophils undergoing 
NETosis in response to cadmium.  
Neutrophils were probed for citrullinated protein (green) and stained for nuclear 
material with DAPI (blue). NETs can be observed from as low as 2.5μM of CdCl2. 
Citrullinated protein can be observed in a cluster of extracellular space at 10μM. 
Concentration of cadmium and magnification for each image can be seen at the 
bottom-left of each image. Green staining was not universally present in each 
treatment group. 
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HL60 cells were treated with 1-ATRA for 3 days and then incubated with or 
without 100nM PMA on 8-well chamber slides. After 3 hours, cells were fixed 
with 4% paraformaldehyde and permeabilized with 0.1% v/v Triton-X100. Cells 
were stained for myeloperoxidase (green) and citrullinated histone-h3 (red), two 
components found in NETs, in addition to DAPI staining (blue) to confirm the 
presence of DNA. 
Figure 3.12 demonstrates an example of using immunofluorescence to 
examine NET production. In theory, DNA and MPO should be visible along with 
citrullinated histone H3. Through immunofluorescence, a triple stained fibre 
should be connected to the nucleus of the cells. These experiments found no 
evidence for a co-localisation of all three proteins, suggesting no classical sign 
of NET production taking place. Links between cells were observed in the form 
of citrullinated histone H3, though no co-localisation with MPO or DNA was 
observed, posing the question that without DNA or myeloperoxidase, what 
exactly is connecting the cells observed in Figure 3.12. 
Unfortunately, this line of research yielded no clear evidence of NETosis. 
Although co-localization of citrullinated histone H3 and DAPI was seen in 
places, the co-localization of the above two proteins and MPO suggested that 
these may not have been NETs. The lack of consistent sign of NETs in 
experiments using PMA posed a challenge in being able to determine if 
cadmium was capable of inducing NETosis, and so an alternative approach was 
used.  
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Figure 3-12 Citrullinated histone H3 is present in projections from HL60 
neutrophils, but not co-localised with DNA or myeloperoxidase.  
HL60 derived neutrophils were stimulated with PMA and immunofluorescent 
staining of citrullinated histone H3 (red), myeloperoxidase (green) and DNA 
(blue). Images were taken at 40x magnification. 
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3.5.3 Live cell imaging of neutrophils induces a form of cell death 
separate to apoptosis 
In order to abrogate the inconsistency posed by immunofluorescence imaging 
of individual cells at a given time point, live cell imaging was chosen as a means 
to determine if NETosis was occurring in a population of cells over time. 
Live cell imaging on the JuLi stage cell recording system was used to establish 
a more objective and quantitative approach for monitoring NET induction.  
Before using primary neutrophils, HL60 neutrophils were employed to establish 
the method for routine use.  
HL60 neutrophils were loaded with DiI (Inivtrogen, UK) to visualise cells, and 
then seeded onto 96-well plates in serum-free media in order to adhere to the 
bottom of the microplate. During this time focal planes were set before adding 
the agonist and fluorescent probes.  100nM PMA alongside both Hoescht stain 
for detection of cellular DNA, as well as SYTOX green, a cell impermeable DNA 
dye used widely to monitor NETosis, was used to detect extracellular DNA.  
The results from live cell imaging demonstrated an interesting phenomenon 
separate to apoptosis that differed from conventional NETosis. Cells treated 
with 100nM PMA rapidly took up Sytox dye inside the cell, before forming a 
circular ring around the cell. In Figure 3.13 evidence of this process can be 
seen, with cells indicated by green circles rapidly forming a ring around the cells 
kept closely associated with the cell membrane.  
The argument for this being NETosis lies upon the postulation that in live-cell 
imaging, no source of shear flow is exerted on the cells, therefore unless 
nuclear DNA is forcibly ejected from the cell, it would remain associated with the 
neutrophil or bound to the plastic immediately surrounding the cell.  
134 
 
  
Figure 3-13 Neutrophils retain DNA around the membrane of the cell in a death process dissimilar from apoptosis when 
exposed to PMA.  
Primary neutrophils were seeded on a 96 well plate and exposed to 100nM PMA in addition to SYTOX green (green), DiI (red) and 
hoescht stain (blue). Green circles indicate cells undergoing the process of “haloing”, whilst red circles identify cells hav ing undergone 
apoptosis and subsequent blebbing. Images were taken 5 minutes apart at 20x magnification.  
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Figure 3.13 also demonstrates that this different to apoptosis, as indicated by 
the red rings. Membrane blebbing can observed in this population of cells, and 
the dissimilarity of the two ringed populations highlights a greater chance of 
NETosis than apoptosis or necrosis. 
To interrogate this further, a more biochemical approach was optimised to 
assay NETosis, using a SYTOX green spectrofluorometric assay. To provide 
more consistently reproducible data that could directly quantify SYTOX green 
fluorescence, a plate-based high-throughput bioassay was used. First 
demonstrated by Gupta and colleagues, this assay allows an easy, reliable 
method to quantify NETosis (120). The principle behind this assay is to directly 
measure the green fluorescence emitted by SYTOX green upon extracellular 
DNA binding using a spectrofluorometer, and comparing cadmium treated 
samples against untreated and PMA-treated populations of neutrophils. This 
then allows the extra validation of generating data points that can undergo 
statistical analysis to determine if cadmium does truly induce NETosis.   
 
3.5.3.1 PMA reliably induces NETosis in a spectrofluorometric SYTOX 
green assay 
A concentration-response of HL60-derived neutrophils treated with PMA (10-
100nM) was performed to find as low a concentration as possible that was 
capable of inducing NETosis as PMA is not a physiological source of PKC 
activation (Figure 3.14).  
HL60-derived neutrophils were seeded in 96 well plates and allowed to adhere 
to the plate for an hour. After this, varying concentrations of PMA were added to 
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each well and incubated for 3 hours. After incubation, SYTOX green was added 
to detect extracellular DNA (exDNA) and therefore quantify NETosis. 
Levels of extracellular DNA detected by SYTOX green upon PMA stimulation 
were within similar quantities between the concentration windows of 50-100nM 
of PMA. At lower concentrations, SYTOX green still detected increases in 
exDNA, though at diminished levels before 50nM. With this in mind, 50nM was 
chosen for future experiments as the optimal concentration to use for SYTOX 
assays. 
3.5.3.2 Cadmium does not induce NETosis as determined by the SYTOX 
green assay 
Once the positive control concentration was established, this system was tested 
against various stimuli to determine if cadmium does truly induce NETosis. In 
addition to cadmium, additional pathological agonists based on the literature 
were used . Bronchiectasis patients with chronic lung infections often are 
infected with P. aeruginosa. It was therefore warranted to test if LPS from this 
microbe was capable of inducing NETosis in a similar manner to other species 
reported in the literature, such as E. coli.  In addition, a further chemical inducer 
of NETosis, ionomycin, was included as a positive control. None of the 
concentrations of cadmium tested significantly changed any exDNA levels 
detected by SYTOX green (Figure 3.15a). In addition to this, none of the 
concentrations of LPS tested changed exDNA levels compared to control. 
Ionomycin significantly increased exDNA levels compared to control 
(p=0.0001). 
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Figure 3-14 Consistent levels of NETosis can be induced by PMA from 
50nM concentrations.  
HL60 derived neutrophils were treated with 10-100nM concentrations of PMA 
and incubated for 3 hours to allow NETosis to occur. SYTOX green was added 
to the plate post-incubation and green fluorescence levels were recorded. 50nM 
induced similar levels of NETosis to higher concentrations used. Data are 
shown as relative fluorescence units of green fluorescence over three 
independent experiments. Data values are presented as mean RFU recorded ± 
SD over three independent experiments. 
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Figure 3-15 Neither cadmium, nor LPS results in a significant increase in 
extracellular DNA levels.  
Isolated primary neutrophils were treated with various doses of cadmium 
chloride and lipopolysaccharide, alongside ionomycin. Cells were incubated for: 
A) 3 hours or B) 24 hours before adding SYTOX green to measure extracellular 
DNA levels. Data are presented as relative fluorescence units ± SD for three 
independent experiments. Statistical significance was tested by one-way 
ANOVA with Holm-Sidak’s post-test. *** = p<0.001 **** = p<0.0001. Dotted lines 
in 3.14b indicate individual comparisons to the control samples. 
139 
 
These data would suggest that neither cadmium nor LPS induce NETosis in a 
3h time window. In order to further evaluate if the neutrophil response was 
delayed, these experiments were repeated with a 24h incubation, before 
measuring exDNA. 
Upon repeating this experiment with a 24h incubation window, all 
concentrations of LPS tested (50, 100, 500 and 1000ng/ml) significantly lowered 
the levels of extracellular DNA in neutrophils (p<0.0001 for all concentrations – 
Figure 3.15b). Cadmium also exhibited this effect at the 50µM concentration, 
with significantly lower exDNA being detected compared to control samples 
(p<0.0001).  Lower concentrations of cadmium caused no significant changes in 
exDNA levels (Figure 3.15b). 
With the effect of direct cadmium exposure not eliciting any response in terms 
of direct NET induction, any effect of cadmium on PMA-induced NETosis was 
examined. Firstly, HL60-derived neutrophils were pre-incubated with cadmium 
chloride for 16 hours in low concentrations (1, 2.5, 5, 10 and 15µM). Cells were 
then treated with 100nM PMA for 3 hours before quantifying DNA with SYTOX 
green. 
Cadmium pre-incubation exhibited no modulatory effect on NET induction in 
PMA-treated neutrophils (Figure 3.16). Statistical analysis showed significant 
differences between the Cd-untreated and Cd-PMA treated cohorts. No 
significance was observed between each cadmium treatment group. 
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Figure 3-16 Overnight pretreatment of cadmium does not enhance 
NETosis in PMA-treated neutrophils. 
 HL60-derived neutrophils were seeded and incubated for 16 hours with low 
doses of cadmium chloride. After this time, cells were exposed to 100nM PMA 
to induce NETosis. After 3 hours, SYTOX green was added to the plate and 
green fluorescence was measured. Statistical significance was tested by a 
within sample two-way ANOVA with Sidak’s multiple comparisons tests 
comparing RFU’s between untreated and PMA treated populations, in addition 
to testing for significance between each individual treatment in each group. No 
statistical significance was observed between any of the PMA-treated 
neutrophils. Data are shown as mean RFU ± SD over three independent 
experiments. **** = p<0.0001. 
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As an enhanced level of ROS production in cadmium and PMA treated 
neutrophils had previously been observed, the effect of concurrent stimulation 
with cadmium and PMA on NETosis induction was also considered. HL60-
derived neutrophils were co-incubated with the same treatment doses as 
observed in Figure 3.16, for 3 hours. Intensity of NETosis was once again 
conducted by measurement SYTOX green fluorescence.  
Of all the treatment dose of cadmium used, 15µM Cd co-incubated with PMA 
caused a statistically significant increase in the quantity of DNA release through 
PMA-induced NETosis compared to “no cadmium” treatment (p<0.001) (Figure 
3.17).  No other treatment of cadmium demonstrated statistically significant 
changes in DNA levels compared to the untreated group.  
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Figure 3-17 Co-treatment of cadmium enhances levels of NETosis at 
higher concentrations.  
HL60-derived neutrophils were seeded and incubated for 3hours with cadmium 
chloride and 100nM PMA. After 3 hours, SYTOX green was added to the plate 
and green fluorescence was measured. 15µM of CdCl2 induced a significant 
increase in extracellular DNA compared to any other treatment used. Statistical 
significance was tested by a within sample two-way ANOVA with Sidak’s 
multiple comparisons. Dotted lines represent comparisons between 15µM 
CdCl2 treatment and the treatment dose in question. Data are shown as mean 
RFU ± SD over three independent experiments. * = p<0.05 ** = p<0.01 
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3.6 Discussion 
Previous studies have demonstrated effects of cadmium on neutrophil function 
(314, 323). These findings were expanded, using a wider range of cadmium 
concentrations in these experiments, focusing on phagocytosis, calcium flux 
and NETosis. Under the test conditions described in this thesis, cadmium did 
not appear to have an adverse effect on any of neutrophil functions examined, 
although cadmium did induce changes in cytosolic calcium levels. Contrary to 
initial findings, cadmium did not induce NETosis when tested via the plate-
based SYTOX green assay. Of interest was the lack of NETosis induced by 
LPS, which has historically been shown as a potent inducer of this process. 
Recently, cadmium has been shown to influence lung injury by enhancing 
neutrophil extracellular traps via a ERK1/2 and p38 MAPK signalling pathway 
(324). However this latter study was performed in mice and might not translate 
to human cells.  In the current work human neutrophils are seemingly resistant 
to cadmium treatment. 
 
3.6.1 Effect of cadmium on cell viability 
Cadmium is a known cytotoxic agent for a variety of cells in the body (24-29). In 
light of this, the lack of cytotoxic response in neutrophils is puzzling, given the 
short-lived nature of the cell, and propensity to die when exposed to toxic stimuli 
during bouts of infection, for example (325). Neutrophils have been previously 
incubated with cadmium chloride for 48 hours at concentrations ranging 
between 0-200µM in concentration (326).  Apoptosis was found to increase 
from 5% in untreated cells, to 40% in neutrophils exposed to 300µM, in a dose-
responsive manner (326). The explanation for differences observed may be due 
to the conditions through which the neutrophils were treated. In the study by de 
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la Fuente et al, isolated mononuclear cells were resuspended in RPMI-1640, 
supplemented with foetal bovine serum, in addition to penicillin and 
streptomycin. This work resuspended neutrophils in HBSS without any other 
forms of supplementation, apart from 10% autologous serum, in order to 
prevent any other influence to cell longevity than the treatment compound in 
question. Even in the untreated group, cells were readily undergoing apoptosis 
within 24 hours, as is accepted to be the standard lifespan of neutrophils in the 
body (327). 
It may well be that the concentrations of cadmium that were used in these 
experiments were simply too low to exhibit cytotoxicity in neutrophils. 
Macrophages are resistant to apoptosis when exposed to cadmium, requiring a 
concentration of 200µM in order to undergo apoptosis. This suggests that the 
phenomenon of cadmium resistant cytotoxicity may not be restricted to 
neutrophils alone (300). 
A human is thought to possess approximately 26ml of lung lining fluid (328). 
From this, it may be postulated that an inhaled dose of 2.2µg Cd from a 
cigarette would result in the lung fluid containing up to 1µM of cadmium 
(although localised concentrations could be higher), which then poses the 
question of how relevant the tolerance limits are for immune cells when such 
levels of exposure are unlikely to be encountered in vivo? The levels of 
cadmium in the lungs may be further estimated through measurements of 
cadmium in BAL fluid of smokers, which found a concentration 0.8µg/L, which 
translates to 0.185nM resting concentration, further lending credence to the 
10% lung retention of cadmium estimated by Mannino et al. (6, 7, 65). 
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3.6.2 The effect of cadmium on neutrophil function 
It has been reported that cadmium diminishes the response of the respiratory 
burst in neutrophils and macrophages when challenged by bacterial stimuli 
(329). This has been theorized by Loose et al to be due to an inhibitory effect of 
cadmium on myosin ATPase (329). This was subsequently disproved by 
Nimura et al, who found that cadmium actually plays a stimulatory role on 
myosin ATPases, with cadmium ions mimicking the role of Ca2+ ions and 
subsequently enhances enzyme activity (330). In plants, cadmium increases 
levels of H2O2, through interaction with NADPH oxidase (331-334). In 
macrophages, cadmium increases production of superoxide and nitric oxide 
over a 48 hour period from 400nM exposure (335). This may be due to 
activation of oxidative stress inside the cell, rather than the immunological 
function of the respiratory burst, however. Freitas et al. found that the 
respiratory burst in neutrophils was induced by 500 and 1000µM of CdCl2 in a 
luminol chemiluminescence assay (336). Furthermore, these same 
concentrations also enhanced ROS production in PMA stimulated neutrophils. 
Freitas et al. treated neutrophils with PMA and cadmium in a similar 
experimental style as performed in this thesis, though only uses a blank as a 
control for the experiment, not a negative treatment control. However, Freitas et 
al. used a luminol chemiluminescence assay to measure ROS and reported 
production in neutrophils from 0.5-1mM treatments. However, luminol directly 
interacts with various heavy metal ions, including copper and cadmium, which 
may be giving false-positive reads in assays due to direct chemical reaction, as 
opposed to inducing production of ROS which then reacts with the detection 
agent (337, 338). 
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Contrastingly, Zhong et al. reported no production of ROS upon cadmium 
stimulation, providing conflicting reports as to whether or not cadmium induces 
the respiratory burst in neutrophils (339). These data agree in part with the latter 
study: It has been shown that cadmium by itself does not induce the respiratory 
burst in neutrophils through usage of the highly accurate DHR123 dye (322). 
However, this work has also shown that cadmium enhances production of ROS 
in neutrophils stimulated by PMA. This resembles similar findings by Ramirez et 
al, who noted increases in nitric oxide production in macrophages incubated 
with PMA and cadmium, as opposed to PMA alone. Taken together, this may 
suggest that cadmium by itself does not affect the respiratory burst in 
neutrophils, though may prime them for an even stronger response once 
stimulated by other means (340). 
The process of phagocytosis appears to be modulated somewhat by exposure 
to cadmium. Greenspan et al noted a diminished phagocytic response in 
macrophages exposed to 100 and 200µM of CdCl2, remaining relatively 
unmodified when macrophages were exposed to 20 and 50µM concentrations 
(341). These results somewhat reflect these findings, as phagocytosis was 
unaffected by any of the concentrations of cadmium chloride that were tested. 
These differences may simply reflect the different cell types utilised, i.e. primary 
human neutrophils versus alveolar macrophages from rats. Levy et al reported 
no influence of cadmium on the ability for macrophages to bind to 
immunoglobulins through Fc receptors, or complement through complement 
receptors, though did affect the process of endocytosis, with cells displaying a 
delayed ability to clear ingested particles (323). 
Although not ideal, hemocytes (from molluscs) are comparable to human 
neutrophils, so allow us to somewhat draw parallels to mammalian cell 
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functioning (342). Research on the effect of cadmium on hemocyte 
phagocytosis found reduced phagocytic capacity of cells, though the authors 
concluded this may be as a result of reduced cell viability (343). 1mM of CdCl2 
inhibits 20-70% of phagocytosis in a variety of hemocytes isolated from various 
bivalve species, though this was unaffected in concentrations lower than this 
(344). 
A common theme can be noticed throughout these positive results in the 
literature. Interference of phagocyte functions is perturbed by cadmium only at 
supra-physiological levels of 100µM or above. This far exceeds the 
physiological levels that would likely be encountered by cells in the body, and is 
the main reason why it was decide to keep the experimental concentrations in 
this thesis between 1-100µM. 
In all the assays used, cadmium did not directly stimulate any neutrophil 
functions. The only response observed was during the respiratory burst, in 
which neutrophils stimulated with PMA appear to produce a greater amount of 
ROS in the presence of low concentrations of cadmium.  Phagocytic capacity 
was not affected by cadmium treatment, nor did it affect the quantity of particles 
internalised by phagocytosis. 
Calcium levels inside cells have long been known to increase upon cellular 
exposure to cadmium (345). Of all the heavy metals (cadmium, cobalt, nickel, 
iron and manganese,) cadmium evokes the strongest release in a variety of 
cells, typically increasing calcium levels 10-fold (345, 346). In murine 
neutrophils, Mei et al. reported a diminished calcium mobilisation response in 
cadmium-pretreated neutrophils upon stimulation with fMLP (347). The authors 
also reported reduced levels of phosphorylation of p38 and ERK1/2, indicating 
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that cadmium may interfere with cell signalling pathways in these cells (347). 
The authors concluded that this may interfere with chemotactic response to 
bacterial peptides. 
This data is in line with the literature, in that it has shown that in human 
neutrophils, cadmium induces an increase in cytosolic calcium levels. This 
increase may affect the second messenger systems inside the cell, which may 
result in aberrant responses to external stimuli. Protein kinase C activity is 
enhanced through cadmium displacing the Zinc ion on the enzyme, resulting in 
a greater response when stimulated by PMA in fibroblasts (348). This may 
account for the greater respiratory burst when cadmium was co-incubated with 
PMA. 
The lack of reactive oxygen species production from cadmium alone in these 
experiments however, would indicate that cadmium may not be directly 
stimulatory in neutrophils. The effect may be more of a priming nature, in which 
neutrophil activity is enhanced by cadmium, to an exaggerated degree. This 
effect could partly explain cadmium-induced inflammatory processes. 
 
3.6.3 The controversy of NETosis in the scientific literature 
NETosis remains an elusive concept in research in terms of how reliable 
published literature is in reporting NETosis through experimental means. Konig 
et al reported various issues with groups reporting NETs, and how valid were 
the findings (111). The authors argue that certain NET process that have been 
reported as NETs may in fact be morphologically similar, yet still different. They 
also argue that NETosis is NADPH oxidase dependent, any form of NET that 
does not utilise this pathway is in fact not NETosis.  
149 
 
During the process of discerning if cadmium induces NETosis in neutrophils, 
several conflicting points were encountered. Firstly, the standard culture 
conditions used to induce NETosis are contradictory in that culture medium 
contains certain compounds that theoretically inhibit the detection of neutrophil 
extracellular traps. Foetal bovine serum, a vital component of tissue culture 
practice, contains DNAses that degrade nuclear material, in addition to 
antioxidants that may attenuate ROS production required for NET creation (349, 
350). Additionally, tissue culture media are frequently supplemented with 
penicillin/streptomycin. Interestingly, streptomycin inhibits PAD4 in micromolar 
concentrations (351). Standard media preparation estimates that 1% 
streptomycin equates to roughly 17µM concentration, therefore would strongly 
inhibit PAD4, resulting in a lack of appropriate activation during pathways that 
may be citrullination-dependent. 
Furthermore, using cytospins as a means of cellular fixation before conducting 
immunofluorescent staining may lead to false-positive results. This preliminary 
data found evidence of NETosis upon overnight incubation of cadmium. Upon 
subsequent repeats, it was evident that the fibres observed through microscopy 
although appearing to be NETs, were possibly nuclear material that was 
released outside of the cells during the centrifugation process. Certain studies 
use this technique to discern NET production, but it may be wise to avoid this 
appproach to ensure accurate depiction of NETs (352-354). 
Live cell imaging as reported in the literature also poses several questions 
pertaining to the reliability of the data. Some studies show results typical of 
those found via immunofluorescent staining (113, 120). These data 
demonstrated the formation of ring-like structures that were anchored to the 
membrane of cells that stained positive for SYTOX green upon stimulation with 
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PMA. In live cell imaging, cells are focused and observed over a period of time 
to monitor changes through use of various dyes. In this system, no source of 
shear flow is present to exert any force on the cells and therefore direct 
movement of DNA to form the typical strands of DNA observed by 
immunofluorescent staining. In the study by Gupta et al, for example, a 
probable source of lateral flow is required to tease out the strand-like SYTOX 
green signal during NETosis (120). 
It is acknowledged that visualisation of NETosis can be challenging, such that 
newer dyes (such as cytotox green) are being manufactured that may improve 
the reliability of data obtained using live cell imaging (355). 
After trying immunofluorescence and live-cell imaging, the most reliable data 
was obtained through spectrofluometric quantification of extracellular DNA 
using SYTOX green. This assay provided high throughput, quantifiable data, 
though presents caveats itself. Firstly, SYTOX green is a non-permeable DNA 
dye, which in theory has several strengths in quantifying NETosis, as it 
theoretically only binds to DNA from cells that have undergone the process of 
NETosis. However, this dye also binds DNA from cells that have undergone 
apoptosis, as shown from the live cell imaging data. This potentially means that 
the spectrofluorometric assay could detect both NETosis and apoptosis, though 
given these results only show a significant increase in DNA levels upon PMA 
treatment, the question really is if PMA induces apoptosis in neutrophils.  Saito 
and colleagues have reported PMA-induced apoptosis, citing observations of 
chromatin condensation upon treatment independent of caspase-3 (356). This 
is not the first time PMA-induced apoptosis has been reported, though both 
Takei et al. and Saito et al.  state that this was a form of cell death separate to 
conventional apoptotic pathways (127, 356), and may therefore have been 
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NETosis, with these studies being published before the ground-breaking work 
by Brinkmann et al. opened the door to this new insight on neutrophil biology 
(108). It can therefore be assumed that PMA may be inducing negligible 
amounts of cell death in neutrophils compared to the large quantities of 
NETosis usually reported. 
More interestingly, no levels of NETosis were observed upon stimulating 
neutrophils with LPS. This has historically been shown to stimulate neutrophils 
into undergoing NETosis (reviewed in (113)). The reasons for this may be due 
to lack of second stimulus such as ATP, as LPS is thought to prime neutrophils 
before subsequent activation by another molecule (357). Nevertheless, 
Brinkmann and colleagues still observed formation of NETs in response to LPS 
alone (108). 
Another explanation for the lack of NET induction may be due to pH of the 
media in question. Lipopolysaccharide-induced NETosis is influenced by pH, 
with higher pH inducing a greater level of NETs, being non-existent at pH 6.6, 
yet substantially increasing at pH 7.8 (358). As pH was not factored in during 
the design of these experiments, nor was this novel data available at the time, 
this may also have impacted on these data. 
3.6.4 Conclusion 
Based on these data, it can stated that cadmium has no clear effect on 
neutrophil function. However, it appears that cadmium may prime, or modulate 
neutrophil responses through enhancement of protein-kinase C function, which 
in turn results in greater responses from activation of this pathway when further 
stimulated by PMA. The increase in cytosolic calcium levels upon cadmium 
exposure may also influence other secondary messenger systems inside the 
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cell, though which functions may be affected by this remains unknown. These 
changes ultimately result in greater levels of ROS production and NETosis, 
which has consequences in inflammatory events, as this enhanced response 
may result in host tissue damage. The argument may be made once again that 
15µM of CdCl2 is not physiologically relevant, however the use of greater 
concentrations of cadmium in the cadmium-PMA co-incubation SYTOX green 
assay may reveal a more exaggerated response than what has already been 
observed. The lack of apoptotic cell death upon cadmium exposure highlights 
that those pathways are not initiated. Having examined whether cadmium may 
contribute to RA pathogenesis through neutrophil dysfunction, it was decided to 
examine the effect of RA serum on neutrophils, to determine if serum from 
patients with varying degrees of clinical severity had any direct influence on 
neutrophil functions in vitro. 
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4 The effect of rheumatoid arthritis patient 
serum on the neutrophil response 
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4.1 Introduction 
Neutrophils are present at all stages of RA pathology, from both the onset of the 
disease, to the ongoing pathology once immune tolerance has broken down 
(245). The objectives of this chapter were to: 
• Examine the effect of RA serum on the neutrophil respiratory burst, 
NETosis and calcium flux 
• Ascertain if RA serum from patients with varying disease severity 
correlates with any dysfunctional responses seen in neutrophils 
• Investigate whether elevated levels of individual clinical parameters 
(anti-CCP, RF, DAS-28) in RA serum contribute to altered functioning of 
healthy neutrophils 
 
4.2 Cohort serology 
Sera from RA patients across the South-West of the UK were gathered based 
on a variety of patient selection criteria. The intention with this cohort was to 
discern the influence of cadmium levels (determined through measurement of 
patient urine samples) on clinical serological scores.  The concentrations of two 
stable isotopes of cadmium (Cd-111 and Cd-112) were independently 
measured at the SAS Trace Element Laboratory in Guildford, Surrey, by 
inductively coupled plasma mass spectrometry.  The average values in nmol/L 
were calculated between these two isotope cadmium species and used as a 
value for clinical correlation analysis. In addition to urine samples, serum was 
collected from over 200 individuals, with all patient history including smoking 
status, age and urinary cadmium level (Table 4.1). Measurement of urinary 
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cadmium levels for the population were performed before the project began, 
though ideally, serum measurement would have been preferable.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4-1 A summary of RA patient cohort exposed to varying levels of cadmium.  
This table summarises the various clinical history of the patient serum samples collected in 205 RA patients.   
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A Spearman’s rank correlation coefficient was used to compare urinary 
cadmium level against RF, Anti-CCP, DAS28 and age. A highly statistically 
significant correlation was observed between cadmium and RF levels 
(P=0.0004, r=0.2393). To confirm the general correlation between RF and CCP 
typically found in RA patients, a Spearman’s rank correlation was performed 
between these two parameters (359). Rheumatoid factor titres statistically 
significantly correlated with anti-CCP (p< 0.0001, r = 0.3395).  
To further discern the influence of cadmium on clinical measurements, the 
cohort was sorted by urinary cadmium level into upper and lower (75% and 
25%) quartiles. An analysis was done to compare RF, anti-CCP and DAS28 
scores between the upper and lower quartiles and tested for statistically 
significant differences.   
The low-cadmium quartile had levels between 0.054 and 0.296 nmol/L of 
cadmium, and the high-cadmium quartile ranged between 0.7902 and 7.3 
nmol/L. Statistical analysis through spearman’s rank correlation coefficient 
demonstrated that RF titres were significantly higher (p=0.0017) in the 
cadmium-high group compared to the cadmium-low group (Figure 4.1). Anti-
CCP titres and DAS-28 scores were not significantly different between these 
two groups (p=0.4682 and p=0.0878, respectively). 
To evaluate any further potential relationships between cadmium and RA, the 
cohort was also divided into ever and never smokers. Comparisons between 
RF, CCP, DAS28 and urinary cadmium levels in these two groups were 
calculated (Figure 4.2). Urinary cadmium levels were statistically significantly 
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higher in the ever smoking group (p=0.0014), as expected. Rheumatoid factor 
was also significantly higher in the ever smoking cohort (p=0.0351).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-1 Rheumatoid factor titre, but not anti-CCP titre of DAS-28 score, is 
significantly higher in RA patients with a higher urinary cadmium level.  
The lowest and highest quartiles of urinary cadmium level in a cohort of 200 RA patients were 
compared to one another and rheumatoid factor titre, anti-CCP titre and DAS-28 scores were 
compared between the two groups. Mean rheumatoid factor levels were significantly higher in 
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the highest Cd-level quartile of RA patients, although DAS-28 and anti-CCP levels were not 
statistically significantly different between these two groups. .Statistical significance was tested 
by Mann-Witney test. *** = p<0.005  
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Figure 4-2 Cadmium levels and rheumatoid factor levels are significantly 
elevated in RA ever smokers vs RA never smokers, but not disease 
activity or anti-CCP titres.  
The cohort of RA patients was separated into never smokers and ever smokers, 
and Mann-Whitney tests were used to test for statistical significance between 
RF, urinary Cd level, anti-CCP and DAS-28 levels. RF and urinary Cd levels in 
ever smoking cohort were significantly higher than the never smoking cohort.    
* = p<0.05, ** = p<0.01. Error bars are displayed as Median ± IQR.  
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Disease activity scores and anti-CCP antibody titres were not significantly 
different between the two groups (p=0.9943 and p=0.5946, respectively). Once 
again, Spearman’s rank correlation was employed to test differences between 
cadmium level and smoking. Spearman’s rank correlation coefficients and the 
corresponding p values are shown in Table 4.2. In the never smoking cohort, 
urinary cadmium level statistically significantly correlated weakly with anti-CCP 
levels (r = 0.2586, p=0.0272). 
No statistical significance was observed between urinary cadmium levels, and 
RF and DAS-28 levels in the never smoking cohort. In the ever smoking cohort 
however, a different trend was observed. Urinary cadmium levels significantly 
correlated with RF titre (r=0.2279, p=0.0066), but not anti-CCP or DAS-28.After 
having examined this cohort of RA patients to establish any potential 
relationship between cadmium on RA patient outcomes, anti-immunoglobulin 
antibodies in the form of RF titres appear to correlate with urinary cadmium 
level.  
4.3 Experimental work  
Having first looked at the effect of cadmium directly on neutrophil function, it 
was decided to replicate these functional assays with the serum of specifically 
selected RA patients with varying degrees of RA severity. Given the association 
between elevated Cd and RF in RA smokers, it was decided to see if serum 
factors in these patients altered neutrophil function. Eight RA patients were 
chosen that had high or low levels of the following parameters: urinary cadmium 
level, rheumatoid factor, anti-CCP or DAS-28. In addition to this, four healthy 
donors were used to act as a non-disease control. The full clinical data for these 
12 individuals can be found in Table 4.3. 
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Table 4-2 Urinary cadmium levels in RA patients correlate with RF titres in ever smokers, but not never 
smokers.  
A cohort of RA patients was separated into never and ever smoking groups. Correlations between the three 
serological markers and urinary Cd level were analysed using Spearman’s rank correlations. In the ever smoking 
group, urinary Cd levels correlated weakly positively. * = p<0.05 ** = p<0.01  
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Table 4-3 Clinical information regarding samples used for neutrophil 
functional assays.  
The serum of eight rheumatoid arthritis patients and four healthy control 
patients was selected for neutrophil functional assays. The RA patients were 
selected as a result of a key serological identifier as shown in the right hand 
column. 
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Serum components are known to alter neutrophil function (360). Selected sera 
were first used to test their effect on altering the respiratory burst in 
neutrophils.Neutrophils were isolated from healthy controls, resuspended in 
HBSS and incubated with DHR123 in addition to a 1:10 dilution of sera from the 
chosen individuals as described in Table 4.3. In addition, autologous donor 
serum was used as a control. In these preliminary data, none of the serum 
samples tested induced ROS production in isolated primary neutrophils (Figure 
4.3). To ensure the assay was working correctly, neutrophils were stimulated 
with a potent ROS agonist – 100 nM PMA, which increased fluorescence 100-
fold above non-PMA treated neutrophils.  
Next, the ability of patient sera to induce calcium flux in healthy isolated 
neutrophils was investigated. The first step was to examine calcium flux in 
neutrophils following a similar format to the experiments conducted with 
cadmium (Section 3.4). Primary neutrophils were isolated from whole blood 
and incubated with the calcium dye fluo-4-AM diluted in HBSS for 1 hour at 
37oC. After incubation, baseline calcium level was measured by flow cytometry 
before adding an aliquot of serum (final dilution - 1:10) to neutrophils and 
measuring the change in calcium above basal levels in each sample.  
Sera from two of the RA patients did induce statistically significant calcium 
release in neutrophils (Figure 4.4). These were RA84 (p=0.0271) and RA86 
(p=0.0289), which had the highest anti-CCP titre and highest DAS-28 score 
respectively. 
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Figure 4-3 Serum from RA patients or healthy donors does not induce 
production of reactive oxygen species in primary neutrophils.  
Primary neutrophils were isolated and treated with a 1:10 dilution of serum 
sample. No increase in fluorescence was observed upon serum treatment, 
suggesting that neither healthy or RA patient serum induces the respiratory 
burst in neutrophils. Data values are shown as average MFI ± SD of two 
independent experiments. 
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Figure 4-4 Serum from RA patients with high disease activity or high anti-
CCP titre induced significant increases in baseline calcium level.  
Neutrophils were incubated with the calcium dye fluo-4-AM for 1 hour before 
measurement of baseline cellular calcium level via flow cytometry. After this 
initial measurement, serum samples were added to cells at a 1:10 dilution and 
the calcium level was measured once more. Of all the serum samples tested, 
RA84 and RA86 (highest anti-CCP serum and highest DAS-28 serum, 
respectively), were the only samples that significantly increased calcium levels 
compared to unstimulated (HBSS) neutrophils. Statistical analysis tested for 
significance by RM two-way ANOVA with Tukey’s multiple comparisons test. 
Data are shown as mean MFI ±SD over two independent experiments. * = 
p<0.05.  
 
166 
 
Statistical significance was tested via use of within sample two-way ANOVA 
with Tukey’s multiple comparisons test.  Noting minimal and isolated changes in 
neutrophil ROS and calcium flux changes upon serum exposure across all 
serum samples tested, it was investigated further to establish if RA serum was 
capable of inducing NETosis in neutrophils, as literature demonstrates a high 
propensity of RA patient neutrophils to undergo NETosis (249, 361). In RA 
patients, this is thought to be driven by RF immunoglobulin complexes in the 
form of IgA or IgM bound to IgG (205). With this cohort of varying degrees of 
disease severity, and serology, an investigation into if NETosis was being 
induced by components of RA patient serum was conducted, and further, if 
clinical serology from the sera used to alter healthy neutrophil function 
correlated with the extent of induced DNA released observed. 
HL60 derived neutrophils were seeded onto 96-well plates and allowed to 
adhere to the bottom of the microplate. Post incubation, a 1:10 final dilution of 
either healthy serum or RA patient serum was added to the cells, but also in 
‘cell free’ wells to measure the quantity of any contaminant DNA in each serum 
sample. After a 3h incubation, SYTOX green was added to quantify extracellular 
fluorescence and indirectly confirm NETosis. After quantification, cell-free 
serum sample RFUs were subtracted from the triplicate serum sample RFUs 
and then blank corrected. 
Unexpectedly, the healthy control sera, rather than the RA patient sera induced 
statistically significant increases in release of extracellular DNA from HL60 cells 
compared to non-sera treated cells (p= 0.0115) (Figure 4.5). Moreover, when 
compared to one another, sera from healthy subjects appeared to induce more 
NETosis than RA sera (p = 0.0002). 
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Figure 4-5 Healthy control serum significantly increases extracellular 
DNA, but not RA serum in HL60 derived neutrophils.  
HL60 derived neutrophils were seeded onto a 96 well plate and treated with a 
1:10 dilution of either RA patient or healthy control serum. After 3h incubation 
extracellular DNA was measured by SYTOX green addition. The serum of 
healthy control patients significantly increased extracellular DNA (p=0.0293) 
compared to no significant increase with RA serum (p=0.5680) when 
statistically analysed to the control cells. The increase in DNA between the 
healthy serum and RA serum was also statistically significant (p=0.0002). 
Statistical analysis was performed using a Kruskal-Wallis test with Dunn’s post-
test. Data are shown as the median relative fluorescence units as a normalised 
unit to unstimulated cells. * = p<0.05, ** = p<0.001, *** = p<0.005. Data are 
derived from two independent experiments. 
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Nevertheless, a correlatelation was calculated between the degree of 
extracellular DNA release induced by RA sera with clinical serological data to 
discern if RF had any influence of the degree of DNA release occurring in the 
HL60-derived neutrophils. Spearman’s rank test was used to test if the quantity 
of DNA release correlated to RF, anti-CCP or DAS28 values (Figure 4.6). 
Rheumatoid factor (r=0.03214, p=0.8359), anti-CCP (r=0.03478, p=0.8227) and 
DAS-28 (r=-0.1421, p=0.3756) showed no correlation with DNA release from 
HL60 cells using RA patient serum. This indicates that it is unlikely that RA 
patient serum induces NETosis in HL60-derived neutrophils, and any increases 
in extracellular DNA because of RA sera addition are not related to any 
influencing factor or RA serological markers. Alternatively suppressive factors in 
sera may have influenced the results of the assay.  
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Figure 4-6 The degree of extracellular DNA release induced by rheumatoid 
arthritis patient serum does not correlate with any of the clinical 
serological markers used to monitor RA progression.  
The RFUs of the RA serum (n=44) from the SYTOX green assay were 
normalised to the untreated RFUs. These values were then compared to A) 
rheumatoid factor, B) anti-CCP and C) DAS-28. Statistical analysis used 
spearman’s rank correlation coefficient to test for statistically significant 
correlations. None of the clinical markers significantly correlated with the 
normalised RFU values. Each graph displays both the r value and p value of 
each comparison. 
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4.4 Discussion 
In this section, it has been shown that urinary cadmium levels correlate with RF 
titres in ever-smokers. In this cohort of 200+ RA patients, that in the context of 
urinary cadmium levels, the highest quartile has significantly higher RF titres 
than the lowest quartile. Studies investigating the relationship between RA and 
cadmium are relatively novel, with Joo and colleagues providing the only real 
additional evidence that such a relationship exists (315). This stresses the 
novelty of this finding, and the correlations found within it may support the 
hypotheses posed by this research group (321, 362, 363). 
Examination into the effect of other heavy metals in RA populations is also 
rather scant. Irfan et al. measured the levels of lead, cadmium, nickel and 
chromium in RA patients in Pakistan and found significant increases in these 
serum levels compared to control patients (n=100 for both) (364). In terms of 
why these metals may be influencing RA pathology, Goldberg et al. found that 
silver, mercury and lead negatively affected collagen synthesis in human 
synovial cells, and thus may exacerbate the rate at which the synovium is 
degraded compared to patients where lower levels of heavy metals are present 
(365). 
In a more general sense however, it appears that in healthy isolated 
neutrophils, that the serum of RA patients does not contain any abnormal 
proteins that may evoke a dysfunctional response. In RA patients, neutrophils 
are shown to display irregular responses. In synovial fluid, RA patient 
neutrophils spontaneously release high levels of ROS (366). Cell-free synovial 
fluid from RA patients, and to a lesser extent, serum, also induce the respiratory 
burst in healthy neutrophils (367).  The diminished response seen by serum 
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found to increase respiratory burst activity to roughly 175% (367). This study 
pooled the serum samples of 7 patients however, citing high variability. 
This may well mean that the reason for the lack of response found by the 
respiratory burst experiments could be attributed to insufficient 
immunostimulatory molecules in each serum sample. The aim was to determine 
if patient serum with varying degrees of disease severity induced differing levels 
of neutrophil stimulation. As insufficient responses were observed from single 
serum samples, the data suggests that no single component of RA patient 
serum modulates the neutrophil respiratory burst in healthy neutrophils. This 
contradicts the findings of Chowdhury et al, who found that serum from RA 
patients induced ROS production in healthy neutrophils (368). The differences 
between these results could be due to methodology. The authors do not state 
serum dilution used in these experiments, nor do they state if serum was pooled 
during these assays. Given prior literature regarding RA serum and the 
respiratory burst in neutrophils, it may well be that the serum samples from RA 
patients were pooled together. The artificial experimental system in itself has 
flaws, in that these experiments were healthy neutrophils exposed to RA serum 
for the first time, in contrast to certain reports in the literature where RA 
neutrophils are exposed to autologous RA serum. The differences may be 
explained to the fact that it is constant exposure to these serum elements that 
may drive dysfunctional responses.  
Neutrophils in RA patients have impaired calcium signalling when activated by 
Fc gamma receptors (369). Other cells in RA, such as T lymphocytes also show 
reduced levels of calcium release upon stimulation (370). This suggests that 
cellular dysfunction in RA leucocytes may be somewhat influenced by reduced 
calcium signalling. Rheumatoid factor cross-links with membrane bound IgG on 
172 
 
neutrophils and results in increases in cytosolic calcium levels via activation of 
the FcγRIIIb receptor (371, 372). This would suggest that in the calcium flux 
experiments, that the RA serum with high levels of RF could induce flux in 
healthy neutrophils. In all the serum samples used, the only two samples that 
resulted in increases in cytosolic calcium levels were RA84 and RA86. If RF 
was capable of increasing calcium levels in neutrophils, then calcium levels 
should have increased upon addition of serum samples RA165 and RA188, 
which had RF titres greater than these. The other potential causative agent for 
these cytosolic increases may be anti-citrullinated protein antibodies. RA84 
contained by far the highest ACPA titre, yet small levels of RF. The paradoxical 
positive increases seen by RA84 and RA86 but not RA165 and RA188 may 
suggest that neither RF nor anti-CCP increases cytosolic calcium levels in 
healthy neutrophils. It may well be that the responses observed in these 
samples are driven by other components in the serum, such as cytokines, which 
were not accounted for in these experiments. It would be of great interest to 
examine the response in neutrophils to synovial fluid of these patients, as 
synovial fluid is a more direct reflection of the inflammatory environment in RA. 
Furthermore, synovial fluid in RA patients inhibits neutrophil apoptosis, which 
could result in dysfunction through prolonged overactivation (246). It would also 
be a good opportunity to examine the function of RA patient neutrophils in the 
above assays used in order to correlate the responses with clinical parameters.  
Neutrophil extracellular trap formation has previously been shown by 
Chowdhury and colleagues to occur upon stimulation of healthy neutrophils with 
RA patient serum and synovial fluid (368). In this study, healthy neutrophils 
were isolated from donors and incubated with RA patient serum or synovial 
fluid, or healthy donor serum (368). The authors found via 
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immunohistochemistry that RA serum, and to a greater extent, RA synovial 
fluid, induced NETosis in neutrophils (368). Issues with reporting NETosis via 
immunohistochemistry have been previously reported. The authors also used a 
sandwich ELISA targeting myeloperoxidase and cellular DNA, to confirm 
NETosis in neutrophils. In RA patient serum samples, higher levels of these 
NET remnants were present. 
Nevertheless, the results found by these experiments through usage of the 
SYTOX green assay showed no NETosis from incubation of HL60-derived 
neutrophils with a 1:10 dilution of RA patient serum. It may be that a 1:10 
dilution is too dilute to elicit cellular changes, and so higher concentrations may 
initiate cellular responses not seen in assays. Intriguingly, in these experiments, 
healthy control serum resulted in a greater amount of extracellular DNA release. 
This could suggest that RA serum may contain factors that are capable of 
suppressing NETosis, as opposed to inducing it (112, 373-375). 
 
4.5 Conclusion 
In a cohort of patients with varying degrees of disease severity, smoking status 
and urinary cadmium level, it appears that cadmium may influence RF titres. 
Urinary cadmium levels were significantly higher in a subpopulation of this 
cohort with a history of smoking compared to a subgroup that had never 
smoked. In addition to this, urinary cadmium levels correlated with RF titres in 
this subgroup, suggesting that cadmium may play a role in the formation of the 
rheumatoid factor autoantibody complex in smokers. 
Overall, it appears that RA patient serum does not induce any noticeable 
response in either isolated primary neutrophils or HL60-derived neutrophils. The 
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respiratory burst is unaffected by RA patient serum, despite literature showing 
strong evidence for this. Explanations for these differences may be due to lack 
of pooling the RA serum. Some samples have shown to induce calcium release 
in primary neutrophils however, the unique serological marker for these 
samples (highest anti-CCP titre and DAS-28 score, respectively) is not 
highlighted in the literature as a potential reason for increases in cytosolic 
calcium levels. Similarly, RA patient serum non-significantly increases 
extracellular DNA levels, though it appears that healthy control serum increases 
these levels to a significant level, suggesting a potential suppressive effect in 
the RA serum samples in this cohort.   
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5 Modifications to IgG as a potential link to 
rheumatoid arthritis 
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5.1 Introduction 
Having noted the potential enhancing effect of cadmium on NADPH-oxidase 
mediated processes (Chapter 3) and subsequently finding that RF titres of RA 
patients are higher in patients with higher cadmium levels (Chapter 4), a 
retrospective approach to analyse RA patient sera was used in order to look for 
any relevant protein modifications. Having noted the potential role of cadmium 
in RA at both ends of the disease spectrum (initiating and end-point) via calcium 
flux and the respiratory burst, other possible triggers of RA disease pathology 
that remain unanswered were investigated. The objective of this chapter were 
to:  
• Use mass spectrometry to precisely identify protein modifications in RA 
patient serum previously shown to contain citrullinated proteins via 
western blotting 
• Given the relevance to RA, focus specifically on modifications to IgG that 
are likely to be highly prevalent in RA patient sera 
• Establish an in-house capture ELISA that could detect patient antibody 
binding to modified and unmodified variants of Fc fragments, to help 
confirm mass spectrometry findings 
 
5.2 Cohort Serology 
During this project, access to a biobank of sera from RA patients with (n=50, 
RA) and without bronchiectasis (n=52, BRRA), and bronchiectasis (n=122, BR) 
alone patients was available. Further information on this cohort is shown in 
Table 5.1.  
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Table 5-1 Patient and disease control demographic for the second 
cohort of serum samples used.  
Abbreviations: DAS-28 = Disease Activity Score in 28 joints tested, IQR = 
Interquartile range. This figure has been adapted from the work of Clarke et al 
(216). 
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As previously stated in Section 1.4.2, up to 30% of BR patients may develop 
RA, and the mechanisms through which this seroconversion occurs is unknown 
(259). This cohort has been reported on previously, with the sample collection 
being undertaken by Dr Liz Perry (277, 282, 283). Serological measurements 
on this cohort have been previously published, with the most significant findings 
being related to the differences between BRRA patients and RA patients alone. 
The RA cohort was specifically chosen for having no history of lung disease, as 
opposed to the BRRA cohort, where 58% had bronchiectasis before onset of 
RA symptoms.  In general,  the BRRA cohort presented with greater disease 
activity scores and higher anti-CCP and RF positivity than the RA only patients 
(283). Smoking was not a confounder for any of the serological findings. 
This cohort has previously been used to investigate the role of anti-calreticulin 
and anti-citrullinated calreticulin antibodies as a prognostic biomarker for double 
seronegative (RF-negative and anti-CCP negative) RA patients, published in 
2017 (216). More recently, this cohort was used to publish findings that the sera 
of patients with BRRA have increased levels of Galectin-9, and that Galectin-9 
can induce PAD4 activation in neutrophils (376). 
Subsequent to the 2017 study, four of the BR-only patients developed RA 12-18 
months after serum sample collection (herein referred to as BRsero). It was of 
great interest to ascertain if the serum characteristics of these four individuals 
differed from other BR patients. In the BR-only cohort, these four individuals 
tested positive for both RF and ACPAs at the time of sampling and were the 
only subjects in the 122 sample cohort to do so. 
Given the positivity for antibodies and immune complexes in these particular 
samples, the proteomic profile of the immunoglobulins was analysed to discern 
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if any differences were present between BRRA, RA and healthy serum, and 
also the serum of these four individuals. 
The ultimate aim of this chapter was to explore this valuable cohort of RA 
patients on a proteomic level via usage of mass spectrometry.  
 
5.3 Western blotting for citrullinated proteins 
As explained previously in Section 1.4.1.3, in this cohort of patients, antibodies 
to citrullinated calreticulin were observed in 49% of RA/BRRA/BRsero 
(collectively referred to as RAany) samples, but not healthy control samples 
(216).  Following on from prior work detecting these antibodies in the serum, the 
presence of citrullinated calreticulin in these serum samples was examined to 
determine if serum citCRT was expressed at higher levels in RAany patients than 
healthy donors.  
Representative serum samples from the different patient/control groups were 
selected for immunoblotting; two healthy controls and BR patients, two 
seroconverted BR samples and four RA and BRRA serum. In brief, samples 
were run on a 8-16% Tris/Glycine/SDS gradient gel and transferred onto a 
nitrocellulose membrane via semi-dry transfer with the Bio-Rad turboblot 
(Section 2.1.2.) The blot was probed for citrullinated protein with an anti-
citrulline antibody (ab100932, Abcam, UK), followed by a near infrared 
secondary ab and then imaged on a LiCor scanner. Citrullinated protein was 
present in high levels in all bar one (lane 10) of the ten RAany serum samples 
(lanes 6-9, 11-15), but not the healthy control or BR only samples (lanes 1, 2, 4 
and 5) (Figure 5.1).  
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Figure 5-1 Citrullinated protein is present in the serum of patients with 
rheumatoid arthritis, bronchiectasis with rheumatoid Arthritis, and 
seroconverted bronchiectasis  patients.  
A) Serum samples were loaded onto a commercial Tris/Glycine/SDS 8-16% 
gradient gel and SDS-PAGE and immunoblot performed. The membrane was 
probed for citrullinated protein. B) After imaging the membrane, densitometry 
was used to measure the intensity of citrullinated protein in each sample. The 
cohort of each sample is listed below the graph.   
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Densitometry was used to quantify band at the 50kDa region The RAany 
samples contained roughly 1.5-4 times the quantity of citrullinated protein 
compared to the healthy and BR only samples. Mass spectrometry was then 
used to identify the citrullinated protein species within this band. 
5.4 Proteomic analysis 
 A selection of samples were chosen for further proteomic analysis from the 
cohort shown in Table 5.1; four RA, BR and BRRA, and 10 healthy control 
serum samples to be probed via mass spectrometry. The demographics for 
these samples are listed in Table 5.2. Samples were run according to the same 
method shown above (Section 5.2). Once the gel run had completed, proteins 
were then visualised with Coomassie blue staining. Bands were excised around 
the 50kDa size range, as this was where the majority of citrullinated protein in 
each sample was detected (Figure 5.2). These bands were then tryptic 
digested and protein identification revealed by mass spectrometry.  
As discussed in Section 2.4.3, proteins identified were scrutinised for peptide 
sequences containing citrullinated arginines, or carbamylated lysines using the 
Proteome Discoverer 1.4 software. The choice for these two amino acid 
modifications pertains to the nature of autoantibodies found in RA. Citrullination 
and carbamylation are PTMs through which ACPAs and Anti CarPs form, 
respectively.  
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Table 5-2 Demographics of individual subjects including age, gender, smoking status, 
anti-CCP and RF test result and interpretations.               
 ID: identifier; CCP: cyclic citrullinated peptide; RF: rheumatoid factor; ACR: American College 
of Rheumatology; BR: bronchiectasis; RA: rheumatoid arthritis; F: female; M: male. *: 
bronchiectasis patients who went on to develop RA 12–18 months post-sampling. Age of the 
control samples is presented as median with interquartile range. 
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Figure 5-2 Example of serum sample bands excised for mass 
spectrometric analysis.  
After SDS-PAGE, proteins within the gel were stained by Coomassie blue and 
protein bands were excised below the albumin band around 50kDa. Excision 
first performed between sample lanes, and then between protein bands. Bands 
were then analysed by mass spectrometry.  
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Modified peptide sequences were detected by “peptide spectrum match” (PSM) 
counts, which refers to the frequency with which a given peptide sequence was 
counted by the mass spectrometer. Across all samples test, over 300+ proteins 
were found to be detected in the protein bands tested ranging from 0.14-95% of 
full protein sequence coverage. Incidence of PTMs in these proteins varied 
drastically, though the two proteins found to be most abundantly modified and 
highly represented in these samples were alpha-1-antitrypsin (uniprot code 
SERPINA1) and the heavy chain of immunoglobulin G (uniprot code IGH@). 
Given the potential significance of these two proteins to the pathology of RA, a 
further set of serum samples (derived from the cohort shown in Table 4.1) were 
subsequently analysed by mass spectrometry following the same process 
described above. The individual serology results from these additional patient 
samples are shown in Table 5.3.  
5.4.1 Alpha-1-antitrypsin modifications 
Alpha-1 antitrypsin was found to be modified in all samples tested, with healthy 
controls and RAany samples exhibiting both citrullination and carbamylation 
modifications (Figures 5.3 and 5.4). By far the most frequent posttranslational 
modification observed was citrullination of the arg220 residue.  
This occurred in 15 of the 26 RA patient sera screened samples tested, and 5 of 
the 10 healthy controls, of which three were never smokers, and three were 
smokers (Figure 5.3).  
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Table 5-3 Demographics of individual subjects in the Cd-RA cohort 
including age, gender, smoking status, anti-CCP and RF test result and 
interpretations.   
ID: identifier; CCP: cyclic citrullinated peptide; RF: rheumatoid factor; ACR: 
American College of Rheumatology; BR: bronchiectasis; RA: rheumatoid 
arthritis; F: female; M: male. 
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Figure 5-3 Citrullination of alpha-1 antitrypsin mainly occurs in RA patients.  
 The arginine sites on alpha-1 antitrypsin that registered peptide sequences that had been citrullinated in the samples analysed by 
mass spectrometry. Arginine 220 was by far the most commonly citrullinated amino acid. Underneath each arginine residue, the 
serum samples that registered these modifications are listed as follows: red - RAany patient, black – healthy control (non-smoker), 
green – healthy control (ever smoker). Protein modelling was performed using the UCSF Chimera software. 
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Figure 5-4 Carbamylation of alpha-1 antitrypsin mainly occurs in RA patients.  
The lysine sites on alpha-1 antitrypsin that registered peptide sequences that had been carbamylated in the samples analysed by 
mass spectrometry. Underneath each arginine residue, the serum samples that registered these modifications are listed as follows: 
red - RAany, black – healthy control (non-smoker), green – healthy control (ever smoker). Protein modelling was performed using the 
UCSF Chimera software. 
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Further correlation into the frequency of arg220 citrullination was analysed 
statistically. The PSM count of citrullination of arg220 for each sample was 
compared to anti-CCP and RF titres.  
The extent of citrullination of arg220 correlated significantly (r = 0.4487 p = 
0.0413) with anti-CCP titres in all samples (Fig 5.5A). Rheumatoid factor titre 
showed positive correlation with PSMs, but this did not reach the significance 
threshold (r = 0.3991, p = 0.0731). Interestingly, the patient sample with the 
greatest quantity of citrullination at numerous arginine sites was a female BRRA 
patient who had never smoked with no single noticeable aspect of serology 
accounting for this increased protein citrullination; the patient’s ACPA titres 
were positive, yet no higher than any other samples. The only distinguishing 
characteristic of this patient was the duration of RA of 30 years prior to 
bronchiectasis diagnosis.  
Carbamylation modifications on various lysine residues were less frequently 
observed across all samples, though were seen more commonly in the RAany 
samples or healthy control smokers. The patient sample with the relatively 
highest degree of lysine carbamylation was from a female BRRA never smoker 
with even lower serological scores than the aforementioned BRRA patient. An 
element of homogeneity was observed in terms of PSM counts across all 
samples. Of the samples that registered carbamylation of lysine across all 
residues detected, PSM counts for each sample ranged between 1 and 4 for 
each sample. 
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Figure 5-5 The quantity of citrullination of the amino acid residue arginine 
220 on alpha-1 antitrypsin significantly correlates with anti-CCP 
serological scores, but not rheumatoid factor.  
The number of peptide sequences containing a citrullinated arginine 220 
residue across the 21 positive samples detected via mass spectrometry (PSM 
count). Spearman’s rank correlation coefficient was used to compare PSM 
counts for arg220 the clinical serological markers A) anti-CCP titre and B) RF 
titre. 
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Noting the indistinguishable differences between all disease cohorts, it may be 
concluded that lysine carbamylation of A1-AT is not associated with RA 
pathology. 
5.4.2 Modifications to immunoglobulin G 
Various forms of the Ig heavy chain (IGH) sequence were found to be modified 
in the samples tested, the majority of which belonged to the IgG1-3 class. 
Citrullination and carbamylation were detected across all regions of the heavy 
chain, with lysine carbamylation more evident than arginine citrullination (Figure 
5.6). Of particular note, specific arginines in RA patients IgGHC appeared to be 
more susceptible to PTM and at a greater frequency than HC patient IgGHC. 
The HC regions of IgG where modifications were found to be most concentrated 
in the RAany samples were the amino acid sequences associated with C1q 
binding to IgG and the RF IgM-IgG binding site (377, 378). The locations of 
these sites, including the peptide sequences are shown in Figure 5.7. 
Carbamylation occurred very commonly in these two sites in the RAany samples, 
though citrullination of the arginine residue in the RF binding site sequence was 
restricted to only certain RA samples (Table 5.3).  
Carbamylation and citrullination in other regions of the Ig heavy chain were 
observed in most samples irrespective of disease or healthy status, suggesting 
some PTMs occur naturally. The quantity of peptide sequences found to contain 
carbamylated lysines was found to be statistically significantly higher (p= 
0.0359) in the RAany samples compared to the healthy control samples (Figure 
5.8A). Citrullinated arginine residues were not significantly higher (p = 0.1373) 
compared to healthy control samples (Figure 5.8B).  
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To confirm the increased levels of citrullination and carbamylation in 
immunoglobulins as determined by mass spectrometry, sera from the mass 
spectrometry analysis cohort were immunoblotted and probed for anti-citrulline 
and carbamylation residues. Briefly, IgG was isolated from sera via FPLC and 
the purified IgG for carbamyl-lysine and citrulline. Immunoblotting confirmed the 
presence of citrullinated and carbamylated residues on this protein (Figure 5.9). 
Interestingly, despite greater quantities of carbamylated lysine being detected in 
the Ig compared to citrulline by mass spectrometry, immunoblotting appeared to 
show greater relative quantities of citrulline than carbamyl-lysine (Figure 5.9B 
vs Figure 5.9D), this might be reflective of the avidity of the commercial 
antibodies used for detection. 
Nevertheless, having noted the presence of both carbamylated lysine and 
citrulline in the IgG isolates, these type of modifications to IgG were tested to 
see if they were responsible for the formation of RF, and if RA patient antibody-
antibody complexes had antibodies formed to IgG molecules that contained 
these posttranslational modifications. 
5.4.3 Preparation of Fc fragment isolates from pooled sera 
After noting the increased presence of citrullination and carbamylation in the 
CH2 RF binding region of the heavy chain of immunoglobulin G, modifications to 
the Fc region of IgG led to a greater recognition by RA patient antibodies were 
examined, as modifications to this region were found to be substantially 
elevated in the RAany cohorts. With modifications to other regions having been 
observed in all samples, those specific to the Fc component of immunoglobulins 
were examined to see if they could be a potential driving factor in RA pathology.  
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Figure 5-6 Protein modelling of the heavy chain of immunoglobulins and the 
modified amino acid residues detected by mass spectrometry.  
A) The lysine residues on IgG heavy chain are shown in blue. Post-translationally 
modified lysine residues found by mass spectrometry are shown in red. B)  The 
arginine residues on Ig heavy chain are shown in blue. Post-translationally modified 
arginine residues found by mass spectrometry are shown in red. 
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Figure 5-7 Protein model of the heavy chain of immunoglobulins, the sub 
regions of the molecule, and the binding sites of C1Q and rheumatoid 
factor.  
The C1q binding site is highlighted in blue. The RF binding site is highlighted in 
red. 
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Table 5-4 Summary of the post-translational modifications found in all of the 36 serum samples. 
Each column details if the region in question was found to be carbamylated (carb) or citrullinated (cit). Citrullination and 
carbamylation are found freuquently in RAany samples in the region where IgM binds IgG in RF formation.  
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Figure 5-8 Carbamylated lysine residues, but not citrullinated arginine residues 
in the heavy chain of immunoglobulins are detected in significantly higher 
quantities in RA serum than in healthy control samples.  
The PSM counts for carbamylated lysine residues were totalled for each serum sample 
tested. Carbamylation was statistically significantly higher in RAany samples compared 
to healthy control samples. Statistical significance was tested by Mann-Whitney. * = 
p<0.05 
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Figure 5-9 SDS–PAGE and immunoblots of purified IgG for citrullination 
and carbamylation. 
 A) Representative Coomassie-blue-stained isolated total IgG from patients and control 
sera used to blot for citrulline. B) Immunoblot of IgGs probed with anti-citrulline. C) 
Representative Coomassie-blue-stained isolated total IgG from patients and control 
sera used to blot for carbamylation. D) Immunoblot of IgGs probed with anti-carbamyl-
lysine. For C) and D), individual sample cohort identifiers are shown.   
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Figure 5-10 Fast protein liquid chromatography confirmation of IgG and 
Fc fragment purification.   
A) IgG purification from commercially available serum. B) Papain treated IgG 
samples that were repurified via FPLC. The green boxes represent the elution 
window through which IgG or Fc fragment bound to the column was eluted to 
reveal pure protein. A280 represents an estimate of protein concentration. 
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To test this hypothesis, Fc fragments were generated and the serum antibody 
response against them was measured. To generate the Fc fragments, IgG from 
commercially available serum was purified through FPLC (Figure 5.10A). 
Once purified, papain was used to digest the bonds between the Fc region and 
the Fab region of IgG. Papain was chosen to preserve the disulphide bonds 
between each heavy chain, in the Fc fragment, to mimic the biological Fc 
component of IgG as closely as possible. Upon papain treatment, samples were 
run once again on the FPLC, using as protein G column for purification.  
During repurification, the cleaved Fab region of IgG can be seen in Figure 
5.10B as the small peak to the left of the elution window. The pure Fc fragment, 
or uncleaved IgG, then eluted off of the protein G column. With eluted protein 
consisting of either cleaved Fc fragment, or uncleaved whole IgG, SDS-PAGE 
was performed to confirm if full cleavage had taken place. The post-papain IgG 
elution lacked the presence of the heavy chain typically found in the 50-60kDa 
region in IgG. As samples were reduced using DTT, the majority of protein in 
the Fc isolate was in the 22-28kDa region, indicating that papain cleavage had 
taken place and therefore Fc fragment had been successfully isolated (Figure 
5.11). After Fc fragment isolation, the protein was citrullinated and carbamylated 
to mimic the protein species observed by mass spectrometry. As the process of 
citrullination is enzymatic (PAD-driven), and carbamylation is chemical 
(potassium cyanate driven), the Fc fragment was first citrullinated and then 
carbamylated to avoid any potential changes to the Fc fragment that may make 
the enzyme:protein reaction unsuccessful.  
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Figure 5-11 Fc fragment cleavage was confirmed via SDS-PAGE.  
Whole IgG isolates, runoff from FPLC post-papain cleavage, and eluted IgG 
from FPLC post-cleavage was loaded onto 8-16% Tris/Glycine/SDS gels and 
stained with Coomassie blue. 
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After modification of the Fc fragment was analysed via mass spectrometry to 
confirm that citrullination and carbamylation had taken place, and determine if 
PAD was capable of enzymatically modifying this protein in vitro.  
Mass spectrometry revealed that carbamylation had occurred on most lysine 
residues, though citrullination had occurred at lower levels. Having successfully 
modified the Fc fragment, the serum antibody response was measured in the 
samples collected earlier.  
5.5 Assessment of serum antibody response to unmodified and 
citrullinated and carbamylated Fc fragment  
As rheumatoid factor is an immune complex composed of IgM or IgA bound to 
IgG (Section 1.4.1.3,) the antibody binding to the Fc fragments was assessed 
(as outlined in the template shown in Methods Table 2.2.). 
A 1:50 dilution of serum from BR, BRRA, RA, and HC serum samples was first 
used to ascertain if the antibody responses differ between different disease 
cohorts and healthy samples. 
In total, over 400 serum samples were screened consisting of all the RA (n = 
266 ) and BRRA (n = 50  ) and HC samples (n = 71 ) , in addition to select BR 
samples (n = 32 ) were tested. The results from the ELISA analysis are shown 
below.  
All of the absorbance values for the four parameters tested can be seen in 
Figure 5.12A-D.  In the unmodified Fc fragment response (Figure 5.12A), the 
RA and BRRA IgM response is significantly higher than the HC (p<0.0001 for 
both) and BR (p=0.0443 and p=0.0141, respectively).  
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Figure 5-12. The absorbance values for the serum IgM and IgA response 
to unmodified and double-modified Fc fragment. 
 A) Serum IgM response to unmodified Fc fragment. B) Serum IgA response to 
unmodified Fc fragment.  (C) Serum IgM response to citrullinated and 
carbamylated Fc fragment. (D) Serum IgA response to citrullinated and 
carbamylated Fc fragment. Statistical significance was analysed using a 
Kruskal-Wallis test with Dunn’s comparison post-test. *p<0.05 **p<0.005 
***p<0.001 ****p<0.0001. Bars are displayed as median with interquartile range. 
HC = Healthy Control, RA = rheumatoid arthritis, BRRA = bronchiectasis with 
rheumatoid arthritis, BR = bronchiectasis only. 
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This difference is completely negated in the serum IgM response to citrullinated 
and carbamylated Fc fragment, where the response seen is not significantly 
different across all cohorts tested (Figure 5.12C).  
In the context of the IgA response, the BRRA cohort demonstrated significantly 
higher titres of IgA binding to the unmodified Fc fragment compared to HC (p = 
0.0029) and RA (p<0.0001) serum samples (Figure 5.12B). The BR cohort also 
displayed significantly higher binding than the RA cohort (p = 0.0037). Perhaps 
the most interesting finding from the inter-cohort comparisons however, is that 
the IgA response to citrullinated and carbamylated Fc fragment is statistically 
significantly lower (p<0.0001) in the RA cohort compared to all other cohorts 
tested (Figure 5.12D). No difference in OD450nm was seen between the HC, 
BRRA and BR cohort responses.  
Further examination of the changes in IgM and IgA response between 
unmodified and cit/carb Fc fragment were performed. Both the RA and BRRA 
cohorts had a significantly lower (p<0.0001 for both) IgM response to mod-Fc 
than unmodified Fc fragment (Figure 5.14). The IgA response to mod-Fc in HC 
samples was significantly higher than unmodified Fc (p = 0.0223), whilst the RA 
response was significantly lower (p = 0.0016).  
Finally, the OD450nm values were compared against anti-CCP, RF and DAS28 
scores of the same samples. The rationale for this was to see if anti-citrullinated 
protein antibody titres (through anti-CCP measurement) influenced the 
response to Fc fragment that had been citrullinated. Similarly, as the IgM 
binding site of IgG in RF was found to be post-translationally modified, that the 
RF titre may somewhat influence findings also.  
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Figure 5-13 Histograms displaying the change in serum antibody binding 
between unmodified and citrullinated and carbamylated (mod) Fc fragment.  
Each cohort response is shown. In RA and BRRA cohorts, the serum IgM response to 
mod-Fc is significantly lower than the unmodified response. In the HC cohort, the IgA 
response to mod-Fc is significantly higher than the response to the unmodified Fc 
fragment. In the RA cohort, the serum IgA response to mod-Fc is significantly lower 
than the unmodified fragment. Statistical significance was tested by Mann-Witney test. 
* p<0.05, ** p<0.005, **** p<0.0001. Values are displayed as median OD450nm ± 
interquartile range. HC = Healthy Control, RA = rheumatoid arthritis, BRRA = 
bronchiectasis with rheumatoid arthritis, BR = bronchiectasis only. 
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Paradoxically, for anti-CCP, RF and DAS28, the strongest correlations for both 
the subjects IgM and IgA binding to IgG were found in the unmodified Fc 
fragment groups as opposed to the citrullinated and carbamylated fragments of 
IgG (Table 5.4). 
The same pattern is seen in the BRRA cohort for the IgM response also, with 
these parameters also correlating more strongly in the UT-Fc response 
compared to the mod-Fc response. Interestingly, for the IgA response however, 
mod-Fc correlates more positively than UT-Fc for anti-CCP, RF and DAS28 
(Table 5.4).  
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Table 5-5 Spearman’s rank correlation coefficient for OD450nm versus 
clinical serological scores for rheumatoid arthritis patients with and 
without bronchiectasis.  
In each cell is the r value calculated by spearman’s rank correlation coefficient, 
and the level of statistical significance measured. * p<0.05, ** p<0.005, *** 
p<0.001, **** p<0.0001 
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5.6 Discussion 
In this chapter, it has been shown that in RA patients with and without 
bronchiectasis that the heavy chain of IgG, and alpha-1 antitrypsin display high 
levels of citrullination and carbamylation compared to healthy people.  
5.6.1 Implications for citrullination and carbamylation of alpha-1 
antitrypsin 
Alpha-1 antitrypsin has long been known to be associated with RA 
pathogenesis (379, 380). Alpha-1 antitrypsin is a serine protease of which the 
primary target is neutrophil elastase, the antimicrobial protein released by 
neutrophils during bouts of inflammation (381). Additional functions of this 
protein focus on a modulatory role, with A1AT modulating IL-8 and TNFα levels 
(382). Deficiency of this enzyme, most commonly through genetic defects 
(A1ATD), is associated with COPD, bronchiectasis, and autoimmunity in 
general (383-387). The discovery of citrullination and carbamylation of A1AT in 
these samples is of great importance, as PAD2 and PAD4 release is increased 
in A1ATD patients, suggesting that A1AT may have some role in ACPA 
generation (388). The authors of this study also found increased quantities of 
citrullinated proteins and PAD4 present in the BAL fluid of A1ATD patients. 
Deficiency of A1AT has also been detected in a subset of RA patients, with 
heterozygosity for the deficiency gene leading to increased ACPA titres in RA 
patients (382). Furthermore, A1AT therapy through intravenous infusions, or 
gene therapy improves the symptoms of mice experimentally given RA (380).     
Carbamylated A1AT is a target of anti-CarPs in RA patients, which exist in 
higher levels compared to healthy controls (389). These data confirm the 
findings of Verheul et al, whilst adding to these through discovery of citrullinated 
arginine residues on this protein also. As previously discussed, citrullination and 
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carbamylation, though different PTMs, share the same result in that protein 
function or structure may be changed to due to neutralisation of the amino acid 
charge on the lysine or arginine residue. High levels of citrullination of Arg220 of 
A1AT in RA patients significantly correlated with ACPA titres in the samples 
tested.  
This may suggest that in RA, this protein is wholly post-translationally modified, 
potentially resulting in loss of function. The presence of anti-CarPs to this 
protein also pose the question of whether or not ACPAs directed against 
citrullinated A1AT exist also. Nevertheless, the implications of these PTMs 
present an in vivo opportunity for NE to remain active for longer periods of time, 
potentially contributing to damage of host tissue during bouts in inflammation. In 
BR patients, NE activity correlates with the rate of decline in lung function and 
infections (390, 391). This may mean that in BRRA patients, A1AT modification 
could be one of the initiating mechanisms through which autoantibody formation 
occurs.  
5.6.2 Implications for citrullination and carbamylation of the heavy chain 
of IgG 
Carbamylation of IgG has been identified in vivo previously by Koro and 
colleagues (392).  This work adds to these findings through the additional 
presence of citrullination of IgG in RA patients. Of particular note is the 
carbamylation and citrullination observed at or near the binding site of the C1q 
complement protein, or the IgM binding site in rheumatoid factor (234, 377). As 
stated in the introduction, the mechanisms through which RF forms is however 
unknown (Section 1.4.1.3).  
Although the interaction between IgM and IgG is well known as RF, the more 
frequently observed modifications to the C1q-binding region in this study are 
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more interesting. General carbamylation of IgG substantially decreases C1q 
binding and was found by Koro et al to decrease the incidence of complement-
mediated cytotoxicity (392). By inhibiting complement activation through 
modification to this region, this prevents further activation of the complement 
cascade. The complement cascade is integral to removal of immune 
complexes, and decreased clearance of immune complexes is associated with 
the pathogenesis of not just RA, but systemic lupus erythematosus (393, 394). 
Adversely, complement protein complexes are elevated in the synovial fluid of 
RA patients, with C1q-C4 complexes correlating with disease activity scores, 
thus calling into question the functional consequences of carbamylation of the 
C1q binding site (395).  
On the one hand, Koro et al used IgG that had been chemically modified in 
vitro, and tested the complement protein response to this modification, 
potentially resulting in more exaggerated levels of the modification taking place, 
and reporting drastically lower interaction between C1q and IgG. This could 
mean that overmodification of the protein results in reduced binding capacity 
from structural changes to the protein closing off the binding site of C1q. 
Citrullination and carbamylation of certain proteins results in greater binding 
affinity to certain targets, suggesting that in vivo levels of these modifications 
may enhance the binding affinity, leading to overactivation in RA (396-398). 
Carbamylation also increases the hydrogen bonding capacity of the protein in 
question, further strengthening the idea this modification enhances binding 
affinity, rather than inhibiting it (399).  This is supported by a wide body of 
evidence showing that immune complexes activate the complement system 
rather avidly (400-404).  
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The presence of carbamylation of this site so frequently in RA samples used in 
the mass spectrometry analysis cements the notion that modification of this site 
plays some sort of role in RA pathology, though the effect on complement 
activation is currently unknown. It could be that the physiological or pathological 
levels of carbamylation that occurs in the IgG molecule (as shown by these 
data) enhances biological activity. However, in vitro chemical modification may 
produce non-physiological levels of carbamylation which inhibit C1q binding. 
This would be an intriguing avenue for further experimentation. 
Although Koro et al focused on the ability of C1q to bind IgG, and the 
associated complications, the modifications seen in the RF binding site propose 
the first possible mechanism through which the RF autoantibody may develop. 
Carbamylation of the CH2 region of IgG has been reported previously in vivo, 
with the PPKPK motif close to the RF binding site being also detected by Koro 
et al through in vitro carbamylation (392).  
The assays that measure RF titres in patient serum typically use recombinant 
IgG, or Fc fragments to assess the presence of autoantibodies (405). As PTMs 
were found in the Fc region in RA patients, a novel approach was used to 
modify the Fc component of IgG to either confirm that 
citrullination/carbamylation is the driving mechanism for RF formation, or 
potentially devise a more sensitive or specific diagnostic assay for RA patients.  
 
5.6.3 The effect of citrullination and carbamylation on the serum IgM and 
IgA response to Fc fragment 
The results from the ELISA paint two very different pictures of serological 
outcomes, based on whether or not the RA patients were also suffering from 
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bronchiectasis. Unsurprisingly, for the IgM response, the untreated Fc fragment 
correlated the most strongly for both RA and BRRA patients. This refers to the 
experimental principle behind the RF clinical assay itself, in that this was 
effectively the most similar experimental design to the clinically-used assay.  
The diminished response in all cohorts to the mod-modified Fc fragment is 
unexpected, as the RA and BRRA patients had demonstrated high levels of 
carbamylation to the CH2 region of their respective IgG heavy chains, and 
therefore should have a greater antibody titre to this modified isoform of the Fc 
fragment. An additional hypothesis to explain the results could be other 
confounding factors not accounted for in the experimental design. Serum 
components such as complement proteins may play an influence in the 
antibody binding in this assay. Furthermore, given the complex system of 
antibody-antibody-antibody interactions with this assay, the secondary 
antibodies used in the assay could also highlight potential explanations for the 
results obtained.  
Perhaps the hypothesis put forward for the C1q-IgG interaction seen in the 
study by Koro et al is the same for the results observed from this ELISA. The 
over-carbamylation of this protein may have prohibited anti-carbamylated Fc 
IgM antibodies from binding to their respective epitopes, leading to a reduced 
response. As titres were low across all 400 samples tested compared to UT-Fc, 
it may also be that antibodies to these modified epitopes are actually less 
abundant, and that the autoantibodies in the RA/BRRA cohorts were always 
directed against non-modified residues in IgG, perhaps indicative of a more 
advanced stage of RA, in which IgG itself, in an unmodified form is the target of 
autoantibody production.   
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A different perspective is observed in the context of the IgA response, however. 
Firstly, IgA titres are elevated in RA patients and there is roughly 50% more 
IgM-RF than IgA-RF (406-408). The fact that the serum IgA response to mod-Fc 
correlated more strongly with anti-CCP, RF and DAS-28 than UT-Fc is 
intriguing. The reasons for this are perplexing, given that the proposed reasons 
for reduced IgM binding in the mod-Fc should logically be reflected in the IgA 
binding also. Therefore, it may be differences in the IgA molecule itself that may 
account for the binding capacity of the protein. IgA in serum typically exists as a 
monomer, in addition to having a smaller CH3 region, similarly to IgM (409). As 
IgM is a pentameric molecule, it may be that this monomeric immunoglobulin is 
able to physically bind the protein in ways through which IgM may not. If this 
were to be wholly true however, then the RA only cohort would also 
demonstrate the same outcome, which it does not. Then perhaps, it is a unique 
feature to RA patients with underlying BR, that give rise to this unique result. 
The significance of these findings has yet to be elucidated.  
Immunoglobulin A titres are increased in BR patients. Further to this, IgA is 
synthesised in the body at a much higher rate than IgM at mucosal surfaces 
(409).  Bouts of pulmonary inflammation are all too common in BR patients, as 
recurrent infections are one of the most frequent symptoms of the disease 
(258). This chronic inflammation, coupled with the high synthesis of IgA, may 
create a unique microenvironment specific to BRRA patients, through which 
PTM of IgA readily occurs. The presence of IgA-RF predates the onset of RA by 
roughly 10-15 years, suggesting that mucosal dysfunction may be the driving 
factor in autoantibody development (205, 206, 217). It is plausible then to 
hypothesise that in BR patients, IgA titres are elevated, immune cell 
overactivation occurs, and thus more likely to generate autoantibodies to 
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citrullinated and carbamylated proteins, in this case IgG. These IgA-IgGFc 
antibodies then circulate in the body, kept highly present through chronic 
inflammation, thus explaining the ELISA results obtained.  
The problem then, is how the other cohort IgA responses fit into this hypothesis. 
In the RA cohort, the serum IgA response to mod-Fc fragment is significantly 
lower than the unmodified variant, and the HC samples result in a greater IgA-
Fc response in both UT-Fc and Mod-Fc. The results seen in the RA cohort 
contradict the literature somewhat, as IgA-RF is significantly elevated in RA 
patients compared to healthy controls (205, 410-415). The only unique factor to 
this cohort is that 30-40% of the samples are RF-negative, which may account 
for the low ODs seen in the ELISA. It would be of great importance to measure 
the differences in RF subtypes (IgM-RF, IgA-RF and IgG-RF) in these samples 
in order to see if the IgA-RF response reflects the results observed here in the 
IgA:UT-Fc response.   
5.7   Conclusion 
In this chapter, it has been shown that in a group of 24 RA samples with and 
without BR, that A1AT and the heavy chain of IgG are both citrullinated and 
carbamylated to varying degrees, though in greater quantity than those seen in 
healthy control samples. Of note is that in RA patients, these modifications were 
localised to two specific regions: the C1q binding site, and the IgM binding site 
found in RF.  
In light of this finding, Fc fragments of IgG were generated that were either 
untreated, or citrullinated and carbamylated, and measured the serum IgA and 
IgM to these fragments by ELISA. After testing over 400 samples, it was found 
that the IgM response to unmodified Fc fragment was stronger than the mod-Fc 
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fragment in RA and BRRA patients, and that RF, anti-CCP and DAS-28 
correlated strongly with the IgM:UT-Fc response. The IgA response in RA 
patients was lower than healthy control samples, for unknown reasons. The IgA 
response in BRRA patients was stronger for the mod-Fc fragment than the 
untreated Fc fragment, potentially explained by the influence of bronchiectasis 
underlying the RA disease.  
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6 Overall discussion and future work 
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6.1 Summary of results 
The experiments of this thesis centre on a core rationale of investigating 
potential pathways through which immune tolerance can be broken in RA. This 
project consisted of three questions: one prospective, and two retrospective. 
The rationale behind these questions can be seen in Figure 6.1.  
The first question of “does cadmium exert any changes in neutrophils” is 
nuanced. On the one hand, it was found that cadmium did not alter the function 
of three vital neutrophil processes: the respiratory burst, phagocytosis and 
NETosis. However, it was demonstrated that cadmium exposure in neutrophils, 
results in increases in cytosolic calcium levels, which may affect secondary 
messaging systems inside the cell.  Furthermore, this work shows that cadmium 
may, however, prime both the respiratory burst and NET response for 
subsequent stimulation by PMA; this may be attributable to cadmium altering 
protein kinase c function through displacement of the zinc ion on the protein, 
resulting in greater activation (348).   
This now paints a picture of cadmium not directly causing neutrophil function 
but potentially acting as a priming agent through which subsequent stimuli result 
in an exaggerated response.  This exaggerated response may result in greater 
levels of extracellular carbamylation in activated neutrophils, as discovered by 
Nakabo et al (281). This hypothesis is supported by evidence that cigarette 
smoke exposure in rabbits results in carbamylation of vimentin, and 
subsequently autoantibodies to this carbamylated variant (233). Cigarette 
smoke contains various toxic compounds, though it is the largest source of 
cadmium for the general population. Further to this, it was demonstrated that 
cadmium plays a part in calcium release and PKC activation, which are both 
required to cause neutrophil degranulation (416).  
216 
 
 
Figure 6-1 Summary of the rationale behind the experiments undertaken 
during this thesis. 
In chapter 3, the effect of cadmium on neutrophil functions was assessed. In 
chapter 4, the neutrophil response to RA serum from select patients with 
varying degrees of Cd exposure was investigated. In chapter 5, the proteomic 
changes in RA patient serum samples was analysed against healthy control 
serum, to see if any stark contrasts were observed. The neutrophil function 
response in chapter 4 serves as the link between chapters 3 and 5, tying the 
link between neutrophil functional responses, and RA serum proteomic changes 
together. 
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Therefore, it is proposed that one mechanism through which cigarette smoke 
contributes to breakdown of immune tolerance, is through Cd-induced 
exaggeration of PKC activation, resulting in greater levels of MPO release. Rats 
exposed to Cd demonstrated increased levels of intracellular MPO levels, 
lending further strength to this argument (308).  
To see if these findings possibly persisted in established RA patients, previous 
neutrophil functional assay work was replicated with RA serum, with samples 
consisting of various levels of urinary cadmium, in addition to differing 
serological scores between each sample. The lack of functional responses 
across all assays used are confusing, given that RA serum is known to 
stimulate healthy neutrophils in certain processes, such as the respiratory burst 
(368).  Further to this, the response in one serum sample with the highest level 
of urinary cadmium, and relatively high RF and anti-CCP and DAS28 scores 
may suggest that any influence that cadmium may have on immune system 
functioning in RA patients appears to have long since ceased, as no stimulatory 
effect was seen in this serum sample. Obviously, this is merely the finding of 
one unique patient sample, and so more samples from patients that share these 
characteristic traits would lend more strength to these data.  
It was previously discussed reasons for why these experiments did not replicate 
prior findings, but the low number of serum samples used overall (n=8) may be 
insufficient to state any conclusions found from the respiratory burst or calcium 
flux assays. Even more confusing, is the large quantity of RA patient serum 
used (n=44) in the NETosis induction experiments, once again confounding 
current literature, with RA serum inducing less extracellular DNA release than 
healthy serum samples. Experimental differences may account for this, but 
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taken altogether, it would suggest that cadmium does not attenuate neutrophil 
function adversely in RA patients with a long-standing history of Cd exposure.  
This then means that in a biological setting, the only role that cadmium may 
play in any aspect of immune system functioning, is potentially in the initial 
stages of RA development. Acute doses of Cd exposure in the lungs are the 
most likely scenario through which this dysfunction occurs, typically through 
smoking. The lungs are more likely than the gut to be the site of this, as 
cadmium nanoparticles citrullinate proteins in lung cells, with cytokeratins being 
the most common target (417). Citrullinated cytokeratins are also present in the 
joint of RA patients, further highlighting another mechanism through which 
cadmium may be implicated in RA pathogenesis (418). 
And so the other side of lung-induced RA development is highlighted through 
these experiments into analysing a portion of the proteome in BRRA/RA 
patients. The significance of this cohort of patients was established by this 
group and has built on this strong foundation with additional important findings. 
Firstly, and most notably, the findings of Koro et al have been confirmed 
regarding carbamylation of IgG (392). Whereas they modified IgG in vitro, It has 
shown for the first time, that these same modifications can occur in vivo in RA 
patients. Even more notably, is the discovery of these same modifications in the 
location that IgM binds IgG in RF. The significance of this finding may provide 
potential insights into how this autoantibody immune complex is formed.  
This finding was further explored through isolation of IgG and generating pure 
Fc fragments. Following this, Fc isolates were citrullinated and carbamylated, to 
attempt to somewhat replicate an isoform of IgG that had been found through 
mass spectrometry. The hope was that RA patients would have IgM or IgA 
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antibodies that recognised the modified Fc fragment more avidly than 
unmodified Fc fragment. Unfortunately, the IgM response in RA and BRRA 
patients was greater towards the unmodified Fc fragment. The IgA response to 
UT-Fc and mod-Fc in RA patients was also markedly lower than all of cohorts 
tested. The IgA response in BRRA patients was similar between the two 
variants of Fc fragment, though mod-Fc absorbance values correlated more 
positively with existing serological measurements. The reasons for the 
diminished response to the mod-Fc fragment could possibly be due to 
overmodification of the protein in question, making it an imperfect means to 
assess autoantibody response to carbamylated and citrullinated IgG.  
6.2 Future work 
An obvious flaw with some of these experiments in this thesis involved the use 
of the HL60 cell line in certain assays. If it were possible, these experiments 
would be repeated with primary neutrophils to confirm the initial findings. 
Additionally, some preliminary experiments were performed in duplicate as 
opposed to the accepted standard of at least in triplicate. Providing more time 
was available, the quantity of repeats in some of these experiments would be 
increased in order to strengthen the data.  
The findings of this project provide potential insights into the long-neglected role 
of cadmium in neutrophil function. The two findings that warrant further 
investigation are the potential relationship between cadmium exposure and 
PKC function, and the increase in intracellular calcium levels upon neutrophil 
treatment with cadmium. These results are obviously very generic in terms of 
the downstream effects that could occur as a result of these activation 
pathways. Other functional assays on the effect of cadmium are yet to be 
investigated, such as neutrophil migration or neutrophil adhesion which may 
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provide further answers to the question of whether cadmium negatively 
influences neutrophil biology. 
Protein kinase C is crucial to several downstream processes, most notably 
NADPH oxidase activation in neutrophils. This in turn is critical in activating the 
neutrophil response, with degranulation, ROS production and NETosis all 
arising from this pathway. The most important thing to consider about this 
activation pathway is to attempt to emulate these findings using 
lipopolysaccharide, not PMA, to best reproduce an infection-based model that 
would occur in the pulmonary environment. As PMA is a phorbol ester that does 
not have any biological analogues, it is essential to see if neutrophil responses 
through lipopolysaccharide-induced activation can be influenced by cadmium in 
the same manner.  
The reasons for not using LPS as a stimulatory compound in this thesis arise 
from lack of NET induction during the efforts to generate neutrophil extracellular 
traps despite multiple steps to troubleshoot the issue. Future work would test 
LPS with a variety of second stimuli such as adenosine triphosphate in order to 
confirm the general findings in the literature regarding the role of LPS in many 
neutrophil processes.  
Elevations in calcium signalling pose the most open-ended question of what this 
does to the intracellular signalling. The effect of cadmium on PAD activity in 
neutrophils is crucial to investigate. With evidence emerging of cadmium-
induced citrullination in certain cell types, it could be that cadmium induced PAD 
activation is possible (417). Myeloperoxidase levels are higher in Cd-exposed 
mice, though myeloperoxidase activity has yet to be examined. Answering the 
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question of whether cadmium activates MPO and PAD would then be able to 
state if cadmium contributes to RA through neutrophil dysfunction.  
One such experiment that would help strengthen this line of research would 
involve incubation of neutrophils with IgG after stimulation with PMA/LPS. 
Through this, it would be possible to examine if neutrophils were capable of 
extracellularly modifying immunoglobulin G to the extent that had been 
observed from the mass spectrometry data.  
The results found in this thesis pertaining to the effect of RA serum on 
neutrophil function provide preliminary data on the effect of individual RA patient 
sera with varying degrees of disease severity. Previous studies use pooled 
serum from RA patients, yet this data selected eight serum samples from RA 
patients to assess the response between various parameters, including 
cadmium. Further experiments would expand these experiments to include 
additional samples from each category, as each individual parameter effectively 
had a single sample to assess the neutrophil response. It would also be wise to 
repeat these primary neutrophil assays with two changes to the conditions. The 
first would expand this initial work through using higher serum concentrations to 
determine if RA serum has any effect on healthy primary neutrophils. Secondly, 
and more interestingly, RA patient neutrophils would be used in the assays 
throughout this thesis to see if RA patient autologous serum elicits any changes 
in general function.  
The findings from the mass spectrometry highlight the strongest foundation for 
further RA research. These preliminary findings need to be explored further with 
even more samples being analysed via mass spectrometry. In addition to this, 
Biacore would be used to examine protein-protein interactions between the 
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patient serum antibodies and the modified Fc fragment in order to understand 
the binding kinetics that may explain the findings in Section 5.3.3.  
Although modifications to alpha-1 antitrypsin were observed based on mass 
spectrometric data, this thesis did not investigate this further in terms of 
assessment of the proteomic response to A1AT. This work may prove even 
more relevant to the connection between RA and BR. As previously stated, 
A1AT deficiency is linked already to autoimmune diseases and bronchiectasis, 
though no work on patients that have both these conditions. Therefore, 
measurement of “Anti-A1AT” antibodies, be it through carbamylated or 
citrullinated variants of A1AT, may prove to be useful in predicting RA onset in 
BR patients. In addition to this, exploring the effects of citrullination and 
carbamylation on A1AT function may prove interesting to see if this protein may 
play a role in RA pathology.  
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